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Abstract 
 
Over 20,000 people are diagnosed with cancer every year in Ireland, with 
colorectal and breast cancers contributing significantly to that figure.  Approximately 
8,000 deaths occur annually from cancer and the majority of these patients die 
because their tumour has metastasised to secondary sites in the body.  Current 
treatments of surgery, radiotherapy and chemotherapy are still limited in their 
effectiveness, and have various side-effects and disadvantages.  New anti-cancer and 
anti-metastatic agents are urgently required to decrease the number of deaths 
occurring and more targeted therapies would allow increased doses to be tolerated 
without the corresponding side-effects.  In this study, conjugated linoleic acid (CLA) 
and novel 5-Fluorouracil (5-FU) derivatives were analysed with regards to regulating 
cytotoxicity, cell cycle kinetics, apoptosis, migration, invasion, adhesion, colony 
formation in soft agar and MMP/TIMP levels. 
CLA is a polyunsaturated fatty acid found in the meat and dairy products of 
ruminant animals.  Numerous isomers exist and have previously been shown to 
exhibit anti-cancer activity.  A mix of CLA isomers proved more toxic than the 
individual c9,t11-CLA and t10,c12-CLA isomers to the 4T1 murine mammary and 
Hs578T human breast cancer cell lines.  Treatment with CLA and the isomers 
resulted in a predominant G1 phase arrest in the 4T1 cells.  Migration and invasion of 
the 4T1 cell line was increased after treatment with c9,t11-CLA and decreased after 
treatment with t10,c12-CLA (p<0.05).  The t10,c12-CLA isomer had a significant 
effect on colony formation of the 4T1 cells in soft agar, with a 25-fold increase in 
colonies formed in comparison to the control (P<0.00005).  The c9,t11-CLA isomer 
and CLA also increased the number of colonies formed (p<0.01).  MMP-9 mRNA 
and protein levels were increased following treatment with CLA and t10,c12-CLA, 
which correlated with decreased TIMP-1 mRNA levels.  
5-FU is an antimetabolite agent commonly used in chemotherapy.  Despite its 
widespread use in cancer patients, it has many side-effects and low response rates, 
and is generally used in combination with a number of other agents.  Novel 5-FU 
derivatives were synthesised and their anti-proliferative and anti-invasive activity 
analysed using a murine mammary and a human colon cancer cell line.  Cytotoxicity 
analysis revealed a derivative, compound 10, considerably more toxic than the parent 
 xi
5-FU.  This compound also exhibited toxicity towards a 5-FU resistant cell line and 
caused a dramatic S phase arrest during cell cycle analysis, indicating a different 
mode of action to the parent 5-FU.  A number of these derivatives were synthesized 
as prodrugs, non-toxic agents requiring enzyme activation to release 5-FU.  
Activation of these prodrugs was initially investigated using hypoxic conditions and 
then an E.coli nitroreductase enzyme.  Activation of two prodrugs, compounds 13 and 
14 was confirmed in a cell line expressing this enzyme.  Compound 14 had an IC50 
value that was greater than 73.5-fold lower in the nitroreductase-expressing cell line 
in comparison to the control cell line after treatment for 3 days.  Mass spectrometry 
analysis confirmed production of 5-FU from compound 13 in this cell line.   
This work has looked at two potential new approaches to cancer treatment.  
CLA is part of the growing industry of dietary supplements or functional foods that 
may aid chemoprevention or supplementary chemotherapy.  5-FU has been used for 
decades in chemotherapy regimes.  However, derivatives with increased toxicity or 
specificity will certainly be beneficial to numerous patients.  In the coming years, 
these two approaches promise to signal a major change in the impact of cancer on 
people’s lives and will significantly decrease the rate of fatalities.  
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Chapter 1 
 
Introduction 
1.1 Cancer 
 
1.1.1  Cancer statistics 
 
Statistics from the National Cancer Registry Ireland (NCRI) for the years 
1998 to 2000 state that on average there were 22,019 new cases of cancer and 7,661 
deaths from cancer per annum (Campo et al., 2004).  Of the total annual number of 
new cases, 1,927 patients presented with breast cancer and on average 642 deaths 
occurred as a result.  1,861 patients were diagnosed annually with colorectal cancer 
(CRC), with 915 deaths.  A report produced by the NCRI in June 2006 predicted that 
by the year 2020 there will be 4,734 cases of breast cancer and 3,193 cases of 
colorectal cancer per annum (National Cancer Registry, 2006).  Thus new and 
improved avenues of treatment and care are urgently required.  The focus for a better 
cancer strategy must include chemoprevention through exercise and diet, screening 
for earlier detection, prediction of patient response to different treatments by using 
genomic and proteomic analysis, and more effective anticancer drugs with reduced 
side-effects and resistance. 
 
 
1.1.2  Breast cancer 
 
The human breast consists of 15 to 20 sections called lobes, which are sub-
divided into lobules.  At the end of the lobules are dozens of glands that can produce 
milk.  Thin tubes called ducts connect the lobes, lobules and glands.  Cancer in the 
cells of the ducts (ductal carcinoma) is the most common type of breast cancer.  
Lobular carcinoma, which begins in the lobes or lobules, accounts for approximately 
10% of breast cancers (www.cancer.gov and Cocquyt and van Belle, 2005).  The 
ducts contain a central lumen, which is surrounded by a single layer of luminal 
epithelial cells, outside which is a layer of myoepithelial cells resting on the 
extracellular matrix (ECM) (Figure 1.1).  The myoepithelial cells are seen as having a 
tumour suppression effect, by depositing ECM components and producing proteinase 
inhibitors, with loss of the myoepithelial cell layer observed in invasive tumours 
(Lacroix et al., 2004).  During development, the ducts are formed as the terminal end 
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buds (TEBs) move through the mammary fat pad.  The TEBs are bulbous structures, 
which consist of a mass of body cells surrounded by a layer of cap cells (Figure 1.1).  
The cap cells have a high proliferation rate and eventually give rise to the 
myoepithelial cells of the duct.  The body cells give rise to the luminal epithelial 
cells.  Once the TEBs have completed their development, they regress to form 
terminal ducts.  Upon puberty, lateral and alveolar buds develop in the mammary 
gland and during pregnancy considerable proliferation occurs, giving rise to side 
branches and alveoli (Smalley and Ashworth, 2003).  Upon lactation, the luminal 
cells produce the milk and contraction of the myoepithelial cells squeezes the milk 
out of the alveoli and down the ducts to the nipple (Richert et al., 2000 and Smalley 
and Ashworth, 2003).   
 
 
 
 
Figure 1.1 Structure of the ducts and terminal end buds in mammary gland 
development.  From Smalley and Ashworth, 2003.   
 
 
There are many risk factors involved in breast cancer including older age; 
beginning menstruation at an early age; having no children or having the first child at 
an older age; taking estrogen or progesterone hormones; alcohol intake and being of 
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Caucasian race (www.cancer.gov).  Stages of breast cancer range from Stage 0 to IV.  
Stage 0 refers to carcinoma in situ where abnormal cells are found in the lobules of 
the breast (lobular carcinoma in situ – LCIS) or in the lining of the duct (ductal 
carcinoma in situ – DCIS).  At this stage, precancerous cells are confined and have 
not spread to other tissues.  In Stage IV, the cancer has metastasised to other organs 
of the body, most often the lungs, bones, liver or brain.  The intervening stages are 
differentiated by the increasing size of the primary tumour and the presence or 
absence of cancer cells in the lymph nodes (www.cancer.gov). 
The development of breast cancer begins with atypical epithelial hyperplasia, 
followed by in situ carcinoma, invasive carcinoma and finally metastatic disease 
(Figure 1.2) (LaCroix et al., 2004 and Polyak, 2001).  Nuclear grade, which 
represents the size and shape of the nucleus in tumour cells and the percentage of 
tumour cells that are in the process of dividing or growing, correlates with outcome in 
cases of DCIS.  High grade DCIS has a 25-30% rate of local recurrence while low 
grade has 0-5% recurrence rate after 12 years follow-up (Polyak, 2001).  Also, high-
grade tumours tend to recur within a shorter time period than low grade (Lacroix et 
al., 2004).  High grade DCIS and high grade invasive ductal carcinoma (IDC) are 
more likely to be estrogen receptor (ER) and progesterone receptor negative, to 
exhibit amplification of erythroblastic leukaemia viral oncogene homolog 2/human 
epidermal growth factor receptor 2 (ERBB2/HER2), p53 mutations, decreased bcl-2 
levels and have higher proliferation and apoptosis rates in comparison to low grade 
DCIS/IDC (Polyak, 2001 and Lacroix et al., 2004). 
 
 
Normal Epithelium Hyperplasia In situ carcinoma Invasive carcinoma Metastasis
 
 
Figure 1.2 Progression of breast cancer from normal epithelium to metastasis.  
Adapted from Polyak, 2001. 
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Microarray studies of breast tumours have identified a number of major 
phenotypes including a ‘luminal epithelial/ER-positive’ subtype, a ‘normal breast-
like’ subtype, ‘basal/myoepithelial’ subtype and ‘ERBB2+’ subtype.  The luminal 
epithelial/ER-positive subtype accounts for 60-65% of tumours, which are generally 
low-grade.  The basal/myoepithelial and ERBB2+ subtypes are associated with poor 
clinical outcome.  These microarray studies have identified expression signatures, 
which can predict the occurrence of metastasis or 10-year survival rates, giving the 
possibility of aiding selection of treatment for these patients (Lacroix et al., 2004).   
More than 90% of breast cancers are sporadic or non-hereditary, with the 
remaining 10% of cases being inherited forms (Polyak, 2001).  Breast cancers caused 
by germ-line mutations in the BRCA1 and BRCA2 tumour suppressor genes 
contribute significantly to this 10% figure (Polyak, 2001).  Also, mutations in PTEN, 
TP53, ATM and MCH2/MLH1 genes are associated with hereditary breast cancer 
(Polyak, 2001).   
TP53 is a tumour suppressor gene encoding a transcription factor, p53, which 
is mutated in 15-34% of sporadic breast tumours (Ingvarsson, 1999).  The p53 protein 
is involved in the G1 checkpoint of the cell cycle.  The protein accumulates in the cell 
following DNA damage and, via activation of p21, halts the cell in the G1 phase until 
the damage is repaired (Ingvarsson, 1999).  Mutations in the gene encoding E-
cadherin are found in a majority of lobular breast tumours but not in ductal 
carcinomas.  However, reduced expression of the E-cadherin protein is seen in both 
lobular and ductal breast cancer.  This protein is involved in cell-cell interactions and 
therefore loss of function appears to affect adhesion and consequently facilitates 
invasion (Ingvarsson, 1999).   
Recently, a hypothesis regarding the origin of breast cancer from stem cells 
has been postulated and is now being researched considerably.  It states that only a 
small distinct subset of cells, the breast cancer stem cells (BCSCs), have the ability to 
form new tumours but are extremely efficient at doing so (Al-Hajj et al., 2003).  This 
theory is supported by the fact that stem cells are believed to have a long life in the 
body, therefore allowing a number of mutations to accumulate, and have a large 
replicative potential that could give rise to a mass of tumour cells (Smalley and 
Ashworth, 2003).  Al-Hajj et al. (2003) identified a population of breast tumour cells, 
which had a 10 to 50-fold increase in the ability to form tumours in xenografts when 
compared with the remaining tumour cells.  Ponti et al. (2005) confirmed these 
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results by successfully propagating BCSCs as floating spheres from three patients and 
induced tumours in mice by injecting as few as 103 cells.  
This hypothesis may explain why only a portion of patients with evident 
micrometastasis subsequently develops secondary tumours.  However, stem cells are 
thought to have a slow rate of division, and this theory has a major impact on the 
treatment of breast cancer with the possibility that current treatments may kill off the 
main tumour mass but leave behind the BCSCs (Kalirai and Clarke, 2006).  This 
would allow regeneration of the tumour and recurrence of the disease.  Normal stem 
cells are known to be more resistant to chemotherapy than their mature cell 
counterparts due to increased levels of anti-apoptotic proteins and membrane 
transporter proteins (Al-Hajj et al., 2003 and Reya et al., 2001).  Hence, new 
therapies targeting specific markers of BCSCs are required in conjunction with 
current treatments to ensure complete elimination of all tumour cells, including the 
BCSCs. 
 
 
1.1.3  Colorectal Cancer 
 
Colorectal cancer refers to cancer of the colon or large intestine and the 
rectum.  Using the Dukes’ staging to describe the progression of colorectal cancer, 
stages A and B describe cancers confined to the bowel wall, in stage C the cancer has 
spread to the lymph nodes and finally, stage D refers to cases where distant 
metastases are evident (Hendon and DiPalma, 2005 and McLeod et al., 2000).  
Dukes’ staging A-D represents progression of the disease and subsequently survival 
rates after 5 years decrease from >80% for stage A to 5% for stage D (Hendon and 
DiPalma, 2005 and de la Chapelle, 2004).  Due to non-specific or non-existent 
symptoms at early stages, only 10% of patients present with Dukes’ stage A and the 
majority of patients have disease at stage C or D before presentation (McLeod et al., 
2000).  60% of patients will develop metastases, with liver being the most common 
site probably due to the portal drainage of blood from the intestine (McLeod et al., 
2000).  
Risk factors for colorectal cancer include age, family history, diet, smoking 
and conditions such as Crohn’s disease and ulcerative colitis (www.cancer.gov).  
Most colon cancers occur in individuals over the age of 50, with 64 being the mean 
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age of diagnosis for sporadic cancers (Grady, 2006).  Diets high in fat and red meat 
and low in calcium and fibre may increase the risk of colorectal cancer 
(www.cancer.gov and Hendon and DiPalma, 2005).  Crohn’s disease and ulcerative 
colitis cause inflammation of the colon and therefore may contribute to the 
development of CRC (www.cancer.gov).   
Colorectal cancer development begins with aberrant crypt proliferation, which 
leads to benign adenomas, followed by carcinoma in situ and metastatic carcinoma 
(de la Chapelle, 2004).  The progression of colorectal cancer is stepwise and 
generally occurs over a number of years.  The somatic mutations which result in 
colorectal cancer occur in the adenomatous polyposis coli (APC) gene, followed by 
mutations in the Ras family of genes and then subsequent changes in the p53 gene 
(Figure 1.3) (de la Chapelle, 2004 and Michor et al., 2005).  The APC and p53 
pathways are altered in 95% of patients with colorectal cancer, while mutations in the 
Ras pathway are found in 70% of patients (Michor et al., 2005).  Mutations causing 
inactivation of the tumour suppressor APC lead to increased transcription of growth-
promoting genes (Michor et al., 2005 and Hendon and DiPalma, 2005).  H, N and K 
human Ras genes encode four proteins, which play a role in signal transduction via 
the mitogen activated protein kinase (MAPK) pathway (McWilliams and Erlichman, 
2005).  Mutations in the K-ras gene, which lead to over-expression of the protein, 
result in increased cell proliferation and production of matrix-degrading proteases 
(McWilliams and Erlichman, 2005).  Constitutive expression of this gene, as a result 
of missense mutations, occurs in 50% of CRCs (McWilliams and Erlichman, 2005).   
 
 
 
Normal Epithelium Small Adenoma Large Adenoma Carcinoma Metastasis
APC Pathway Ras Pathway p53 Pathway  
 
 
Figure 1.3 Genetic changes in colorectal tumourigenesis.  Adapted from Michor et 
al., 2005.  
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Changes in expression of numerous other proteins also play a role in the 
development of CRC, including epidermal growth factor receptor (EGFR), cyclins, 
members of the bcl-2 family and vascular endothelial growth factor (VEGF) 
(McWilliams and Erlichman, 2005).  EGFR belongs to the human epidermal growth 
factor receptor (HER) family of tyrosine kinases (McWilliams and Erlichman, 2005).  
Activation of the receptor leads to proliferation and production of angiogenic factors 
and matrix metalloproteinases (MMPs).  Up to 77% of colorectal cancers over-
express EGFR and its over-expression inversely correlates with survival (McWilliams 
and Erlichman, 2005).  Cyclin D1, which is involved in the movement of the cell 
through the G1 phase of the cell cycle, is over-expressed in one third of CRCs and is 
associated with poorer prognosis for the patient (McWilliams and Erlichman, 2005).  
Over-expression of cyclin D1 may tie-in with mutations in the APC gene, through 
loss of inhibition of the Wnt-catenin pathway (McWilliams and Erlichman, 2005).  
The complex formed between cyclin dependent kinase 2 (cdk2) and cyclin E is 
involved in initiating progression to the S-phase of the cell cycle.  Activity of this 
complex is increased in 90-100% of colorectal adenomas and carcinomas, promoting 
movement through the cell cycle (McWilliams and Erlichman, 2005).  VEGF plays 
an important role in angiogenesis which is required for tumour growth and 
subsequent metastasis.  Expression of VEGF in primary tumours is inversely 
correlated to survival (McWilliams and Erlichman, 2005).   
Approximately 20-25% of colorectal cancers are familial or hereditary (de la 
Chapelle, 2004).  Hereditary non-polyposis colon cancer (HNPCC), also known as 
Lynch Syndrome, and familial adenomatous polyposis (FAP) are two well-
understood familial syndromes.  HNPCC is the most common type of inherited 
colorectal cancer and accounts for approximately 2% of all cases of colorectal cancer 
(www.cancer.gov).  Mutations linked to HNPCC confer an 80% chance of developing 
the disease (de la Chapelle, 2004 and http://coloncancer.about.com/cs/types/a/ 
TypesOfCRC.htm).  The syndrome also confers predisposition to developing a 
number of other cancers including stomach, ovarian, endometrial and brain (de la 
Chapelle, 2004).  HNPCC is an autosomal dominant condition, caused by aberrations 
in the mutation mismatch repair (MMR) genes MLH1, MSH2, MSH6, PMS2, MLH3 
and PMS1 (de la Chapelle, 2004, Grady 2006 and Hendon and DiPalma, 2005).  
Dysplasia of the mucous membrane of the colon and rectum leads to development of 
adenocarcinomas, in contrast to the standard progression from adenomas to 
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adenocarcinomas (http://coloncancer.about.com/cs/types/a/TypesOfCRC.htm).  FAP 
is also an autosomal dominant syndrome and is caused by mutations in the APC 
tumour suppressor gene (www.cancer.gov and Hendon and DiPalma, 2005).  The 
majority of mutations are insertions or deletions, causing a change in the reading 
frame.  Individuals with germ-line mutations in this gene have almost a 100% chance 
of developing FAP.  Patients with FAP develop hundreds to thousands of adenomas 
in the colon and rectum (www.cancer.gov and de la Chapelle, 2004).  The adenomas 
develop into adenocarcinomas unless treatment is sought.  
 
 
1.2  Invasion and Metastasis 
 
The spread of cancer cells to other sites in the body and the subsequent 
formation of secondary tumours is the main cause of death in cancer patients.  In 
approximately 50% of patients, metastatic disease has already been established at 
diagnosis (Ahmad and Hart, 1997).  Metastasis is a complex process involving 
numerous adhesion factors, motility factors, proteases and angiogenic factors.  Cells 
from the primary tumour must invade through the ECM, intravasate into the lymph or 
blood system, survive in the circulation, arrest and extravasate in a distant organ and 
proliferate successfully to form metastases (Figure 1.4) (Bogenrieder and Herlyn, 
2003).  The limiting factor in this process is growth of the tumour cells at the 
secondary site (Chambers et al., 2002) and less than 0.05% of tumour cells in the 
circulation are capable of forming metastases (Geho et al., 2005).   
Cell adhesion molecules include integrins, the immunoglobulin (Ig) 
superfamily and the cadherins.  The integrin family of membrane proteins consists of 
at least 18α and 8β subunits which heterodimerise and mediate communication 
between the cell and the ECM (Bogenrieder and Herlyn, 2003).  Signals relayed by 
the integrins activate pathways involved in migration and survival (Bogenrieder and 
Herlyn, 2003).  The Ig superfamily comprises transmembrane proteins containing one 
or more Ig-like repeats in their extracellular domain.  They mediate cell-cell 
interactions by binding to similar sequences on adjacent cells (King, 2000) and 
thereby direct the flow of information between cells through various kinases and 
growth factor receptors (Bogenrieder and Herlyn, 2003).  The cadherin subfamily has 
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numerous members involved in calcium-dependent cell-cell adhesion at adherens 
junctions and tight junctions (Cross and Bury, 2003).  The extracellular domain of the 
E-cadherin molecule mediates adhesion to homophilic cells by binding with another 
E-cadherin molecule on an adjacent cell.  The intracellular domain affiliates with 
various catenin proteins, forming the cytoplasmic cell-adhesion complex (CCC) that 
mediates the link to the actin cytoskeleton, strengthening the bond between adjacent 
cells (Bissell and Radisky, 2001 and Cavallaro and Christofori, 2004).  Adhesion 
molecules play a complex role in metastasis; with changes in adhesive preferences 
occurring during the processes of migration, invasion, arrest and extravasation.   
 
 
METASTASIS
PRIMARY TUMOUR
Invasion
Intravasation Extravasation
Circulating
Tumour Cells
 
 
 
Figure 1.4 The process of metastasis of cancer cells involves invasion, intravasation, 
survival in the circulatory system, extravasation and formation of a secondary 
tumour.  Adapted from McDonnell et al., 2006. 
 
 
Another family of molecules that play a critical role in this process are the 
MMPs.  There are over 24 members of this family of protease enzymes, each highly 
conserved, and collectively able to degrade the entire ECM (Lynch and Matrisian, 
2002 and Curran and Murray, 2000).  The ECM is a physical boundary around tissues 
which consists of numerous proteins, proteoglycans and glycoproteins such as 
collagens, gelatin, entactin, fibronectin and laminin (Lynch and Matrisian, 2002).  
The MMPs also degrade non-matrix substrates such as insulin growth factor binding 
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proteins (IGF-BPs), transforming growth factor-β (TGF-β) and E-cadherin (Lynch 
and Matrisian, 2002).   
The MMPs contain a highly conserved three histidine-motif at the catalytic 
site which binds zinc and is essential for activity (Sternlicht and Werb, 2001).  They 
consist of an N-terminal propeptide or pre-domain, a pro-domain and a catalytic 
domain (Lynch and Matrisian, 2002).  The pre-domain is removed once the protein 
has been directed to the endoplasmic reticulum (Sternlicht and Werb, 2001).  The 
majority of MMPs are then secreted as proenzymes or latent zymogens from the cell 
with activation occurring extracellularly by removal of the N-terminal pro-domain.  
The enzymes are thus found in the conditioned medium of cultured cells.  Some 
MMPs contain a transmembrane domain and are known as membrane type-MMPs 
(MT-MMPs).  The majority of MMPs have a hemopexin domain which contains a 
three repeat unit and plays a role in cleavage of substrates and binding of inhibitors 
(Murphy, 1998 and Sternlicht and Werb, 2001).  The tissue inhibitors of 
metalloproteinases (TIMPs) act as inhibitors of the MMPs, by binding to the active 
site of the enzyme in a 1:1 molar ratio.  There are four TIMPs identified to date, they 
are secreted proteins of 20 – 29 kDa in size (Lynch and Matrisian, 2002 and 
Sternlicht and Werb, 2001).   
MMP-2 and MMP-9 are the two gelatinase enzymes, termed due to their 
ability to degrade gelatin.  They have three cysteine-rich repeats within their catalytic 
domain (Sternlicht and Werb, 2001).  Activation of MMP-2 occurs at the cell surface 
involving interactions with TIMP-2 and MT1-MMP.  TIMP-2 binds to the 
membrane-bound MT1-MMP by its N-terminal domain (Egeblad and Werb, 2002).  
The C-terminal domain of TIMP-2 then sequesters the latent MMP-2 to the complex 
while a second MT1-MMP molecule cleaves part of the pro-domain of MMP-2.  
Another MMP-2 molecule is required to cleave the remaining section of the pro-
domain before activation is complete (Sternlicht and Werb, 2001).  Following 
activation, the activity of MMP-2 is partially regulated by interaction with the N-
terminal domain of TIMP-2.  MMP-9 binds to the cell surface hyaluronan receptor 
CD44, which appears to promote tumour cell invasion (Sternlicht and Werb, 2001).  
MMP activity is also controlled by the plasma protein α-macroglobulin, which binds 
MMPs and recruits them to a scavenger receptor.  Endocytosis of the complex occurs, 
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eliminating the MMP protein.  Thrombospondin-1 and -2 also play roles in regulating 
the activity of MMP-2 and MMP-9.   
MMP expression is generally high in the tumour region, due to secretion from 
the cancer cells but also from the surrounding stromal cells.  Expression of MMPs 
generally correlates with the aggressiveness of the tumour and subsequent prognosis 
(Lynch and Matrisian, 2002 and Sternlicht and Werb, 2001).  This has been 
confirmed by animal studies, with over-expression of MMPs contributing to 
tumourigenesis and metastasis while deficiencies of MMPs have shown decreased 
tumour formation (Lynch and Matrisian, 2002).  Increased expression of TIMP-1 has 
also been shown to cause a decrease in tumour formation (Sternlicht and Werb, 
2001).   
 
 
1.3  Treatments 
 
When a patient presents with cancer, there are a number of treatment options 
available depending on the type of tumour and the stage of the disease.  Surgery to 
remove a solid tumour is common, with radiation therapy, chemotherapy and 
hormonal therapy all playing roles in reduction of the size of the tumour prior to 
excision or in the fight against recurrence of the disease.  Chemotherapy given before 
surgery is called neoadjuvant therapy, while adjuvant therapy refers to chemotherapy 
given after surgery.  There are numerous types of chemotherapeutic drugs used in the 
clinical setting.  Alkylating agents, antimetabolites, cytotoxic antibiotics, mitotic 
inhibitors and monoclonal antibodies are the main forms of treatment (Saeb-Parsy et 
al., 1999 and Lazo and Larner et al., 1998).   
Alkylating agents include cyclophosphamide and cisplatin.  They form 
covalent bonds between the bases of DNA, either inter-strand or intra-strand, 
blocking cells from moving from the S phase into the G2 phase and leading to 
apoptosis (Lazo and Larner et al., 1998).  Antimetabolites interfere with the 
metabolic pathways involved in DNA synthesis and include 5-fluorouracil (5-FU) and 
methotrexate (MTX).  5-FU inhibits thymidylate synthesis while MTX inhibits 
dihydrofolate reductase, blocking synthesis of both pyrimidines and purines (Lazo 
and Larner et al., 1998).  Cytotoxic antibiotics are of microbial origin and act to 
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prevent cell division.  The anthracycline doxorubicin is a cytotoxic antibiotic which 
binds DNA, inhibits topoisomerase II activity and thus disrupts DNA and RNA 
synthesis (Minotti et al., 2004).  Epirubicin, bleomycin and mitomycin are other 
cytotoxic antibiotics.  Mitotic inhibitors prevent spindle formation causing cell cycle 
arrest in the mitosis (M) phase and include the plant derivatives vincristine and 
paclitaxel.  
The main monoclonal antibody currently in use is trastuzumab, which blocks 
ERBB2/HER2 signalling.  This receptor is over-expressed in 25-30% of breast 
cancers, due to amplification of the gene.  Over-expression of ERBB2/HER2 has 
been associated with more aggressive disease, higher mortality rates and resistance to 
treatment (Buzder et al., 2005).  Hormonal therapy includes the antagonist Tamoxifen 
which binds ERβ and blocks estrogen-dependent transcription and cell proliferation 
(Lazo and Larner et al., 1998).  Anti-metastatic agents have been given a lot of 
attention as the majority of cancer patients die because their tumour has metastasised 
(Bogenrieder and Herlyn, 2003).  MMP inhibitors have been investigated for several 
decades.  Collagen-based peptidomimetic MMP inhibitors Batimastat and Marimastat 
showed promising results in tumour cell and animal models.  However, clinical 
results were disappointing, with dose-limiting muscular and skeletal pain, partially 
due to the broad-spectrum of MMPs that these drugs inhibit (Hidalgo and Eckhardt, 
2001 and Fisher and Mobashery, 2006).   
While most of the chemotherapies aim to cause apoptosis of the cancer cells, 
there are limitations to this effect due to the nature of solid tumours.  Only a fraction 
of tumour cells are actively dividing at any one time, with the remainder of the cells 
in G0 phase of the cell cycle.  The majority of cancer treatments kill the actively 
dividing cells of the tumour, thus eliminating only a fraction of the cancer cells.  
Combination therapies of the above-mentioned drugs tackle this problem to some 
extent, by using different modes of toxicity.  Side-effects of chemotherapy can 
include hair loss, nausea, vomiting, diarrhoea and immunosuppression.  These are due 
to the nature of most of the drugs which attack rapidly dividing cells of the body.  
Besides the tumour cells, this also includes cells of the hair follicles, bone marrow 
and gastrointestinal tract.  These side-effects can be somewhat reduced by the method 
of administration of the drug to maximise exposure of the tumour cells with minimum 
exposure to non-neoplastic cells.  Resistance to chemotherapeutic agents also causes 
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limitations with regards to the treatment of patients.  Tumours may be intrinsically 
resistant to the therapy or may acquire resistance following repeated doses (Lazo and 
Larner et al., 1998 and Liang et al., 2002).  This can be due to a decrease in uptake of 
the drug or increased production of transmembrane pumps which rid the cell of the 
drug.  Up-regulation or mutation of target proteins may also play a role in resistance, 
or changes in DNA repair mechanisms and anti-apoptotic proteins (Lazo and Larner 
et al., 1998). 
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1.4  Objectives of thesis 
 
• The main objective of this thesis was to explore two possible new avenues for 
the treatment of cancer: CLA and novel 5-FU derivatives.  These represent 
two different approaches to anticancer therapy.   
• CLA is a component of dairy products and meat from ruminant animals and 
could be supplemented in the diet as a component of a functional food.  The 
aim of chapter 3 was to look at the effect of a mixture of CLA isomers and 
two individual isomers on cell proliferation, cell cycle kinetics and apoptosis 
in murine mammary and human breast cancer cell lines.   
• Investigation of in vitro cell invasion, migration, adhesion and colony 
formation in soft agar following CLA treatment was conducted to determine 
effects on these processes.  MMP and TIMP expression at the mRNA and 
protein levels was quantified to examine changes at the molecular level. 
• 5-FU has been used extensively in chemotherapy regimens for a number of 
decades, but with dose-limiting toxicities and low response rates.  5-FU 
derivatives, including prodrugs, may provide a more targeted therapy to 
tumour cells, thus reducing side-effects and offering more efficacious 
treatments.  
• Chapter 4 focused on a number of novel 5-FU and 5-Fluorouridine (5-FUrd) 
derivatives with nitro-benzyl, ester and acid side-chains.  Cytotoxicity of these 
compounds was examined in a murine mammary cancer cell line, a human 
colorectal cancer cell line and a 5-FU resistant human colorectal cancer cell 
line.  The effect of these derivatives on cell cycle kinetics, apoptosis, 
migration, invasion and soft agar colony formation was investigated.   
• A sub-set of these compounds was designed as prodrugs and this aspect was 
the focus for chapter 5.  Activation of the prodrugs was assessed under 
hypoxic conditions and by enzymatic cleavage with the E. coli nitroreductase 
enzyme.  Cytotoxicity in a cell line transfected with the cDNA for this enzyme 
was examined along with mass spectrometry analysis to confirm activation.  
Analysis of the 5-FU prodrugs as substrates for the enzyme was conducted 
using enzyme kinetics studies.  A human colorectal cancer cell line was 
transfected with the cDNA for nitroreductase and cytotoxicity examined. 
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Chapter 2 
 
Materials & Methods 
2.1  Materials 
 
All general-purpose reagents and chemicals used in the experimental work were of 
analytical grade and, unless otherwise stated, were obtained from Sigma-Aldrich Inc., 
Dublin, Ireland. 
1 kb DNA ladder was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
5-Fluorouracil and 5-Fluorouridine derivatives were provided by Dr. Ian Gray and 
Dr. Kieran Nolan, School of Chemical Sciences, Dublin City University, Ireland.  
Acetonitrile was supplied by Labscan, Stillorgan, Co. Dublin, Ireland. 
Acid phosphatase assay was kindly donated by Dr. Robert O’Connor, National 
Institute for Cellular Biotechnology, Dublin City University, Ireland. 
Agar noble was supplied by Difco, distributed by Unitech, Dublin, Ireland. 
AMP-D1 kit containing Deoxyribonuclease I, was supplied by Sigma-Aldrich Inc., 
Dublin, Ireland. 
Amicon® Ultra-4 Centrifugal Filter Devices with Ultracel-10 membrane were 
supplied by Amicon Ltd., Limerick, Ireland. 
Anti-MMP-2 antibody (GL8) was obtained from Dr. Andrew Docherty, Celltech, 
Slough, England. 
Anti-MMP-9 antibody (Ab2) was supplied by Calbiochem, distributed by Merck 
Biosciences, Nottingham, England. 
Baby Hamster Kidney (BHK) cells transfected with the human MMP-9 cDNA 
(BHK92) were obtained from Professor Dylan Edwards, University of East Anglia, 
Norwich, England. 
Bacto-tryptone was supplied by Oxoid Ltd., Basingstoke, Hampshire, England, 
distributed by Fannin Healthcare, Ireland.  
Bacto-yeast extract was supplied by Oxoid Ltd., Basingstoke, Hampshire, England, 
distributed by Fannin Healthcare, Ireland. 
Bacto-yeast agar was supplied by Oxoid Ltd., Basingstoke, Hampshire, England, 
distributed by Fannin Healthcare, Ireland. 
BD BiocoatTM MatrigelTM Invasion Chambers were supplied by Becton Dickinson 
Labware, Bedford, MA, USA. 
BD FalconTM TC Companion Plates were supplied by Unitech, Dublin, Ireland. 
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Blue/Orange Loading Dye was supplied by Promega, distributed by the Medical 
Supply Company, Dublin, Ireland. 
Bradford reagent for protein quantification was supplied by Sigma-Aldrich Inc., 
Dublin, Ireland. 
Bovine serum albumin was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
CB1954 was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Cell culture medium (Dublecco’s Modified Eagle’s Medium [DMEM] and McCoys 
5A medium) and the supplements L-glutamine, sodium pyruvate, insulin, fetal bovine 
serum (FBS), 5-Fluorouracil and penicillin/streptomycin, all supplied by Sigma-
Aldrich Inc., Dublin, Ireland. 
Cell freezing medium was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
CellTiter 96® AQueous One Solution Cell Proliferation Assay was supplied by 
Promega, distributed by Medical Supply Company, Dublin, Ireland. 
ChemichromeTM Western Control was supplied by Sigma-Aldrich Inc., Dublin, 
Ireland. 
Chloroform was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Conjugated linoleic acid was supplied by Nu-Chek-Prep Inc., Minnesota, USA.  
Crystal violet was supplied by Lancaster Synthesis, Eastgate White Land, 
Morecambe, England.  
Diethyl pyrocarbonate (DEPC) was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Dimethyl sulfoxide (DMSO) was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
dNTP Mix was supplied by Merck Biosciences, UK. 
F179 and F184 plasmids were kindly provided by Dr. Steve Hobbs, CRUK Centre for 
Cancer Therapeutics, Institute of Cancer Research, Surrey, UK. 
FalconTM cell culture inserts were supplied by Becton Dickinson Labware, Bedford, 
MA, USA. 
GeneJuice® Transfection Reagent was supplied by Novagen, Merck KGaA, 
Darmstadt, Germany. 
Glycogen was supplied by Ambion Inc., Cambridgeshire, England. 
Guava® NexinTM Kit was supplied by Guava® Technologies Inc., Hayward, 
California, USA.  
Guava® Cell Cycle Reagent was supplied by Guava® Technologies Inc., Hayward, 
California, USA.  
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HCT116 parental and HCT116 5-FU-resistant cell lines were kindly provided by 
Professor Patrick G. Johnston, Department of Oncology, Cancer Research Centre, 
Queen’s University Belfast, Belfast, Northern Ireland. 
Hyperfilm was supplied by Amersham Biosciences, Buckinghamshire, UK.  
IGEPAL was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Max Efficiency DH5α competent cells were supplied by Invitrogen, distributed by 
Bio-sciences, Dublin, Ireland. 
MemCodeTM Reversible Protein Stain Kit was supplied by Pierce Chemicals, 
distributed by Medical Supply Company, Dublin, Ireland. 
MMLV-RT was supplied by Promega, distributed by Medical Supply Company, 
Dublin, Ireland. 
Nicotinamide adenine dinucleotide (NADH) was supplied by Sigma-Aldrich Inc., 
Dublin, Ireland. 
Nitrocellulose membranes, supported, 0.45 µm pore size supplied by Sigma-Aldrich 
Inc., Dublin, Ireland. 
Nitroreductase was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Novagen SpinPrepTM Plasmid Kit was supplied by Merck Biosciences, UK. 
Novex® development buffer 10X, pre-cast 10% Zymogram (Gelatin) Gel, Tris-Glyine 
SDS running buffer and Zymogram renaturing buffer supplied by Invitrogen, 
distributed by Bio-sciences, Dublin, Ireland. 
NuPAGETM 4-12% Bis-Tris gels, LDS sample buffer, antioxidant, sample reducing 
agent and transfer buffer were supplied by Invitrogen, distributed by Bio-sciences, 
Dublin, Ireland. 
Oligo (dT)15 Primers supplied by Promega, distributed by the Medical Supply 
Company, Dublin, Ireland. 
Polymerase chain reaction (PCR) 100 bp low ladder supplied by Sigma-Aldrich Inc., 
Dublin, Ireland. 
PCR primers were supplied by MWG Biotech, Ebersberg, Germany. 
P-Iodonitrotetrazolium Chloride was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Phosphate buffered saline (PBS) tablets supplied by Oxoid Ltd., Basingstoke, 
Hampshire, England. 
Phosphoric acid (HPLC grade) was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
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Plastic consumables for cell culture were supplied by Sarstedt, Sinnottstown Lane, 
Drinagh, Co. Wexford, Ireland. 
Protease Inhibitor Cocktail was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Proteinase K was supplied by Roche Diagnostics GmBH, Mannheim, Germany, 
distributed by Fannin Healthcare, Ireland. 
Puromycin dihydrochloride was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Qiagen Maxi-prep plasmid kit was supplied by QIAGEN Ltd., Crawley, West Sussex, 
England.  
Restriction enzymes were supplied by Promega, distributed by Medical Supply 
Company, Dublin, Ireland. 
RNA Sample Loading Buffer was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
SigmaMarkerTM Wide Molecular Weight Range was supplied by Sigma-Aldrich Inc., 
Dublin, Ireland. 
Super Signal West ECL detection kit obtained from Pierce Chemicals, Rockford, Il., 
USA. 
SYBR SafeTM DNA gel stain was supplied by Molecular Probes/Invitrogen, 
distributed by Bio-sciences, Dublin, Ireland. 
Taq polymerase and Magnesium Chloride were obtained from Sigma-Aldrich Inc., 
Dublin, Ireland. 
TIMP recombinant proteins were supplied by Chemicon International, Temecula, 
California, USA. 
Tissue culture plates 96, 24 and 6 well obtained from Sarstedt, Sinnottstown Lane, 
Drinagh, Co. Wexford, Ireland. 
TRI REAGENTTM was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Trypsin-EDTA was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
Trypan blue was supplied by Sigma-Aldrich Inc., Dublin, Ireland. 
V79-C and V79-NTR cell lines were supplied by Morvus Technology Ltd., Salisbury, 
UK. 
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2.2  Methodology 
 
2.2.1  Cell culture methods 
 
All cell culture techniques were performed in a sterile environment using a 
Holten HB2448 laminar airflow cabinet.  Cells were visualised with an Olympus CK2 
inverted phase contrast microscope. 
 
2.2.1.1 Cell lines 
 
The following cell lines were used in this study: 4T1, Hs578T, SW480, 
HCT116 parental, HCT116 5-FU-resistant, V79-NTR and V79-C.  4T1 (ATCC No 
CRL-2539), Hs578T (ATCC No HTB-126) and SW480 (ATCC No CCL-228) were 
obtained from the American Type Culture Collection (ATCC).  4T1 is a murine 
mammary cancer cell line.  Hs578T is a human breast carcinoma cell line.  SW480 is 
derived from a human colorectal adenocarcinoma.  HCT116 parental and 5-FU-
resistant cell lines were kindly provided by Professor Patrick G. Johnston, 
Department of Oncology, Cancer Research Centre, Queen’s University Belfast, 
Belfast, Northern Ireland.  HCT116 parental (HCT(P)) is a human colorectal 
carcinoma cell line.  The HCT116 5-FU-resistant (HCT(R)) cell line was established 
from the HCT(P) cell line by repeated exposure to stepwise increasing concentrations 
of 5-FU (Boyer et al., 2004).  The V79-NTR and V79-C cell lines were obtained from 
Morvus Technology Ltd., Salisbury, UK.  V79-NTR and V79-C are Chinese hamster 
lung fibroblast cell lines.  V79-NTR had been transfected with the cDNA for the 
Escherichia coli nitroreductase (NTR) enzyme, while V79-C was transfected with the 
control vector.  Cell lines were routinely tested for mycoplasma contamination in the 
Conway Institute, University College Dublin. 
 
2.2.1.2 Sub-culturing of cells 
 
The cell lines under study were maintained in medium as outlined in Table 
2.1.  Cells were cultured in 25 cm2 or 75 cm2 tissue culture flasks and incubated in a 
humid, 5% (v/v) CO2 atmosphere in a 37°C Thermo Electron Corporation cell culture 
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incubator.  All cell lines were adherent and required trypsinisation for harvesting of 
cells prior to sub-culturing.  For trypsinisation, the growth medium was aspirated and 
the flask rinsed with 1.5 ml trypsin ethylenediamine tetraacetic acid (EDTA) (0.025% 
(w/v) trypsin with 0.02% (w/v) EDTA in 0.15 M Phosphate Buffered Saline (PBS), 
pH 7.4).  2.5 ml of fresh trypsin was then placed in each flask and the flask incubated 
at 37°C for 10-15 minutes or until all the cells had detached from the surface.  The 
cell suspension was pipetted up and down gently to aid detachment of the cells from 
each other.  3 ml medium was added to the flask and the total volume was removed to 
a sterile universal container and centrifuged at 720 g for 5 minutes in an Eppendorf 
Centrifuge 5804.  The supernatant was poured off and the cells were resuspended in 
culture medium and seeded at relevant cell density, with 13 ml of medium in total in a 
75 cm2 flask and 5 ml in a 25 cm2 flask.  Cells were typically passaged 2-3 times per 
week. 
 
Table 2.1 Medium supplements for individual cell lines. 
 
.2.1.3 Cell counts 
Cells were counted following a 5 minute incubation with trypan blue.  
Typically, a 500 μl aliquot of cell suspension was mixed with 100 μl of trypan blue.  
2μM 5-FU50 μg/ml Streptomycin
1mM Sodium 
Pyruvate
50 U/ml Penicillin2 mM10% (v/v)McCoys 
5A
Human colorectal 
carcinoma resistant to 5-
Fluorouracil
HCT(R)
50 μg/ml Streptomycin
1mM Sodium 
Pyruvate
50 U/ml Penicillin2 mM10% (v/v)McCoys 
5A
Human colorectal 
carcinoma
HCT(P)
10μg/ml 
Puromycin
4 mM10% (v/v)DMEMChinese hamster lung 
fibroblast transfected 
with empty vector
V79-C
10μg/ml 
Puromycin
4 mM10% (v/v)DMEMChinese hamster lung 
fibroblast transfected 
with cDNA for NTR
V79-NTR
50 μg/ml Streptomycin
10μg/ml Insulin50 U/ml Penicillin4 mM10% (v/v)DMEMHuman breast carcinomaHs578T
50 μg/ml Streptomycin
50 U/ml Penicillin2 mM10% (v/v)DMEMHuman colorectal 
adenocarcinoma
SW480
50 μg/ml Streptomycin
50 U/ml Penicillin2 mM5% (v/v)DMEMMurine mammary 
cancer
4T1
OtherPenicillin-
Streptomycin
L-GlutamineFBSMediumDescriptionCell Line
 
 
2
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Follow
 (dilution factor) x 104 (area under the 
coverslip) = viable cells/ml of cell suspension 
 
The required volum sing the following 
quation: 
ity required)/(Cell density have)] x [Volume required] = Volume of cell 
spension to add (with remaining volume made up with medium) 
re trypsinised and centrifuged as per section 
.2.1.2 then resuspended in cell freezing medium and 1 ml was aliquoted into 
cryotub
ion and storage of stocks of conjugated linoleic acid 
p.  The CLA 
ixture of isomers had the following composition: cis9,trans11/trans9,cis11 (~41%), 
trans10
ing incubation, 10 μl of this mixture was added to a Neubauer 
haemocytometer slide and cells counted in the four corner quadrants.  Viable cells 
excluded the dye and remained clear while dead cells stained blue.  Calculation of the 
number of cells per millilitre was as follows: 
 
[(Average no. viable cells per quadrant) x 1.2
e of the cell suspension was then calculated u
e
 
[(Cell dens
su
 
2.2.1.4 Storage and recovery of cells 
 
For long term storage cells we
2
es.  Generally one confluent 75 cm2 flask was frozen down into one cryotube.  
The cells were incubated at -20°C for 30 minutes then transferred to a Sanyo Ultra 
Low -80°C freezer overnight and placed in a Taylor Wharton VHC35 liquid nitrogen 
vessel.  For recovery of cells, a vial was removed from the liquid nitrogen and 
defrosted in a 37°C water-bath.  Cells were removed to 5 ml culture medium in a 
universal tube, centrifuged at 720 g for 5 minutes.  The pellet was resuspended in 
fresh culture medium and added to a 25 cm2 cell culture flask which was incubated at 
37°C, 5% CO2.  
 
2.2.1.5 Preparat
 
Conjugated linoleic acid (CLA) was obtained from Nu-Chek-Pre
m
,cis12 (~44%), cis10,cis12 (~10%), others (~5%).  CLA stocks were made to 
10 mg/ml using filter-sterilised ethanol and stored at -20°C.  Further dilutions were 
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made up fresh in cell culture medium before use in assays.  The top concentration of 
30 μg/ml (107 μM) therefore contained 0.3% ethanol.  Controls were treated with this 
amount of ethanol in medium.  
 
2.2.1.6 Preparation and storage of stocks of 5-FU derivatives 
 
r. Ian Gray and Dr. 
ieran Nolan, School of Chemical Sciences, Dublin City University.  The powder 
was di
.2.2 Cytotoxicity assays  
a specific density, dependent on the cell line and the 
uration of the assay, in 100 μl in 96-well plates and allowed to attach overnight at 
37°C, 5
5-FU derivatives were supplied in powder form from D
K
ssolved in dimethyl sulfoxide (DMSO) to 100 mg/ml and stored at -20°C.  
Further dilutions made up fresh in cell culture medium before use in assays.  
Therefore, the top concentration of 100 μg/ml contained 0.1% DMSO.  Controls were 
treated with this amount of DMSO in medium. 
 
 
2
 
Cells were seeded at 
d
% CO2.  100 μl of a 2X solution of relevant treatment was added to triplicate 
wells and incubated at 37°C, 5% CO2 for the relevant time period.  Standard curves 
were set up for each experiment to ensure cells were in the exponential phase of 
growth.  Cells for treatment were seeded at the second highest point on the standard 
curve.  The CellTiter 96  AQ  One Solution Cell Proliferation Assay (MTS), 
crystal violet assay and acid phosphatase assay were used to quantify cytotoxicity.  
For the MTS assay, 40 μl of the MTS was added to each well, allowed to develop in a 
37°C incubator for 1-4 hours, after which time the absorbance was read at 492 nm on 
the Tecan Sunrise multiwell plate reader.  The crystal violet assay involved aspiration 
of medium, cells were washed twice with sterile PBS, fixed with 100 μl 10% 
formalin for 10 minutes and stained with 100 μl 0.25% aqueous crystal violet for 10 
minutes.  The 96-well plate was allowed to dry and cells could be visualised using a 
microscope and photographed.  The stain was then eluted with 100 μl 33% glacial 
acetic acid and absorbance read at 570 nm.  The acid phosphatase assay involved 
aspiration of medium then cells were washed twice with sterile PBS.  The p-
®
ueous
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nitrophenyl phosphate was dissolved in sodium acetate buffer (0.1 M, pH 5.5, 
containing 0.1% Triton X-100) to a concentration of 10 mM.  100 μl of this solution 
was added to each well.  The plate was covered loosely with tin-foil and incubated at 
37°C for 2 hours.  To stop the reaction, 50 μl 1 M NaOH was added to each well and 
the absorbance read at 405 nm.   
Percentage cell death was calculated in relation to control cells as follows: 
 
[100-{(AbsSample - AbsBlank /AbsControl - AbsBlank)*100}] = % Cell Death 
Results .  
.2.3 Hypoxic experiments 
 were carried out in collaboration with Dr. Judith 
armey, Royal College of Surgeons in Ireland, Education and Research Centre, 
Beaum
.2.4  Flow cytometric analysis 
 
ll Analysis (PCA) system was used for flow 
cytome ic analysis of cells, including cell cycle analysis and apoptosis assays. 
 
 
 6-well plates and allowed to attach overnight.  Treatment 
was added at the specified concentrations and cells were incubated for 3 days.  
Medium
 
 shown are mean cell death values with error bars for standard deviations
 
 
2
 
The hypoxic experiments
H
ont Hospital, Dublin.  Cytotoxicity assays were set up as described in section 
2.2.2 and plates were incubated at 37°C, 5% CO2, 2% O2 in a Thermo Electron 
Corporation cell culture incubator for the relevant time period.  The MTS assay was 
used to calculate cell death as outlined above. 
 
 
2
The Guava® Personal Ce
tr
2.2.4.1 Cell cycle analysis 
Cells were seeded in
 was removed from the cells and retained in a universal tube.  Cells were 
washed with 500 μl trypsin which was removed to the same universal tube.  750 μl 
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trypsin was added to each well and the plate incubated for 10-15 minutes to detach 
the cells.  1 ml medium was added to the wells to stop the action of the trypsin.  The 
cell suspension was removed from the well to the universal tube and was centrifuged 
at 720 g for 5 minutes.  The supernatant was decanted, the cell pellet resuspended in 
PBS and a cell count performed as per section 2.2.1.3.  2 x 106 cells were removed to 
a universal tube and centrifuged at 450 g for 8 minutes with the brake on low.  The 
pellet was resuspended in 1 ml PBS before repeating centrifugation under the same 
conditions.  Half the supernatant was removed and the cell pellet was resuspended in 
the remaining PBS.  Drop-wise, the cell suspension was added to 3 ml ice-cold 70% 
ethanol with vortexing between drops.  The sample was stored at 4°C for a minimum 
overnight incubation.  2 x 105 cells were centrifuged at 450 g for 8 minutes with the 
brake on low, resuspended in PBS, vortexed and allowed to stand for 1 minute.  The 
cells were centrifuged again at 450 g for 8 minutes with the brake on low and 
resuspended in 200 μl Guava® Cell Cycle Reagent.  The suspension was incubated at 
room temperature for 30 minutes, protected from light.  Cells were analysed on the 
Guava® PCA.  Data was analysed using the Multicycle software (Phoenix Flow 
Systems, CA) to determine the cell cycle stages. 
 
2.2.4.2 Apoptosis analysis 
 
Cells were seeded in 6-well plates and allowed to attach overnight.  Treatment 
as added at the specified concentrations and cells were incubated for 3 days.  
Medium
w
 was removed from the cells and retained in a universal tube.  Cells were 
washed with 500 μl trypsin, which was removed to the same universal tube.  750 μl 
trypsin was added to each well and the plate incubated for 10-15 minutes to detach 
the cells. 1 ml medium was added to the wells to stop the action of the trypsin.  The 
cell suspension was removed from the well to the universal tube and centrifuged at 
720 g for 5 minutes.  The pellet was resuspended in 1 ml Guava® Nexin Buffer.  The 
cell suspension was centrifuged at 400 g for 10 minutes at 4°C and the pellet 
resuspended in 1 ml Guava® Nexin Buffer.  A cell count was performed as per section 
2.2.1.3.  2 x 106 cells were centrifuged at 400 g for 10 minutes at 4°C and 
resuspended in 1 ml Guava® Nexin Buffer.  40 μl was removed to an eppendorf tube 
and 5 μl Annexin V-Phycoerythrin (PE) and 5 μl Nexin 7-Amino Actinomycin D (7-
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AAD) added.  This suspension was vortexed briefly and incubated on ice for 20 
minutes, protected from light.  450 μl cold Guava® Nexin Buffer was added to the 
suspension and the sample was analysed on the Guava® PCA.  
 
 
2.2.5 Migration and invasion assays  
d for migration assays and BD BioCoatTM 
atrigelTM Invasion Chambers were used for invasion assays.  Both these chambers 
contain
 
FalconTM cell culture inserts use
M
ed 8 μm pores in a polyethylene terephthalate (PET) membrane.  The cells 
may migrate through the pores from the upper side of the membrane to the lower side.  
Invasion chambers contained an extra coating of MatrigelTM basement membrane 
matrix which the cells must degrade before they can move through the pores.  Both 
assays were carried out in 24-well format.  Figure 2.1 illustrates the arrangement of 
these chambers.  The invasion chambers were stored at -20°C and were brought to 
room temperature for 30 minutes before use.  500 μl serum-free (S0) medium was 
added to each well and the inside of each chamber to re-hydrate the membrane, and 
incubated at 37°C, 5% CO2 for 2 hours.  Cells were treated for 48 hours with a sub-
lethal dose of relevant treatment, trypsinised and counted as described in section 
2.2.1.  750 μl medium containing 20% fetal bovine serum (S20) was added to the 
wells of a BD FalconTM TC Companion Plates (24-well) to act as a chemo-attractant.  
The re-hydration medium was removed from the chamber which was then positioned 
in the companion plate.  5 x 104 cells in 500 μl S0 medium were added to the chamber 
for migration assays and 1 x 105 cells in 500 μl S0 medium were added to the 
chamber for invasion assays.  Relevant treatment was added to the medium in the 
well and in the chamber.  A blank chamber was also used containing medium but no 
cells.  The chambers were incubated at 37°C, 5% CO2 for 24 hours.  Each chamber 
was removed from the 24-well plate, the medium aspirated from within and the cells 
remaining on the top of the membrane removed with a cotton swab dipped in sterile 
PBS.  The cells on the bottom of the membrane were fixed by placing the chamber in 
10% formalin for 10 minutes followed by staining with 0.25% aqueous crystal violet 
for 10 minutes.  The chambers were washed in three consecutive beakers of PBS to 
remove any excess stain and then allowed to dry for 30 minutes in a 37°C oven.  The 
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stain was eluted by soaking in 200 μl 33% glacial acetic acid on a rocking platform 
for 30 minutes.  100 μl was transferred to a 96-well plate and the absorbance read at 
595 nm in a multiwell plate-reader.  100% control chambers were set up using the 
same procedure as above but the cells from the top of the membrane were not 
removed before staining.  The percentage cells migrated/invaded was calculated as 
follows: 
 
  % Migrated/invaded cells = [(ODSample – ODBlank) / (OD100% Control – ODBlank)] x 100 
 
the chambers, mounted on a glass slide and visualised under the microscope.  
Photog
.2.6 Adhesion assays 
d for 3 days, trypsinised and counted as per section 2.2.1.  
 cell suspension was made up to 105 cells per ml and 100 μl aliquoted in triplicate 
into du
.2.7  Colony formation in soft agar assays 
f the soft agar assays.  A solution of 
% noble agar was made up and autoclaved.  467 μl of the 3% sterile noble agar was 
mixed with 1.533 ml S20 medium (yielding a final concentration of 0.7% noble agar), 
 
Following elution of the stain, the membranes were re-stained, removed from
raphs were taken using an Olympus BX51 microscope with an Olympus DP70 
camera attached.   
 
 
2
 
Cells were pre-treate
A
plicate 96-well plates.  The plates were incubated at 37°C, 5% CO2 for 100 
minutes.  The medium and any non-adhered cells were removed from one plate by 
inverting the plate and removing any remaining medium with a pipette.  100 μl 
medium was then added to each well.  20 μl MTS was added to the wells of both 
plates, allowed to develop at 37°C in incubator for 1-4 hours, and the absorbance read 
at 492 nm on the Tecan Sunrise multiwell plate reader.  Results were expressed in 
relation to the 100% control plate – the plate that was not inverted.   
 
 
2
 
Figure 2.2 illustrates the arrangement o
3
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poured quickly into the well of a 6-well plate and incubated overnight at 4°C.  The 
following day, the plates were brought to room temperature.  1.633 ml S20 medium 
was mixed with 267 μl 3% sterile noble agar and vortexed.  Cells were pre-treated for 
3 days, then trypsinised and counted as per section 2.2.1.  100 μl of cell suspension (2 
x 105 cells/ml) was added to the S20/noble agar mix (giving a final concentration of 
0.4% noble agar) and quickly poured on top of the layer plated the previous day.  The 
plate was incubated at 4°C for 5 minutes to set and then placed at 37°C, 5% CO2 
overnight.  2 ml S20 medium was added to each well the following day.  After 
incubation for 10 days, colonies were stained with 1 ml p-iodonitrotetrazolium 
chloride solution (1 mg/ml) and incubated overnight at 37°C, 5% CO2.  Stained 
colonies with a diameter of greater than 100 μm were counted using a graticule 
inserted into the eyepiece of the microscope. 
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Cells
DMEM with 20% FBS
DMEM with 0% FBS
Chamber
24-well plate
Membrane  
 
 
Figure 2.1 Representation of the in vitro migration and invasion assays.  DMEM with 
20% FBS was placed in the well and the pre-treated cells, in DMEM with 0% FBS 
were added to the chamber.  
 
 
 
6-well plate
Cells
DMEM with 0.7% agar
DMEM with 0.4% agar and cells
DMEM with 20% FBS
 
 
 
Figure 2.2 Representation of the colony formation in soft agar assays.  A base layer 
of DMEM with 0.7% noble agar was plated and allowed to solidify overnight.  Cells 
in DMEM with 0.4% agar were plated and incubated overnight.  DMEM with 20% 
FBS was added and the plate was incubated for 10 days. 
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2.2.8  Collection of conditioned medium and RNA from cells 
 
Cells were seeded into 25 cm2 or 75 cm2 flasks and allowed to attach 
overnight at 37°C, 5% CO2.  Cells were treated for 3 days, medium removed and 
replaced with S0 medium – 3 ml for 25 cm2 flask or 5 ml for 75 cm2 flask – and 
incubated for 3-4 hours, 37°C, 5% CO2.  The medium was removed and replaced with 
fresh S0 medium and incubated for 24 hours, 37°C, 5% CO2, then transferred to a 
sterile universal tube and centrifuged at 720 g for 5 minutes.  The supernatant was 
retained and stored at 4°C until analysis as per section 2.2.10.  1ml TRI REAGENTTM 
was added to the cells in the flasks, incubated for 5-10 minutes at room temperature, 
and removed to a sterile eppendorf tube.  This was stored at -80°C for up to a month 
until processing as per section 2.2.9.1. 
 
 
2.2.9  RNA analysis 
 
2.2.9.1 RNA extraction  
 
Samples were removed from the -80°C freezer and allowed to defrost, then 
stored on ice during all subsequent manipulations.  200 μl chloroform was added to 
each tube, shaken for 30 seconds and allowed to stand at room temperature for 15 
minutes.  Samples were centrifuged for 15 minutes at 10,625 g, which resulted in 3 
layers forming.  The top layer contained the RNA and was removed to a fresh sterile 
eppendorf tube, which left the middle layer of DNA and the bottom organic layer 
containing the protein.  500 μl sterile ice-cold isopropanol and 2 μl 5mg/ml glycogen 
was added to the removed RNA layer, allowed to sit at room temperature for 5-10 
minutes, vortexed and incubated overnight at -20°C.  The following day, samples 
were centrifuged for 10 minutes at 10,625 g and the supernatant removed.  The pellet 
was washed with 1 ml 75% ethanol and centrifuged for 5 minutes at 4,150 g.  The 
ethanol was removed and the pellet allowed to air dry at room temperature for 5-10 
minutes.  The pellet was resuspended in 50 μl diethyl pyrocarbonate (DEPC) treated 
water and stored at -80°C.  
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2.2.9.2 Quantification and electrophoresis of RNA 
 
5 μl RNA was added to 495 μl DEPC treated water.  The absorbance was read 
at 260 nm and 280 nm on an Agilent 8453 UV/vis spectrophotometer, using DEPC 
treated water as blank.  The absorbance at 260 nm was used to calculate the 
concentration of RNA in the sample because 40 μg/ml RNA had an absorbance of 1.  
The ratio of 260 nm/280 nm reflected the purity of the sample.  A ratio of 1.8 was 
recommended, a higher ratio indicated protein contamination and a lower ratio 
indicated organic solvent contamination.  The quality of RNA was examined by 
running 1 μg on a 1.2% agarose gel.  1 μg RNA was made up to 5 μl with DEPC 
treated water.  2 μl RNA Sample Loading Dye (containing ethidium bromide) was 
added to each sample, heated to 65°C for 10 minutes to denature the RNA and then 
ran on the gel.  The gel was then visualised using an Ultraviolet Products (UVP) High 
Performance Ultraviolet transilluminator and photographed using Olympus C400 
Zoom digital camera.  Two bands for 28S and 18S subunits should be seen on the gel.  
The 28S band should be approximately twice the intensity of the 18S band if the 
RNA is intact. 
 
2.2.9.3 Reverse transcription 
 
RNA prepared in section 2.2.9.1 was subjected to Deoxyribonuclease (DNase) 
treatment followed by reverse transcription (RT) to yield cDNA.  2 μg RNA was 
made up to 8 μl with DEPC treated water.  1 μl 10X reaction buffer and 1 μl DNase I 
(1 unit) was added to the RNA and incubated at room temperature for 15 minutes, to 
eliminate any DNA remaining in the sample.  1 μl of stop solution (50 mM EDTA) 
was added and the samples were heated to 70°C for 10 minutes in an Eppendorf 
Mastercycler Personal PCR machine.  1 μl Oligo (dT)15 primer (0.5 μg) was added to 
each sample and heated to 70°C for 10 minutes to melt the secondary structures in the 
RNA.  Samples were placed on ice and the following reagents added, giving a total 
volume of 20 μl: 
 
o 4 μl 5X MMLV-RT Buffer  
o 1 μl dNTP Mix (giving final concentration of 0.5 mM) 
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o 2 μl DEPC treated water  
o 1 μl MMLV-RT (200 units) 
 
The samples were incubated at 37°C for 1 hour for cDNA synthesis followed by 2 
minutes at 95°C in Eppendorf Mastercycler Personal PCR machine.  Samples were 
stored at 4°C until required for PCR analysis. 
 
 
2.2.9.4 Polymerase chain reaction 
 
For polymerase chain reaction (PCR) amplification, 5 μl RT product was added to the 
following reagents: 
 
o 34.5 μl sterile water 
o 5 μl 10X reaction buffer 
o 2 μl MgCl2 (giving final concentration of 1 mM) 
o 1 μl dNTP Mix (giving final concentration of 0.2 mM) 
o 1 μl Forward Primer (100 pmol) 
o 1 μl Reverse Primer (100 pmol) 
o 0.5 μl Taq Polymerase (2.5 units) 
 
Samples were amplified using the following cycle in the PCR machine: 
 
o 1) 95°C   3 minutes   Initial Denaturation 
o 2) 95°C   1 minutes   Denaturation 
o 3) Annealing Temp  3 minutes   Primer Annealing 
o 4) 72°C   3 minutes   Extension 
o 5) 72°C   10 minutes   Final Elongation 
o Steps 2-4 were repeated for 30 cycles before proceeding to step 5 
 
Annealing temperatures varied for different primers and are listed in Table 2.2 
along with the primer sequences and product sizes.  PCR products were run on 
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agarose gels (1-1.5% depending on size of product).  The agarose gels were made up 
using Molecular Probes SYBR SafeTM DNA gel stain.  15 μl PCR products were 
mixed with 3 μl 6X blue/orange loading dye and ran on the gel along with the PCR 
100 bp low ladder.  The gels were visualised using the UVP High Performance 
Ultraviolet transilluminator, photographed using an Olympus C400 Zoom digital 
camera and densitometry analysis performed using the AlphaEaseFCTM Software 
from Alpha Innotech. 
 
 
Table 2.2 Details of primers used for PCR.  
 
58.5°C237 bpForward: TGC CGG TAA TTA CGT GTT CAReverse: ACC TGT TTT GCC ATC CAC TCNTR
58.5°C189 bpForward: TTT GCC TTC CTG TTT TTG CTReverse: ATA ATA CCG CGC CAC ATA GCAmpicillin
64°C341 bpForward: TGC AGC TGC TCC CCG GTG CACReverse: TTA TGG GTC CTC GAT GTC GAGTIMP-2
62°C584 bpForward: CTG TGC CCC ACC CCA CCC ACReverse: AAG GCT TCA GGT CAT CGG GCTIMP-1
61°C467 bpForward: GTA TGG TCG TGG CTC TAA GC Reverse: AAA ACC CTC TTG GTC TGC GG MMP-9
60°C475 bpForward: CCG CCC TGC AGG TCC ACG ACG GCA TReverse: CTG AGA TCT GCA AAC AGG ACA TTG TMMP-2
56°C554 bpForward: TCA GGA GGA GCA ATG ATC TTG AReverse: GAA ATC GTG CGT GAC ATT AAG GAG AAG CTActin
Annealing 
TemperatureProduct SizePrimersGene
 
 
 
 
2.2.10 Analysis of protein levels 
 
2.2.10.1 Concentration and quantification of protein in conditioned medium 
 
Conditioned medium collected in section 2.2.8 was concentrated using 
Amicon® Ultra-4 Centrifugal Filter Device with Ultracel-10 membrane.  The 
conditioned medium was added to the top of the filter unit and centrifuged at 7,500 g 
using a fixed angle rotor for 10-12 minutes until the desired final volume was 
reached.  The concentrated conditioned medium was removed to a fresh eppendorf 
 34
tube and quantified using the Bradford assay.  Bovine serum albumin (BSA) 
standards ranging from 0.2 to 1.4 mg/ml were prepared in water for the standard 
curve.  5 μl of standards and samples was aliquoted in triplicate into a 96-well plate 
along with S0 medium as a blank for the samples.  250 μl Bradford reagent was added 
to each well, the plate covered in tin-foil and incubated at room temperature for 10-40 
minutes.  Absorbance was read at 595 nm and concentration of samples calculated by 
extrapolation from the BSA standard curve.  
 
2.2.10.2 Gelatin zymography 
 
10% 1 mm Novex® pre-cast zymogram gels were used.  Conditioned medium 
samples containing equal amounts of protein were made up to 12.5 μl with sterile 
water and mixed with 12.5 μl 2X Novex® tris-glycine SDS sample buffer and loaded 
on the gel.  Novex® tris-glycine SDS running buffer was used to fill the Scie-Plas 
vertical gel rig and the gel was run at 125 V until the dye front reached the end of the 
gel.  After electrophoresis, the gel was washed with Novex® zymogram renaturing 
buffer for 30 minutes, then Novex® zymogram developing buffer for 30 minutes and 
finally incubated with fresh Novex® zymogram developing buffer for 24 hour and 
stained with Coomassie blue stain [0.5% (w/v) Coomassie Brilliant Blue in acetic 
acid:isopropanol:H2O (1:3:6, v/v/v)].  After de-staining with acetic 
acid:isopropanol:H2O (1:3:6, v/v/v), clear bands appeared against the blue gel, 
corresponding to degradation of gelatin in the position of a gelatinase enzyme.  Gels 
were photographed using an Olympus C400 Zoom digital camera and a light box.  
Densitometry analysis was performed using the AlphaEaseFCTM Software from 
Alpha Innotech.  Baby Hamster Kidney (BHK) conditioned medium was used as 
control.  This cell line constitutively expressed MMP-2 and was transfected with the 
cDNA for human MMP-9. 
 
2.2.10.3 Reverse zymography 
 
Reverse zymography was used to investigate the levels of TIMP proteins in 
conditioned medium samples.  The gels were made as follows: 
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Resolving gel: 
 
o 2.5 ml buffer A (1.5 M Tris-HCl, pH 8.8; 0.4% (w/v) SDS) 
o 2.5 ml 3 mg/ml gelatin stock  
o 5 ml 30% acrylamide stock 
o 1 ml BHK medium 
o 100 μl 10% ammonium persulphate 
o 20 μl TEMED 
 
Stacking gel: 
 
o 0.8 ml buffer B (0.5 M Tris-HCl, pH 6.8; 0.4% SDS) 
o 0.5 ml 30% acrylamide stock 
o 2 ml distilled water 
o 50 μl 10% ammonium persulphate 
o 20 μl TEMED 
 
The resolving gel ingredients were mixed and poured.  Once this had set, the stacking 
gel was added, the comb inserted and allowed to set.  Conditioned medium samples 
containing equal amounts of protein were made up to 12.5 μl with sterile water and 
mixed with 12.5 μl 2X Novex® tris-glycine SDS sample buffer and loaded on the gel.  
Novex® tris-glycine SDS running buffer was used to fill the Scie-Plas vertical gel rig 
and the gel was run at 125 V until the dye front reached the end of the gel.  After 
electrophoresis, the gel was washed with Novex® zymogram renaturing buffer for 30 
minutes, then Novex® zymogram developing buffer for 30 minutes and finally 
incubated with fresh Novex® zymogram developing buffer for 48 hours and stained 
with Coomassie blue stain.  After de-staining with acetic acid:isopropanol:H2O 
(1:3:6, v/v/v), blue bands appeared against the clear gel, corresponding to bands of 
TIMPs where the gelatin had not been degraded by the MMPs in the BHK medium.  
TIMP recombinant proteins were used as positive controls.  Gels were photographed 
using an Olympus C400 Zoom digital camera and a light box.  Densitometry analysis 
was performed using the AlphaEaseFCTM Software from Alpha Innotech. 
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2.2.10.4 Western blotting 
 
NuPAGETM Novex 4-12% Bis-Tris gels were used for western blotting.  
Conditioned medium samples containing equal amounts of protein were made up to 
16.25 μl with sterile water and mixed with 6.25 μl NuPAGETM 4X Lithium Dodecyl 
Sulphate (LDS) sample buffer and 2.5 μl NuPAGETM Reducing Agent, heated to 
65°C for 10 minutes and loaded on the gel.  Sigma ChemichromeTM western control 
was used as a ladder and positive control for transfer and detection.  Following 
vertical electrophoresis, the proteins on the gel were transferred to a nitrocellulose 
membrane using horizontal electrophoresis.  This involved putting the gel into a gel 
cassette sandwich as follows: sponge - 2 x filter paper – gel - nitrocellulose - 2 x filter 
paper - sponge.  The proteins were transferred for 1 hour in a Bio-Rad Mini 
PROTEAN 3 cell wet transfer apparatus with an ice block to maintain a low 
temperature and with a magnetic stirrer to keep the temperature constant throughout 
the apparatus.  The membrane was stained with MemCodeTM reversible protein stain 
kit and photographed.  This involved rinsing the membrane with ultrapure water, then 
incubating with the stain for 30 seconds.  The membrane was rinsed three times with 
De-stain solution and incubated for 5 minutes in the De-stain solution.  The 
membrane was rinsed four times with ultrapure water and agitated for 5 minutes in 
ultrapure water, then photographed using an Olympus C400 Zoom digital camera and 
a light box.  The Eraser solution was added to the membrane and agitated for 2 
minutes until the stain was removed.  The membrane was rinsed four times and 
agitated for 5 minutes in ultrapure water.  The nitrocellulose membrane was then 
washed with blocking solution (5% dried milk in Tris Buffered Saline with Tween – 
TBST [1 mM Tris pH 8.0, 150 mM NaCl, 0.05% Tween]) for 2 hours at room 
temperature on a rocking platform.  The primary antibody was added in 5 ml TBST 
and incubated overnight at 4°C on a rocking platform.  The membrane was washed 
three times for 10 minutes with TBST and incubated with the secondary antibody in 5 
ml TBST for 2 hours at room temperature on a rocking platform.  This was followed 
by three 10 minute washes with TBST and development with Pierce Supersignal 
Enhanced Chemiluminescence (ECL) Kit.  500 μl of Pierce Supersignal® west pico 
luminol/enhancer solution was mixed with 500 μl Pierce Supersignal® west pico 
stable peroxide solution and added to the membrane.  A piece of Amersham 
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Biosciences hyperfilm was applied to the nitrocellulose membrane in a dark room.  
The film was exposed for a certain length of time and then developed using the Hyper 
Processor (Amersham Pharmacia Biotech).  The ChemichromeTM Western Control 
contains ColourburstTM markers and a band of mouse IgG, which binds the primary 
and secondary antibodies and thus reacts with the ECL reagents and appears as a band 
on the film when exposed.  The films were photographed using an Olympus C400 
Zoom digital camera and a light box.  Densitometry analysis performed using the 
AlphaEaseFCTM Software from Alpha Innotech. 
 
 
2.2.11 Nitroreductase enzyme assays 
 
2.2.11.1 Enzyme assays 
 
The substrates, CB1954 and the 5-FU derivatives, were dissolved in 50 mM 
sodium phosphate buffer (pH 7.0) and stored at -20°C.  The co-factor, nicotinamide 
adenine dinucleotide (NADH), was dissolved in 0.01 M Tris buffer (pH 8.5) to 10 
mg/ml (13.5 mM), aliquoted and stored at -80°C.  The nitroreductase (NTR) enzyme 
was dissolved in sterile water to 1 mg/ml, aliquoted and stored at -20°C.  The enzyme 
reactions were carried out in 96-well plates in 50 mM sodium phosphate buffer with 
the following components: 500 μM NADH, 3 μg/ml NTR and varying concentrations 
of substrate (CB1954 or 5-FU derivatives).  After addition of the enzyme, the 
absorbance was read at 340 nm using the Tecan Sunrise multiwell plate reader and 
the plate was incubated at 37°C.  Absorbance at 340 nm was read every 5 minutes for 
1 hour.   
 
2.2.11.1.1 Enzyme kinetics studies 
 
Enzyme kinetics of the compounds was analysed using the Lineweaver-Burk, 
Hanes-Woolf and Eadie-Hofstee plots, as well as the non-linear regression software 
Enzfitter (Elsevier Biosoft) to calculate the Michaelis constant (Km) and maximum 
velocity (Vmax).  Determination of kcat was then calculated from the equation:  
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  kcat = Vmax / Et 
 
where Et was the total enzyme, and was calculated as follows: 
 
Concentration used in reaction (g.ml-1) / Molecular weight (g.mole-1) = Et (mole.ml-1) 
 
For these experiments, 3 μg/ml enzyme was used, with molecular weight of 24,000 
g.mole-1.  Thus: 
 
Et (mole.ml-1) = 3 x 10-6 g.ml-1/ 24,000 g.mole-1 = 1.25 x 10-10 mole.ml-1  
 
 
2.2.11.2 Enzyme assays using cell lysates 
 
Cells were trypsinised and centrifuged as per section 2.2.1.2 and frozen.  500 
μl lysis buffer (PBS containing 1% IGEPAL, 1% protease inhibitor cocktail) was 
added to frozen cell pellets, thawed at 37°C, pipetted up and down, incubated for 5 
minutes at -80°C and thawed at 37°C, pipetted up and down.  Samples were 
centrifuged at 12,500 g for 3 minutes and supernatant retained for assay.  Total 
protein in the samples was quantified using the Bradford assay as outlined in section 
2.2.10.1.  The supernatant was concentrated when required using the Amicon® Ultra-
4 Centrifugal Filter Device with Ultracel-10 membrane.  An aliquot of the 
supernatant was added to a 96-well plate containing 200 μM substrate (CB1954 or 5-
FU derivatives) and 500 μM co-factor, NADH, in 50 mM sodium phosphate buffer, 
pH 7.0.  Absorbance at 340 nm was read upon addition of supernatant and every 5 
minutes after incubation for 2 hours. 
 
2.2.11.2.1 Specific activity 
 
Specific activity (Units/mg) of the sample was calculated using the equations:  
 
   1) A340nm = ε.c.l     Beer Lambert Law 
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A = Absorbance  
ε: Molar absorption co-efficient of NADH, 6.3 x 103 mole-1 cm-1
c: Concentration moles/L 
l: path length 
 
2) 
Specific Activity  = 
Change in concentration over time x Volume of solution in well
Volume of original sample x Concentration total protein  
 
Specific activity is expressed as Units/mg, with 1 Unit equivalent to 1 μmol.min-1. 
 
 
2.2.12 Liquid chromatography-mass spectrometry (LC-MS) 
 
2.2.12.1 Sample preparation for LC-MS 
 
Compound 13 was diluted in fresh medium to a concentration of 75 μM.  An 
aliquot was frozen immediately and another aliquot incubated for 5 days at 37°C and 
then frozen.  Compound 13 in medium was added to the V79-C and V79-NTR cells 
and incubated for 5 days before removal to a universal and storage at -20°C for 
analysis.  
 
2.2.12.2 Sample analysis by LC-MS 
 
Solvents for extraction were HPLC grade; LC-MS solvents and water were 
LC-MS grade.  The following solutions were added to 50 μl of sample in order: 20 μl 
of 1% phosphoric acid, 250 μl of acetonitrile followed by mixing on a vortex for 
several seconds and finally 1 ml of ethyl acetate with further vortex mixing.  The tube 
was then centrifuged at 12,500 g in a microfuge to pellet non-dissolved components 
and clarify the liquid layers.  1.2 ml of the solvent mixture was evaporated by vacuum 
drying on a Heto Holten Maxi-prep system.  The sample was reconstituted in 40 μl of 
LC mobile phase and 20 μl was injected automatically using the instrument 
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autosampler.  Analysis of levels of compound 13 and 5-FU was performed by LC-MS 
using a GE Healthcare MDLC system coupled to Thermo Scientific LTQ hybrid 
Mass Spec detector.  Chromatographic conditions: A Thermo Scientific Hypercarb 
LC column was employed with a 5 μm particle size and 100x 2.1 mm dimensions. 
The LC mobile phase consisted of two components, 0.1% formic acid and 100% 
acetonitrile.  A gradient elution methodology with a 300 μl/minute flow-rate was 
employed.  Each chromatographic run began with 89% formic acid, 11% acetonitrile.  
This rose to 100% acetonitrile in a linear gradient over 6 minutes.  At 11 minutes the 
gradient switched back to 11% acetonitrile over 1 minute and flow continued for a 
further 3 minutes to give a total run time of 15 minutes.  Mass spectral conditions: 
Analysis was performed in negative ion mode.  The detector was tuned individually 
to 5-FU and to compound 13 using direct infusion.  With the resulting tune methods, 
tune method 1 (5-FU) was used for the first 7.5 minutes of analysis and switched to 
the tune method 2 (compound 13) for the remainder of the analysis.  Data on the ions 
from 100 to 350 Da was collected. 
 
 
2.2.13 Plasmid DNA preparation 
 
All bacterial work was carried out using aseptic technique in a Gelman 
Sciences Australia Laminar Flow hood.   
 
2.2.13.1 Transformation 
 
F179 and F184 DNA plasmids were supplied on sterile discs of filter paper.  
See Appendix A for plasmid maps.  Each disc was transferred to a sterile eppendorf 
tube, 10 μl sterile Tris-EDTA (TE) buffer added and incubated overnight at 4°C.  The 
tube was centrifuged and the TE removed to a fresh sterile eppendorf tube.   
 
Luria-Bertrani (LB) broth was prepared by adding the following to 1 L of water:   
 
o 10 g Bacto-tryptone 
o 5 g Bacto-yeast extract 
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o 10 g NaCl 
 
The pH was adjusted to 7.5 with NaOH and the solution autoclaved. After allowing 
the LB broth to cool to 55°C, ampicillin was added to a final concentration of 100 
μg/ml.  LB agar plates were made using LB broth, as above, with 15 g yeast agar 
added before autoclaving.  Ampicillin was added, to a final concentration of 100 
μg/ml,  after cooling to 55°C and approximately 20 ml was poured into 100 mm petri 
dishes, allowed to set and stored inverted at 4°C for up to a month.   
An aliquot of MAX Efficiency® DH5αΤΜ competent cells was thawed on ice 
and 2 μl (1 μg) plasmid DNA added.  The tube was mixed by tapping gently, placed 
on ice for 30 minutes and transferred to a water bath at 42°C for 45 seconds to heat-
shock the cells.  The tube was placed back on ice for 2 minutes.  900 μl room 
temperature SOC medium (supplied with the competent cells) was added to the cells 
and incubated in HT Orbital Shaker incubator at 37°C for 1 hour with gentle agitation 
(200 rpm).  5 μl, 10 μl, 100 μl and 300 μl were spread onto LB agar plates, 
containing 100 μg/ml ampicillin, and incubated overnight at 37°C in an inverted 
position.  Three control plates were also set up, one with nothing added, one with just 
SOC medium and one with SOC medium and bacteria which had not been 
transformed with the plasmid DNA.  These were used to confirm the sterility of the 
plates, of the SOC medium and the cytotoxicity of the ampicillin, respectively.   
 
2.2.13.2 Plasmid DNA mini-prep 
 
Upon formation of colonies, a sterile pipette tip was used to transfer bacteria 
from an individual colony to a 25 ml universal tube containing 5 ml LB broth culture 
with 100 μg/ml ampicillin and incubated overnight at 37°C and 200 rpm.  A control 
was set up with LB broth but no cells added.  These cultures were used to prepare the 
plasmid DNA using the Novagen SpinPrepTM Plasmid Kit.  1.5 ml culture was 
transferred to a sterile eppendorf tube and centrifuged at 7,500 g for 1 minute.  The 
pellet was resuspended fully in 100 μl resuspension buffer and vortexed gently.  200 
μl lysis buffer was added, mixed by gentle inversion and the sample incubated for 5 
minutes at room temperature.  400 μl neutralisation buffer was added, the tubes 
inverted gently and centrifuged for 10 minutes at 14,500 g.  650 μl supernatant was 
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added to the filter unit, positioned in a receiver tube, and centrifuged at 14,500 g for 
30 seconds.  The flow-through was discarded, 650 μl wash buffer added and 
centrifuged for 30 seconds at 14,500 g.  The flow-through was again discarded, the 
filter and tube centrifuged for 2 minutes at 14,500 g and the filter transferred to an 
eluate receiver tube.  30 μl pre-warmed elute buffer was added to the filter, incubated 
for 3 minutes at 50°C and centrifuged for 1 minute at 14,500 g.  This step was 
repeated for maximum yield.  The elution was stored at 4°C until digestion.  
 
2.2.13.3 Plasmid DNA digestion 
 
To confirm the presence of the plasmid, enzymatic digestion was performed 
by making the following mixture: 
 
o 5 μl Elution 
o 2 μl 10X Reaction buffer 
o 1 μl Restriction enzyme 
o 12 μl Sterile water 
  
If a double digest was performed i.e. two restriction enzymes, 1 μl of each was added 
and the amount of water reduced accordingly.  This mixture was incubated in a 37°C 
water bath for 3 hours.  5 μl of digested sample was mixed with 1 μl 6X blue/orange 
loading buffer and ran on a 1% agarose gel made with Molecular Probes SYBR 
SafeTM DNA gel stain, along with 2.5 μl of the undigested plasmid and 10 μl 1 kb 
DNA ladder.  The gels were visualised using the UVP High Performance Ultraviolet 
transilluminator, photographed using Olympus C400 Zoom digital camera.  Eco RI 
restriction enzyme was used to digest F179 plasmid and Bam HI and Xho I restriction 
enzymes were used to digest F184.   
 
2.2.13.4 Plasmid DNA maxi-prep 
 
Following confirmation of the presence of the plasmid by restriction enzyme 
digest, the culture volume was increased to obtain higher yields of plasmid DNA.  
400 μl of culture from the mini-prep was added to 100 ml LB broth and incubated 
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overnight at 37°C, 200 rpm.  The Qiagen Maxi-prep kit was used to purify the 
plasmid DNA.  Bacterial cells were harvested by centrifugation at 6,000 g for 15 
minutes at 4°C in Beckman CoulterTM AllegraTM 64R Centrifuge.  The supernatant 
was drained from the tubes and the pellets resuspended in 10 ml resuspension buffer 
containing RNase A.  10 ml lysis buffer was added, mixed by inversion and incubated 
at room temperature for 5 minutes.  10 ml chilled neutralisation buffer was added, 
mixed by inversion and incubated on ice for 20 minutes, followed by centrifugation at 
10,000 g for 45 minutes at 4°C.  The supernatant was removed to a fresh tube and 
again centrifuged at 10,000 g for 30 minutes at 4°C.  The supernatant was added to 
the Qiagen-tip 500, which had been equilibrated and washed with proprietary buffers.  
The DNA was eluted into a fresh universal tube with 15 ml elute buffer.  10.5 ml 
isopropanol was added to precipitate the DNA and centrifuged at 10,000 g for 45 
minutes.  The pellet was washed with 5 ml 70% ethanol and centrifuged at 10,000 g 
for 45 minutes at 4°C.  The supernatant was carefully removed and the pellet allowed 
to air dry for 5-10 minutes.  50 μl TE buffer, pH 8.0, was used to dissolve the DNA.  
Plasmid digests were carried out as described in section 2.2.13.3. 
 
2.2.13.5 Quantification of plasmid DNA 
 
5 μl plasmid DNA suspension was added to 495 μl sterile water.  The 
absorbance was read at 260 nm and 280 nm on an Agilent 8453 UV/vis 
spectrophotometer, using sterile water as blank.  The absorbance at 260 nm is used to 
calculate the concentration of DNA in the sample as 50 μg/ml DNA has an 
absorbance of 1.   The ratio of 260 nm/280 nm reflects the purity of the sample.  A 
ratio of 2 is recommended.   
 
2.2.13.6 Glycerol stocks of transformed bacteria 
 
800 μl of freshly grown culture was added to 200 μl sterile 50% glycerol 
stock and 200 μl aliquots added to sterile eppendorf tubes which were stored at -
80°C. 
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2.2.14 Transfection 
 
2.2.14.1 β-galactosidase transfection 
 
Transfection of the HCT116 cell line with the plasmid pCH110, containing 
the lac Z gene, was performed to determine transfection efficiency.  See Appendix A 
for plasmid map of pCH110.  1.3 x 106 cells were seeded in a 25 cm2 flask and 
allowed to attach overnight.  20 μl GeneJuice® Transfection Reagent was added drop-
wise to 300 μl DMEM (with no supplements), vortexed and incubated at room 
temperature for 5 minutes.  10 μg pCH110 was added to this solution and mixed by 
gentle pipetting, giving a DNA (μg):GeneJuice® (μl) ratio of 1:2.  This mix was 
incubated for 15 minutes at room temperature.  Medium was removed from the flask 
and cells washed with 3 ml sterile PBS.  3 ml medium (with additives) was added to 
the flask and the DNA/GeneJuice® mix was added drop-wise and incubated at 37°C, 
5% CO2 for 4 hours.  3 ml fresh medium was added and incubated for 48 hours at 
37°C, 5% CO2.  The medium was aspirated and the cells rinsed twice with 3 ml sterile 
PBS.  3 ml fix solution (0.2% glutaraldehyde, 0.1 M phosphate buffer pH 7.3, 5 mM 
EGTA pH 8, 2 mM sterile MgCl2) was added and incubated for 10 minutes at room 
temperature, this step was repeated twice.  3 ml rinse solution (0.1 M phosphate 
buffer pH 7.3, 2 mM sterile MgCl2, 0.24 mM sodium deoxycholate, 40 μl IGEPAL) 
was added and incubated for 10 minutes at room temperature, this step was repeated 
twice.  1.5 ml stain solution (1 mg/ml X-gal, 1.65 mg/ml potassium ferricyanide and 
1.65 mg/ml potassium ferrocyanide in 10 ml rinse solution) was added and incubated 
overnight at 37°C.  In cells containing the plasmid, production of the β-galactosidase 
protein from the lac Z gene caused the cells to turn blue in the presence of the 
substrate, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal).  Stain solution 
was aspirated and the cells were rinsed twice with 3 ml rinse solution.  3 ml sterile 
PBS was added.  Blue and clear cells were counted in 10 fields using the microscope 
and transfection efficiency calculated as follows:   
 
(No. blue cells/Total no cells (blue and white))*100 
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Photographs were taken using an Olympus BX51 microscope with an 
Olympus DP70 camera attached.  The flask was stored at 4°C after replacing the PBS 
with 3 ml 10% glycerol. 
 
2.2.14.2 Nitroreductase transfection 
 
HCT116 cells were transfected with F179, the control plasmid, and F184, the 
plasmid containing the cDNA for E.coli nitroreductase enzyme.  1.3 x 106 cells were 
seeded in a 25 cm2 flask and allowed to attach overnight.  20 μl or 50 μl GeneJuice® 
Transfection Reagent was added drop-wise to 300 μl DMEM (with no supplements), 
vortexed and incubated at room temperature for 5 minutes.  10 μg plasmid DNA was 
added to this solution and mixed by gentle pipetting, giving a DNA (μg):GeneJuice® 
(μl) ratio of 1:2 and 1:5.  This mix was incubated for 15 minutes at room temperature.  
Medium was removed from the flask and cells washed with 3 ml sterile PBS.  3 ml 
medium (with additives) was added to the flask and the DNA/GeneJuice® mix was 
added drop-wise and incubated at 37°C, 5% CO2 for 4 hours.  A control flask which 
was not transfected was also set up.  In the 1:2 ratio flasks, 3 ml fresh medium was 
added, while in the 1:5 flasks, the medium was removed and replaced with 5 ml fresh 
medium.  The flasks were incubated for 48 hours at 37°C, 5% CO2.  The medium was 
aspirated, replaced with fresh medium containing 2 μg/ml puromycin dihydrochloride 
and incubated at 37°C, 5% CO2.  The medium was replenished every 2-3 days until a 
stably transfected cell line was established.  All cells in the control flask died after 1-2 
weeks treatment with puromycin dihydrochloride.  
 
2.2.14.3 DNA extraction using proteinase K 
 
To confirm the presence of the plasmid in the transfectants, DNA was 
extracted and PCR performed.  Medium was removed from a confluent flask of cells 
and rinsed twice with 5 ml sterile PBS.  1 ml sterile PBS was added and a sterile cell 
scraper used to detach the cells from the bottom of the flask.  The cell suspension was 
transferred to a sterile eppendorf tube and centrifuged at 665 g for 5 minutes.  The 
pellet was resuspended in 100 μl PCR lysis buffer (100 μl 10X PCR buffer, 891 μl 
sterile water, 4.5 μl IGEPAL, 4.5 μl Tween 20).  1 μl proteinase K was added to the 
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resuspended cells and incubated at 65°C for 10 minutes.  The solution was pipetted 
up and down, 1 μl proteinase K added and incubated at 65°C for 50 minutes, followed 
by incubation at 95°C for 10 minutes to inactivate the proteinase K.  The solution was 
centrifuged at 10,625 g for 5 minutes and the supernatant removed to a fresh tube and 
stored at 4°C.  The DNA was quantified and 1 μg used for amplification in PCR as 
described in section 2.2.9.4.   
 
 
2.2.15 SDS gel electrophoresis of cell extracts 
 
A NuPAGETM Novex 4-12% Bis-Tris gel was used for the SDS gel 
electrophoresis.  Protein samples from cell pellets were made up to 16.25 μl with 
sterile water and mixed with 6.25 μl NuPAGETM 4X LDS sample buffer and 2.5 μl 
NuPAGETM Reducing Agent, heated to 65°C for 10 minutes and loaded on the gel.  
NuPAGETM 2-(N-morpholino) ethane sulfonic acid (MES) SDS buffer was used to 
fill the Scie-Plas vertical gel rig and the gel was run at 125 V until the dye front 
reached the end of the gel.  Recombinant NTR protein was used as a positive control.  
The gel was stained with Coomassie blue stain and de-stained in water.  Blue protein 
bands were visible against a white background.  Gels were photographed using an 
Olympus C400 Zoom digital camera and a light-box. 
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Chapter 3 
 
Evaluation of the biological effects of conjugated linoleic 
acid on murine mammary and human breast cancer cell 
lines 
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3.1 Introduction 
 
3.1.1 Fatty acids and cancer 
 
Fatty acids are the simplest form of lipids.  Polyunsaturated fatty acids 
(PUFAs) are fatty acids with two or more carbon-carbon double bonds, of which 
there are four families: n-3, n-6, n-7 and n-9.  The nomenclature refers to the position 
of the first double bond from the methyl end of the molecule (Jiang et al., 1998).  The 
metabolism of n-3, n-6 and n-9 PUFA families is shown in Figure 3.1.  Desaturases, 
referred to as ∆4/5/6, introduce double bonds into the molecules while elongation of 
the carbon chain is carried out by elongases (Jiang et al., 1998).  The ∆4/5/6 
nomenclature refers to the position at which the double bond is introduced – for 
example ∆4 desaturase will introduce a double bond between carbon atoms 4 and 5 
from the carboxyl end (Rose and Connolly, 1999).  There is competition between the 
desaturases that act on the n-3, n-6 and n-9 fatty acids.  The n-3 fatty acids have the 
greatest affinity for these enzymes followed by the n-6 family, and so the ratio of n-
3:n-6 fatty acids in the diet will determine metabolism along these pathways (Rose 
and Connolly, 1999 and Das, 2006).   
The essential fatty acids (EFAs) linoleic acid (LA) and α-linolenic acid 
(ALA) cannot be synthesised within the human body and so they must be consumed 
in the diet (Jiang et al., 1998).  LA is the most abundant PUFA in the western diet and 
is found mainly in cereals, eggs, poultry, vegetable oils, whole-grain breads, 
margarines and baked goods (Whelan and McEntee, 2004 and Das, 2006).  ALA is 
found in canola, flaxseed, linseed and rapeseed oils; walnuts and leafy green 
vegetables.  The average daily intake of EFAs in Europe and the US is 7-15 g/day 
(Das, 2006).  LA and ALA play a role in providing energy to the body, form part of 
cellular membranes and can also be converted to eicosanoids.  Eicosanoids are 
derived from dihomo-γ-linolenic acid (DGLA), arachadonic acid (AA) and 
eicosapentanoic acid (EPA).  They include prostaglandins, thromboxanes and 
leukotrienes, which are chemical transmitters for a variety of intercellular and 
intracellular signals (Rose and Connolly, 1999).   
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Figure 3.1 PUFA metabolism of n-3, n-6 and n-9 families.   
 
The relationship between fatty acids and cancer has been the subject of 
intensive research and debate over several decades.  Studies involving women who 
migrated from Japan to the United States reported an increase in breast cancer risk 
after just one generation in the United States.  This was thought to be the result of the 
dietary fat differential between these societies (Rose and Connolly, 1999).  Western 
society tends to have a higher intake of n-6 fatty acids, particularly LA (Stoll, 1998).  
Hubbard et al. (1998) used fish oil and safflower oil – rich in n-3 and n-6 fatty acids 
respectively – to investigate the effects on murine mammary tumourigenesis.  The 
fish oil diet resulted in longer latency and slower growth of tumours, as well as 
decreased primary nodules and total metastatic load in spontaneous metastasis 
models, indicating a significant effect of the n-3 fatty acids in fish oil on primary 
breast cancer growth and metastasis (Hubbard et al., 1998).  There is also some 
argument that it is not the total consumption of fats but the balance between types of 
fats that is important, with a diet richer in n-3 fats having more beneficial effects 
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(Greenwald, 1999).  Maillard et al. (2002) examined the levels of fatty acids in breast 
adipose tissue of 241 patients with invasive, nonmetastatic breast carcinoma and 88 
patients with benign disease.  They found an inverse correlation between the ratio of 
n-3/n-6 fatty acids and breast cancer risk, with a p-value of 0.00002.  Fatty acids have 
been reported to have similar effects in colorectal cancer (Whelan and McEntee, 
2004).  
 
 
3.1.2 Conjugated Linoleic Acid 
 
Conjugated Linoleic Acid (CLA) is a term used to describe a group of 
positional and geometric isomers of LA (Figure 3.2) (Pariza et al., 2000).  The double 
bonds in CLA are conjugated or contiguous i.e. they are not separated by a methyl 
group as in LA.  The double bonds are found at positions 7 and 9, 8 and 10, 9 and 11, 
10 and 12, 11 and 13 or 12 and 14, and each double bond can be in either the cis (c) 
or trans (t) configuration (Lee et al., 2005).  The variation between the position and 
configuration of the double bonds gives rise to numerous different isomers (Lee et al., 
2005).  It has been suggested that only a few of these isomers are biologically active 
(Hubbard et al., 2003).   
The major naturally occurring dietary isomer is cis-9, trans-11 (c9,t11-CLA), 
also called rumenic acid (Pariza et al., 2000 and Belury, 2002a).  After c9,t11-CLA, 
the major isomers found in food rank as follows: t7,c9-CLA > 11,13-CLA (c/t) > 
8,10-CLA (c/t) > trans10,cis12-CLA (t10,c12-CLA) > other isomers (Belury, 2002a).  
Commercial preparations of CLA contain mainly the c9,t11-CLA and the t10,c12-
CLA isomers in equal amounts and thus they have been the most extensively studied 
isomers (Wahle et al., 2004).  In this thesis, the term ‘CLA’ refers to a mixture of 
isomers, while properties relating to the individual isomers will be specified.   
CLA is found in meat and dairy products from ruminant animals, which 
includes sheep and cows.  The c9,t11-CLA isomer is produced by microbial 
biohydrogenation of LA and ALA by rumen bacteria (Miglietta et al., 2006a and 
Roche et al., 2001).  Linoleate isomerase converts LA into c9,t11-CLA, which is then 
absorbed (Figure 3.3).  c9,t11-CLA can also be converted to vaccenic acid in the 
rumen and then reverted back to CLA by desaturase enzymes in mammalian cells 
(Pariza et al., 2000 and Bauman et al., 1999).   
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Linoleic acid
c9, t11-CLA
t10, c12-CLA
 
 
Figure 3.2 Structure of t10,c12-CLA, c9,t11-CLA and LA. From Pariza et al., 2001.  
 
 
Linoleic Acid
cis-9,cis-12 C18:2
CLA
cis-9,trans-11 C18:2
Isomerisation
Vaccenic Acid
trans-11 C18:1
Reduction Desaturase
(In tissues)
 
 
Figure 3.3 Production of c9,t11-CLA from LA and vaccenic acid.  Adapted from 
Bauman et al., 1999.  
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The c9,t11-CLA isomer accounts for approximately 90% of the total CLA 
content in dairy products (O’Shea et al., 1998).  CLA content in food varies from 0.2 
mg/g in corn and peanut oils, 17 mg/g in beef and 30 mg/g in milk-fat (O’Shea et al., 
1998).  CLA levels in milk can vary depending on the type of feed given to the cows, 
with forage and grain reducing CLA levels in comparison to milk from pasture-
grazing animals.  Seasonal variation also occurs with lower levels in spring than in 
summer (Roche et al., 2001).   
CLA was first identified as an anticarcinogen in fried ground beef (Ha et al., 
1987).  Since then, CLA has also been shown to exert beneficial effects against 
atherosclerosis, diabetes and obesity (Wahle et al., 2004 and Belury, 2002b).  For this 
reason, there has been widespread interest in CLA as a functional food, defined as a 
food ingredient that provides beneficial effects beyond the traditional nutrients it 
contains (Bauman et al., 1999).  While early research analysed the effect of a mixture 
of CLA isomers, recent studies have also included the individual isomers and have 
shown that they can work through different cell signalling pathways and have 
different effects on cell functions and metabolism (Wahle et al., 2004).   
 
 
3.1.3 Effect of CLA on mammary tumourigenesis in vivo 
 
Numerous studies have been conducted using rats to determine the effect of 
CLA on mammary tumourigenesis.  Details of the experiments discussed in this 
section are outlined in Table 3.1.  The anti-cancer properties of CLA in mammary 
cancer were first investigated by Ip et al. (1991).  This was also the first report to look 
at cancer prevention using a dietary form of CLA.  The CLA used was a mixture of 
isomers but contained predominantly c9,t11-CLA/t9,c11-CLA (~42.5%) and t10,c12-
CLA (43%).  Rats were fed CLA, in the form of free fatty acids, starting two weeks 
prior to induction of mammary cancer by treatment with a single dose of dimethyl-
benz(a)anthracene (DMBA).  The rats were maintained on diets supplemented with 
0.5%, 1% or 1.5% CLA until the end of the experiment, thus they were exposed to the 
CLA prior to, during, and after DMBA treatment at 10 mg.  The 1% and 1.5% diets 
produced a statistically significant (p<0.05) reduction in tumour incidence (Ip et al., 
1991).  Investigation of the incorporation of CLA into the mammary tumours showed 
a 20-fold increase of CLA levels in rats fed the 1.5% diet in comparison to the 
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control.  The c9,t11-CLA isomer alone was found to be incorporated into 
phospholipids.  The authors also found that CLA acted as an effective antioxidant in 
the mammary tissues, possibly accounting for the antitumourigenic effect (Ip et al., 
1991).   
In a further study, Ip et al. (1994) decreased the levels of dietary CLA to 0.05-
0.5% and decreased the DMBA dose to 5 mg.  The number of tumours in rats fed a 
diet supplemented with just 0.1% CLA was significantly reduced compared to the 
control (p<0.05).  An experiment was also undertaken to analyse the effect of short-
term CLA exposure on mammary carcinogenesis.  Rats were fed 1% CLA from 
weaning until 1 week after treatment with 10 mg DMBA – a total of 5 weeks.  This 
period covered rat mammary gland maturation to the adult stage, with differentiation 
of the terminal end buds into alveolar buds and lobules.  Feeding with CLA during 
this time period significantly reduced the number of mammary tumours that 
developed, indicating a lasting protection against subsequent cancer risk (Ip et al., 
1994).   
When administering a single carcinogen dose to rats at 56 days of age, Ip et 
al. (1995) narrowed down the requirement of exposure to CLA to 21 – 42 days of age 
in order to reduce tumourigenesis.  Feeding of CLA after treatment with the 
carcinogen only exhibited an anti-cancer effect if the intake was continuous, for both 
carcinogens methylnitrosourea (MNU) and DMBA (Ip et al., 1995 and Ip et al., 
1997).  In order to determine the influence of the amount and composition of total 
dietary fat on the anti-carcinogenic effects of CLA, Ip et al. (1996) looked at varying 
fat sources in rats.  The diets contained either high corn oil (unsaturated fats) or high 
lard (saturated fats) content.  The authors found a reduction in tumour incidence 
following CLA feeding independent of the level of fat in the diet (Ip et al., 1996).   
Thompson et al. (1997) investigated further the timing of CLA exposure, 
comparing a 6-month continuous feeding treatment and a 1-month CLA feeding 
protocol during the period of mammary morphogenesis.  Animals fed 1% CLA from 
weaning (21 days) to 50 days of age (group B), as well as animals fed 1% CLA from 
55 days of age to the termination of the experiment (group C), both showed a 
reduction of approximately 50% in the total number of tumours, when compared to 
the control.  A group of rats exposed to the same level of CLA for the total time 
period i.e. from weaning to termination of the experiment (group D), only showed a 
reduction of approximately 57%.  Thus the effect of the CLA feeding was not 
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additive, suggesting that there may be different mechanisms of inhibition depending 
on the timing of CLA exposure i.e. during mammary gland morphogenesis or during 
tumour progression.  The authors suggested that the small difference observed 
between the effect of CLA on groups B and D may be due to modification, during 
mammary gland maturation, of the development of a subset of target cells.  The CLA-
resistant cells were therefore available for carcinogen targeting.  CLA feeding after 
carcinogen administration, was only effective against the transformed cells that 
originated from the CLA-sensitive progenitors, thus a similar reduction in tumour 
incidence was observed (Thompson et al., 1997).   
In an experiment feeding rats with high CLA butter fat, it was confirmed for 
the first time that CLA in a food form had anti-cancer properties (Ip et al., 1999).  
CLA feeding during pubescent mammary gland development down-regulated 
mammary epithelial growth, decreased the population and proliferative activity of the 
target TEB cells, and therefore reduced mammary cancer risk when the rats were 
challenged with a carcinogen (Ip et al., 1999).   
While I have concentrated here on the effects of CLA on mammary 
tumourigenesis, there have also been extensive studies on the effects in other types of 
cancer.  The earliest work investigating the anti-cancer effects of CLA looked at skin 
carcinogenesis (Ha et al., 1987) and forestomach tumourigenesis (Ha et al., 1990) in 
mice.  Since then, CLA has been shown to inhibit the growth of the HepG2 hepatoma 
cell line (Igarashi et al., 2001), the PC-3 prostate cancer cell line (Palombo et al., 
2002) the colorectal cancer cell lines Caco-2 (Kim et al., 2002), HT-29 and MIP-101 
(Palombo et al., 2002), among others. 
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Table 3.1 Animal studies investigating the effect of CLA on mammary 
tumourigenesis 
Reference Carcinogen CLA Diet Time/Duration of Exposure 
Ip et al., 
1991 
DMBA, 10 
mg, 51 days 
old 
0.5%/1%/1.5% 
 
From 2 wks before DMBA 
administration to end of experiment 
(total 50 wks) 
Ip et al., 
1994 
DMBA 5 
mg, 50 days 
old 
a) 0.05%/0.1%/ 
0.25% /0.5% 
 
b) 1% 
a) From 2 wks before DMBA 
administration to end of experiment 
(total 36 wks) 
b) From 4 wks before DMBA 
administration to 1 wk after (total 5 
wks) 
Ip et al., 
1995 
MNU, 56 
days old 
1%  21 to 42 days of age 
Ip et al., 
1996 
DMBA 7.5 
mg, 50 days 
old 
1% CLA, in a 
background of 
10%/13.3%/16.7%/ 
20% total fat 
From 1 wk before DMBA 
administration to end of experiment 
(total 24 wks) 
Ip et al., 
1997 
DMBA 10 
mg, 50 days 
old 
1% CLA in a 
background of 20% 
corn oil 
From 4 days after DMBA 
administration, for a total of 4 wks/8 
wks or 20 wks 
Thompson  
et al., 1997 
DMBA 10 
mg, 50 days 
old 
A: Control, 0% CLA 
B: 1% CLA 
 
C: 1% CLA 
 
D: 1% CLA 
 
B: From weaning (21 days) to 50 days 
old 
C: From 55 days to end of experiment 
(total 21 wks) 
D: From weaning to end of 
experiment (total 26 wks) 
Ip et al., 
1999 
MNU (50 
mg/kg), 55 
days old 
Control butter fat 
(0.1% CLA in diet) 
High CLA butter fat 
(0.8% CLA in diet) 
23 – 55 days old 
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3.1.4 Mechanisms of anti-cancer activity of CLA 
 
The experiments outlined above focused predominantly on the effects of CLA 
on mammary carcinogenesis in vivo without looking at the changes at the molecular 
level.  Having confirmed the anti-cancer properties of CLA in numerous animal 
studies from various sources of CLA, attention turned to the mechanisms behind this 
activity.  CLA has been reported to decrease the expression of cell cycle proteins 
cyclin D1 and cyclin A in TEBs and alveolar clusters of the mammary epithelium (Ip 
et al., 2001).  In the MCF-7 breast cancer cell line, CLA increased mRNA and protein 
levels of pro-apoptotic p53 and p21WAF1/CIP1 and decreased anti-apoptotic bcl-2 
(Majumder et al., 2002).  In the MDA-MB-231 breast cancer cell line, which 
expressed mutant p53, mRNA levels of p53 were not affected by CLA but protein 
levels were completely suppressed.  p21WAF1/CIP1 and bcl-2 mRNA and protein 
levels were increased.  Bax and bcl-Xs levels were also increased, giving an overall 
ratio of Bax/bcl-Xs to bcl-2 that would promote apoptosis (Majumder et al., 2002).  
These authors did not investigate the effect on growth of these two cell lines 
(Majumder et al., 2002). 
Tanmahasamut et al. (2004) reported growth inhibition by CLA in the ER 
positive cell line, MCF-7, but not in the ER negative cell line, MDA-MB-231, 
indicating a role of ER in this inhibition.  The authors determined that CLA treatment 
downregulated levels of ERα mRNA and protein, and also interfered with binding to 
the estrogen response elements (EREs).  Results also demonstrated that CLA 
activated a peroxisome proliferator response element (PPRE).  The effect of CLA on 
peroxisome proliferators activated receptors (PPARs) was also examined by 
Maggiora et al. (2004).  An increase in PPARα was noted in a number of cell lines 
following CLA treatment, in conjunction with a decrease in PPARβ/δ.   
CLA has also been reported to modulate AA distribution in MCF-7 and 
SW480 cells (Miller et al., 2001).  AA uptake into monoglyceride fractions in MCF-7 
cells was increased after treatment with CLA and the c9,t11-CLA isomer, while 
uptake into triglyceride fractions was increased in the SW480 cell line.  The c9,t11-
CLA isomer caused a decrease in AA incorporation into phosphatidylcholine and an 
increase into phosphatidylethanolamine in both cell lines.  Treatment with CLA and 
t10,c12-CLA isomer resulted in increased AA uptake into the phosphatidylserine 
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fraction in the SW480 cell line.  AA conversion to PGE2 was inhibited by CLA and 
c9,t11-CLA isomer in both cell lines.  Thus CLA and its isomers resulted in changes 
in AA distribution in cellular lipids and also modulated the prostaglandin production 
within cells.   
One possibility regarding the mechanism of action is that CLA derivatives act 
as a distinct set of PUFAs (Figure 3.4) (Banni et al., 2004).  ∆6 desaturase, elongase 
and ∆5 desaturase enzymes are involved in the metabolism of CLA to new 
metabolites, 18:3, 20:3 and 20:4.  The c9,t11-CLA isomer is metabolized easily to the 
20:4 molecule but t10,c12-CLA appears to be resistant to the elongation and 
desaturation to the 20:3 and 20:4 molecules respectively.  CLA would thus compete 
with LA for the desaturase and elongase enzymes of the PUFA pathways, and the 
CLA metabolites could also compete with LA metabolites for lipid incorporation 
(Banni et al., 2004). 
 
 
18:2 (9c,11t)
18:3 (6c,9c,11t)
20:3 (8c,11c,13t)
20:4 (5c,8c,11c,13t)
18:2 (10t,12c)
18:3 (6c,10t,12c)
20:3 (8c,12t,14c)
20:4 (5c,8c,12t,14c)
∆6 Desaturase
∆5 Desaturase
Elongation
 
 
 
Figure 3.4 Distinct conjugated PUFAs derived from c9,t11-CLA and t10,c12-CLA.  
Adapted from Banni et al., 2004.  
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3.1.5 Invasion and metastasis and CLA 
 
Hubbard et al. (2000) were the first group to describe the anti-metastatic 
effects of CLA by using experimental and spontaneous metastasis models in mice.  
Latency was calculated as the time from injection to when tumours reached a volume 
of 8 mm3.  Exposure to 0.5% and 1% CLA for the duration of the experiment 
increased latency significantly.  However the growth of the tumour, as calculated by 
tumour volume, was not altered by the CLA diets (0.1/0.5/1%).  Spontaneous 
metastasis experiments involved implantation of cells from the 4526 mouse 
mammary tumour into the mammary fat pad followed by removal of the primary 
tumour upon reaching a certain volume.  This mimics the clinical course of breast 
cancer progression.  Mice fed 0.1%, 0.5% and 1% CLA had significantly fewer 
pulmonary nodules in comparison to the control.  In experimental metastasis studies, 
tumour cells were injected into the tail vein of the mice but did not result in any 
significant difference in the number of pulmonary nodules.  Tumour burden (the total 
volume of lung nodules per mouse) in these mice was however, significantly 
decreased.  Thus, the authors concluded that CLA not only affected tumour initiation 
and promotion but metastasis as well.   
This group went on to look at the effect of two of the individual CLA isomers, 
c9,t11-CLA and t10,c12-CLA, on murine mammary tumourigenesis (Hubbard et al., 
2003).  Mice were fed diets of 0.1% or 0.25% c9,t11-CLA or t10,c12-CLA or a 
mixed diet containing 0.125% of each isomer.  All diets were found to have no 
significant effect on latency or growth of primary tumours, when compared with the 
control.  For metastasis, there was no significant difference among the different CLA 
diets in the number of pulmonary nodules in the lungs of the mice.  However, 
compared to the control diet, there was a significant difference in the average size of 
nodules in the lungs of mice fed the CLA diets.  The higher concentration of the 
individual isomers had a greater effect on the metastatic nodule size and total tumour 
burden than the lower concentrations.  The mixed CLA diet had a similar effect on 
total tumour burden to the diets containing the lower concentration of the individual 
isomers, thus the anti-cancer effects did not appear to be additive. 
This study (Hubbard et al., 2003) looked more specifically at where along the 
metastasis pathway the CLA effects were exerted – lodgement, survival or growth.  
When compared to the control group, the CLA diets significantly decreased the 
 60
number of cells, which survived and grew as pulmonary nodules.  In all the CLA-fed 
groups, the metastatic tumour burden was significantly decreased compared to the 
control group.  The reasoning for using spontaneous and experimental metastasis was 
to try to determine if the effects of CLA were on early events in the metastatic 
cascade (tumour cell release, entry into bloodstream) or later events (lodgement, 
extravasation and survival).  CLA treatments were consistent in reducing total 
pulmonary tumour burden in both experiments.  This would suggest an effect on 
growth of metastases once they have lodged and survived. 
Harris et al. (2001) looked at the effect of CLA on MMP levels in serum from 
pregnant rats.  The levels of MMP-2 and MMP-9 proteins were shown to be 
decreased in the CLA-fed rats.  Chen et al. (2003) examined the effect of the c9,t11-
CLA isomer on invasion, migration and MMP levels in a human gastric carcinoma 
cell line, SGC-7901.  They reported inhibition of both invasion and migration of cells 
and a corresponding reduction in expression of MMP-9 with an increase in TIMP1 
and TIMP2 mRNA levels.  Kunayasi et al. (2006) found CLA to decrease invasion 
rates of a human gastric cancer cell line, MKN28, and a human colon cancer cell line, 
Colo320.  CLA injections into mice also significantly reduced metastatic foci of both 
cell lines in the peritoneal cavity.  Masso-Welch et al. (2002) investigated the effect 
of CLA on angiogenesis.  Mice fed 1% or 2% CLA for 6 weeks prior to angiogenic 
challenge by Matrigel pellet assay showed significantly decreased functional 
angiogenesis.  The levels of angiogenic inhibition peaked at 1% dietary CLA, with no 
increase observed at 2%.  Levels of vascular endothelial growth factor (VEGF) and 
its receptor, foetal liver kinase-1 (Flk-1/VEGFR-2), were decreased after feeding with 
CLA diets, giving some explanation for the decrease in angiogenesis.  No studies 
have been published to date looking at the effect of CLA or individual isomers on 
MMP levels in breast cancer cell lines.  The effects on invasion, migration and 
angiogenesis illustrate the great potential of using CLA as a multipotent anti-cancer 
agent.   
 
 
3.1.6 Epidemiological studies and CLA 
 
Despite the significant number of investigations into the effect of CLA on 
carcinogenesis and mechanisms of action, few epidemiological studies have been 
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conducted to confirm these effects in humans.  Aro et al. (2000) found an inverse 
association between dietary or serum CLA levels and breast cancer risk in 
postmenopausal women.  This correlation did not however extend to premenopausal 
women.  In contrast, the Netherlands Cohort Study found a weak positive association 
between CLA intake and breast cancer risk in postmenopausal women (Voorrips et 
al., 2002).  Chajes et al. (2002) investigated the levels of CLA in breast adipose tissue 
in relation to breast cancer risk.  No significant association was found between these 
two factors.  In a study looking at the relationship of CLA levels in breast adipose 
tissue and the occurrence of metastatic breast cancer, no significant association was 
found (Chajes et al., 2003).  McCann et al. (2004) examined the correlation between 
breast cancer and the intake of CLA and the c9,t11-CLA isomer.  No association 
between intake and the overall risk of breast cancer was observed in premenopausal 
or postmenopausal women.  In non-breast cancer, the only epidemiology study 
published to date was by Larsson et al. (2005).  They found an inverse correlation 
between CLA intake and colorectal cancer risk in a Swedish Mammography cohort of 
60,708 women.   
 
 
3.1.7 Objectives of Chapter 3 
 
CLA has been reported to have significant effects on tumourigenesis in both 
in vitro and in vivo models.  The aim of this present study was to look at the effects of 
a CLA mix, and the individual isomers, c9,t11-CLA and t10,c12-CLA, on cell 
proliferation of the 4T1 murine mammary cancer cell line and the Hs578T human 
breast cancer cell line.  Apoptosis and cell cycle kinetics were analysed following 
treatment of the 4T1 cell line with LA, CLA, c9,t11-CLA and t10,c12-CLA.  
Modulation of invasion, migration, adhesion and colony formation in soft agar by 
CLA was also examined for the first time in a mammary cancer cell line.  The effects 
of CLA on expression of MMP and TIMP levels in breast or mammary cancer have 
not been analysed previously.  Thus protein and mRNA levels of MMP-2, MMP-9, 
TIMP-1 and TIMP-2 following treatment with CLA was investigated to determine the 
effect on the cells at the molecular level.  
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3.2 Results 
 
The 4T1 murine mammary cancer cell line was chosen for the CLA 
experiments because it can form highly metastatic tumours in BALB/c mice.  
Following mammary fat pad injection, spontaneous metastases develop in the lung, 
liver, lymph nodes and the brain (ATCC and Heppner et al., 2000).  This occurs 
without surgical removal of the primary tumour and is an animal model for stage IV 
human breast cancer.  The 4T1 cell line is also one of very few cell lines, of any 
origin, to form bone metastasis (Heppner et al., 2000).  Using this cell line would 
allow animal studies on the effects of CLA to be conducted in BALB/c mice, 
eliminating the need for nude mice.  In order to analyse the effects of CLA on human 
breast cancer cells, the Hs578T human breast carcinoma cell line was used.  This cell 
line was derived from a 74-year old female and while it formed colonies in semisolid 
medium, it was not tumourigenic in mice (ATCC). 
 
3.2.1 Cytotoxicity assay system 
 
Cytotoxicity can be quantified using a number of different assay systems.  We 
assessed three assays for this work – the MTS assay, the crystal violet assay and the 
acid phosphatase assay, as outlined in section 2.2.2.  The MTS assay contained a 
novel tetrazolium compound [3-(4,5-dimethylthiazol-2yl)-5-(3-
carboxymethoxyphenyl)-2-(4-solfophenyl)-2H-tetrazolium], which was bioreduced 
by cells into a coloured formazan product (Figure 3.5) (Promega Technical Bulletin 
245).  This reaction occurs in the presence of metabolically active cells.  The 
absorbance at 492 nm reflected the level of the coloured product in the well and thus 
the number of metabolically active cells.   
The crystal violet assay involved removal of the medium, washing and fixing 
of the cells before staining with a solution of 0.25% crystal violet.  The crystal violet 
stains chromatin and nucleoli.  The cells can be visualized under the microscope and 
photographed.  The stain was eluted with glacial acetic acid and absorbance read at 
570 nm.  Acid phosphatase is an acid hydrolase found in the lysosome of the cell.  
The acid phosphatase assay is based on the hydrolysis of p-nitrophenyl phosphate 
(pNPP) by acid phosphatases in viable cells to produce p-nitrophenol (Figure 3.6) 
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(Yang et al., 1996).  The production of p-nitrophenol is relative to the number of 
viable cells in the well.  Addition of sodium hydroxide to the well produced a colour 
change due to the conversion of p-nitrophenol to p-nitrophenolate and absorbance 
was read at 405 nm. 
Sample standard curves using each assay to quantify cell numbers are shown 
in Figure 3.7 (A-C).  After comparison of these three assays, it was decided to use the 
MTS assay for the cytotoxicity experiments.  The R2 values for the MTS assay were 
consistently higher than the other two assays.  Another important advantage with this 
assay was the absence of the necessity to remove the medium and wash the cells 
before addition of the substrates or stains.  It was felt that this would introduce 
additional error into the results.  With the MTS assay, the substrate was added direct 
to the medium after the treatment period and the coloured product was soluble in the 
medium.  After incubation the plate was simply read using a plate-reader.   
 
 
 
 
 
Figure 3.5 Conversion of MTS into a formazan product by metabolically active cells.  
From Promega Technical Bulletin 245.  
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Figure 3.6 Reaction of pNPP with acid phosphatases and sodium hydroxide to 
produce p-nitrophenolate in the acid phosphatase assay.  From 
http://www.bio.mtu.edu/campbell.  
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Figure 3.7 Standard curves comparing the MTS (A), crystal violet (B) and acid 
phosphatase (C) assays using the 4T1 cell line after incubation for 3 days. 
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3.2.1.1 Optimisation of cell numbers for cytotoxicity assays 
 
Cytotoxicity assays were optimised with regards to cell numbers.  The cell 
numbers chosen to seed into 96-well plates had to allow the cells to proliferate over 
the specified time period without imposing a limitation on space or medium 
supplements.  Cells were required to be in the logarithmic phase of growth in order to 
confirm that the cell death noted upon treatment was in fact due to the treatment and 
not due to insufficient space or lack of essential medium components.  The 
cytotoxicity was examined after treatment for 1, 3 and 5 days, so a range of different 
cell numbers was examined and optimised over these three time points (Figures 3.8 
and 3.9).  The 4T1 cell line was an extremely fast growing cell line and thus cell 
numbers used were lower than for the Hs578T cell line.  Cell numbers used are 
outlined in Table 3.2.  Cells for treatment were seeded at the second highest point on 
the standard curve.  Having determined the optimum cell numbers and the most 
efficient assay, the cytotoxicity of CLA was examined. 
 
 
 
Table 3.2 Cell numbers seeded into 96-well plates for 1, 3 and 5 day assays for the 
4T1 and Hs578T cell lines.  
 
183060Hs578T
612304T1
5 Days3 Days1 Day
Cytotoxicity Assays 
Cells/ml (x103)
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Figure 3.8 Standard curves for the 4T1 cell line for 1 day (A), 3 days (B) and 5 days 
(C).  Cell numbers were optimised for each time point. 
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Figure 3.9 Standard curves for the Hs578T cell line for 1 day (A), 3 days (B) and 5 
days (C).  Cell numbers were optimised for each time point. 
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3.2.2 Cytotoxicity of CLA and individual isomers in the 4T1 murine mammary 
cancer cell line 
 
Cytotoxicity assays were conducted as outlined in section 2.2.2.  Cytotoxicity 
of LA, a mix of CLA isomers (designated ‘CLA’), and two individual isomers, 
c9,t11-CLA and t10,c12-CLA, were tested in the 4T1 cell line over 1, 3 and 5 days.  
The CLA mixed isomers contained c9,t11-CLA/t9,c11-CLA (~41%), t10,c12-CLA 
(~44%), c10,c12-CLA (~10%) and others (~5%).  The range of concentrations tested 
was 18 µM (5 µg/ml) to 107 µM (30 µg/ml), levels found in human serum 
(Tanmahasamut et al., 2004).  LA was also used in these experiments as it has 
previously been shown to have a stimulatory effect on mammary and breast cancer 
cell growth and metastasis (Reyes et al., 2004 and Connolly et al., 1999).  The 
cytotoxicity results are from a minimum of duplicate experiments, completed in 
triplicate.   
Cytotoxicity of LA, c9,t11-CLA and t10,c12-CLA was low over the range of 
concentrations tested after treatment for 1 day  (Figure 3.10).  IC50 values were not 
established for LA, c9,t11-CLA or t10,c12-CLA over the range of concentrations 
tested (Table 3.3).  For CLA, toxicity was only observed at the highest concentration 
of 107 µM, with 100% cell death noted (Figure 3.10).  An IC50 value was established 
for CLA at 98 µM (Table 3.3).  After treatment for 3 days, CLA caused the highest 
toxicity, with an IC50 value of 44 µM (Figure 3.11 and Table 3.3).  Treatment with 
the c9,t11-CLA isomer resulted in toxicity at the two highest concentrations tested, 
with 100% cell death at 107 µM (Figure 3.11).  The IC50 value for c9,t11-CLA was 
82 µM after 3 days treatment (Table 3.3).  The t10,c12-CLA isomer caused 80% cell 
death at the top concentration of 107 µM after treatment for 3 days, with an IC50 
value of 98 µM (Figure 3.11 and Table 3.3).  LA caused low toxicity at the majority 
of the concentrations, with cell death reaching 30% at 107 µM, thus an IC50 value was 
not established (Figure 3.11 and Table 3.3). 
Cytotoxicity over 5 days is illustrated in Figure 3.12.  CLA was the most toxic 
over the range of concentrations tested, with an IC50 value of 58 µM established 
(Figure 3.12 and Table 3.3).  Treatment with the t10,c12-CLA isomer resulted in 
similar toxicity to CLA, with an IC50 value of 62 µM established (Figure 3.12 and 
Table 3.3).  The c9,t11-CLA isomer was less toxic with an IC50 value of 78 µM 
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(Figure 3.12 and Table 3.3).  LA caused low toxicity at the lower concentrations, with 
the cell death rising to 87% at the highest concentration, 107 µM (Figure 3.12).  An 
IC50 value of 100 µM was established for LA over 5 days (Table 3.3). 
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Figure 3.10 Cytotoxicity of LA, CLA, c9,t11-CLA and t10,c12-CLA in the 4T1 cell 
line after treatment for 1 day.  Cell death was low in all instances except following 
CLA treatment at the top concentration of 107 µM.  
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Figure 3.11 Cytotoxicity of LA, CLA, c9,t11-CLA and t10,c12-CLA in the 4T1 cell 
line after treatment for 3 days.  CLA exhibited the highest toxicity towards the cell 
line, followed by the c9,t11-CLA isomer. 
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Figure 3.12 Cytotoxicity of LA, CLA, c9,t11-CLA and t10,c12-CLA in the 4T1 cell 
line after treatment for 5 days.  CLA was the most toxic to the cells, closely followed 
by the t10,c12-CLA isomer and the c9,t11-CLA isomer.  
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Table 3.3 IC50 values for LA, CLA, c9,t11-CLA and t10,c12-CLA in the 4T1 cell 
line after treatment for 1, 3 and 5 days.  
 
 
Mean±SD
(a) IC50 value not reached up to highest concentration tested
62±398±3>107at10c12
78±482±2>107ac9t11
58±344±898±2CLA
100±2>107a>107aLA
5 Days3 Days1 Day
IC50 Values 4T1 Cell Line (µM)
 
 
 
 
3.2.3 Cytotoxicity of CLA and individual isomers in the Hs578T human breast 
cancer cell line 
 
The Hs578T human breast carcinoma cell line was chosen to test the 
cytotoxicity of LA, CLA and the isomers, t10,c12-CLA and c9,t11-CLA.  After 
treatment for 1 day relatively low toxicity was observed for all concentrations of fatty 
acids used (Figure 3.13).  An increase in cell growth was noted at the lower 
concentrations for the t10,c12-CLA isomer and the c9,t11-CLA isomer.  IC50 values 
were not reached over the range of concentrations tested (Table 3.4).   
After treatment for 3 days, cytotoxicity for all fatty acids was low and IC50 
values were not reached over the range of concentrations tested (Figure 3.14 and 
Table 3.4).  CLA proved the most toxic to the Hs578T cells over 5 days, with an IC50 
value of 58 µM (Figure 3.15 and Table 3.14).  The c9,t11-CLA and t10,c12-CLA 
isomers caused toxicity at the highest concentration, 107 µM (Figure 3.15).  IC50 
values for these isomers were 104 µM and 98 µM respectively (Table 3.4).  LA 
showed low toxicity over the range of concentrations tested with no IC50 value 
reached (Figure 3.15 and Table 3.14). 
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Figure 3.13 Cytotoxicity of LA, CLA, c9,t11-CLA and t10,c12-CLA in the Hs578T 
cell line after treatment for 1 day.  Low toxicity was observed over the range of 
concentrations tested. 
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Figure 3.14 Cytotoxicity of LA, CLA, c9,t11-CLA and t10,c12-CLA in the Hs578T 
cell line after treatment for 3 days.  Low toxicity was observed over the range of 
concentrations tested.  
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Figure 3.15 Cytotoxicity of LA, CLA, c9,t11-CLA and t10,c12-CLA in the Hs578T 
cell line after treatment for 5 days.  CLA showed the most toxicity, followed by the 
t10,c12-CLA isomer and the c9,t11-CLA isomer. 
 
 
 
Table 3.4 IC50 values for LA, CLA, c9,t11-CLA and t10,c12-CLA in the Hs578T cell 
line after treatment for 1, 3 and 5 days. 
 
 
98±1>107a>107at10c12
104±2>107a>107ac9t11
58±3>107a>107aCLA
>107a>107a>107aLA
5 Days3 Days1 Day
IC50 Values Hs578T Cell Line (µM)
Mean±SD
(a) IC50 value not reached up to highest concentration tested  
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3.2.4 Guava® cell cycle analysis of 4T1 cells following treatment with CLA and 
individual isomers 
 
Flow cytometry has become a very useful tool to analyse numerous aspects of 
individual cells.  The Guava® PCA is a bench-top cell analyser with extremely user-
friendly interfaces and applications.  This machine was used to analyse the effect of 
the fatty acids on cell cycle kinetics and apoptosis in the 4T1 cell line.  Cell cycle 
stages were analysed using propidium iodide (PI), which intercalates with DNA.  In 
normal cycling cells in culture, the G0/G1 contains quiescent cells and cells preparing 
for DNA replication.  During S phase, replication of the genome occurs with a 
subsequent increase in the amount of PI bound to the genomic DNA (Figure 3.16).  In 
the G2/M phase, the cell has double the amount of DNA as in the G0/G1 phase.  Cell 
division occurs in the M phase, with the individual cells reverting back to the amount 
of DNA of cells in G0/G1.  In this analysis, cells in G0/G1 are referred to as G1 and 
cells in G2/M are referred to as G2.  
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Figure 3.16 Cell cycle analysis from Multicycle software, indicating individual 
populations.  
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4T1 cells were treated with 54 µM and 89 µM of fatty acids for 3 days then 
assessed on the Guava® PCA.  These concentrations were chosen as they covered a 
range of toxicities and would therefore give a good indication of the effect on the cell 
cycle as toxicity increased.  Cells were harvested and prepared as described in section 
2.2.4.1.  Results are representative of three independent experiments.  Data was 
analysed using Multicycle software (Phoenix Flow Systems, CA) which uses a more 
accurate method for deciphering the populations in the different stages.  This software 
uses an algorithm which makes two assumptions – firstly, that the G2/M population 
will have double the DNA content than the G1/G0 and secondly, that the G1/G0 and 
G2/M phases have normal distribution.  The S phase population is then calculated 
accordingly.   
Figure 3.17 and Figure 3.18 show results following treatment with 54 µM of 
fatty acids for 3 days and the results are summarised in Table 3.5.  In comparison to 
the control, all treatments caused a distinct arrest in the G1 population and a decrease 
in the S and the G2 phase populations.  CLA and t10,c12-CLA increased the G1 
phase population to 67.5% and 65.3% respectively while the G1 population for the 
control was 37%.  LA and c9,t11-CLA caused a greater increase in the G1 
population, to 74.4% and 71.7% respectively.  The S phase population for the control 
was 39.7% and following treatment with c9,t11-CLA this population was reduced to 
8.2%, with LA and CLA treatments reducing the populations to 12.5% and 15.4% 
respectively.  LA, CLA, c9,t11-CLA and t10,c12-CLA caused a decrease in the G2 
phase population to 13.2%, 17.1%, 20.1% and 10.2% respectively, in comparison to 
the control (23.2%).   
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Figure 3.17 Cell cycle analysis of 4T1 cells following treatment for 3 days with 54 
µM LA, CLA, c9,t11-CLA and t10,c12-CLA.  X-axis shows DNA content, y-axis 
represents counts of cells.  G1 phase is in light blue, S phase in pink and G2 phase in 
dark blue. 
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Figure 3.18 Cell cycle analysis of 4T1 cells following treatment for 3 days with 54 
µM LA, CLA, c9,t11-CLA and t10,c12-CLA. 
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Table 3.5 Percentages of cell cycle populations following treatment for 3 days with 
54 µM LA, CLA, c9,t11-CLA and t10,c12-CLA.   
 
 
10.224.565.3t10c12
20.18.271.7c9t11
17.115.467.5CLA
13.212.574.4LA
23.239.737Control
G2 (%)S (%)G1 (%)
Cell Cycle Analysis: 54µM
 
 
 
 
Treatment with 89 µM of fatty acids also caused an increase in G1 phase 
population and a decrease in S and G2 phase populations (Figures 3.19 and 3.20, 
Table 3.6).  LA again caused the greatest increase in G1 phase population, at 69%, 
followed by the c9,t11-CLA isomer (65.3%), the t10,c12-CLA isomer (64%) and 
CLA (57.8%).  The effect on the S phase populations varied, the control population 
was 45.4%, with LA causing a decrease to 13.5% while treatment with CLA caused a 
decrease to 29.5%.  Treatment with the c9,t11-CLA isomer and the t10,c12-CLA 
isomer resulted in S phase populations of 22.8% and 20.7% respectively.  Treatment 
with LA only caused a slight decrease in the G2 phase population, from 19.3% for the 
control to 17.5% for LA.  The t10,c12-CLA isomer decreased the G2 phase 
population to 15.3% while CLA and the c9,t11-CLA isomer caused decreases to 
12.7% and 11.9% respectively.  In general there was a decrease in the G1 phase 
population from the lower to the higher concentration of treatment.  The S phase 
population increased following treatment with the higher concentration of LA, CLA 
and the c9,t11-CLA isomer, in comparison to the lower concentration.  There was an 
increase in the G2 phase populations following treatment with the higher 
concentrations of LA, the c9,t11-CLA isomer and the t10,c12-CLA isomer.   
 
 79
LAControl CLA
c9,t11 t10,c12
 
 
Figure 3.19 Cell cycle analysis of 4T1 cells following treatment for 3 days with 89 
µM LA, CLA, c9,t11-CLA and t10,c12-CLA.  X-axis shows DNA content, y-axis 
represents counts of cells.  G1 phase is in light blue, S phase in pink and G2 phase in 
dark blue. 
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Figure 3.20 Cell cycle analysis of 4T1 cells following treatment for 3 days with 89 
µM LA, CLA, c9,t11-CLA and t10,c12-CLA. 
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Table 3.6 Percentages of cell cycle populations following treatment for 3 days with 
89 µM LA, CLA, c9,t11-CLA and t10,c12-CLA.   
 
 
15.320.764t10,c12
11.922.865.3c9,t11
12.729.557.8CLA
17.513.569LA
19.345.435.3Control
G2 (%)S (%)G1 (%)
Cell Cycle Analysis: 89µM
 
 
 
 
3.2.5 Guava® apoptosis analysis of 4T1 cells following treatment with CLA and 
individual isomers 
 
Apoptosis of cells was analysed using two dyes, annexin V and 7-
aminoactinomycin D (7-AAD).  Annexin V binds to phosphatidylserine molecules 
which move to the outer surface of the cell membrane during early apoptosis.  7-AAD 
is a cell impermeable dye and only enters cells late in the apoptotic process once the 
membrane integrity has been compromised.  Hence, healthy viable cells will not have 
staining with either of the dyes.  Cells in the early apoptotic stages will be positive for 
annexin V and negative for 7-AAD and cells going through necrosis or the later 
stages of apoptosis will be positive for both annexin V and 7-AAD.  In Figures 3.21-
3.23, the individual cells are represented by dot-plots, with the x-axis and y-axis 
representing annexin V and 7-AAD staining of the cells respectively.  Healthy cells 
without any dye are present in the lower left quadrant of the dot-plot, while cells 
undergoing apoptosis move firstly into the lower right quadrant (following 
translocation of phosphatidylserine molecule from inner to outer surface to cell 
membrane) then move to the upper right quadrant (following breach of the integrity 
of the membrane).   
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Figure 3.21 Guava® apoptosis analysis of cells, showing quadrants containing viable, 
early apoptotic and late apoptotic cells.  
 
 
Cells were harvested and prepared as described in section 2.2.4.2.  Apoptosis 
analysis was conducted using 4T1 cells treated for 3 days with 54 µM (Figure 3.22) 
and 89 µM (Figure 3.23) of fatty acids.  Results are representative of three 
independent experiments.  Figure 3.24 summarises the data, illustrating the 
percentage of annexin V positive cells, which includes both early and late apoptotic 
cells.  The control cells had approximately 20% apoptotic cells.  Treatment with 54 
µM of t10,c12-CLA caused an increase in apoptotic cells to approximately 40% in 
comparison to the control (p<0.05) (Figures 3.22 and 3.24).  The early apoptotic cells 
can be observed in the lower right quadrant and the cells in late apoptosis or 
undergoing necrosis can be seen in the upper right quadrant.  Treatment with LA, 
CLA and c9,t11-CLA did not cause any significant change in the level of apoptotic 
cells. 
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Figure 3.22 Apoptosis analysis of cells following treatment for 3 days with 54 µM 
fatty acids.   
 
 
After 89 µM treatment, CLA and c9,t11-CLA caused a significant increase in 
the level of apoptotic cells to 75% and 59% respectively (p<0.05) (Figures 3.23 and 
3.24).  The increase in apoptotic cells can be mainly observed in the upper right 
quadrant, indicating an increase of cells either in late apoptosis or undergoing 
necrosis (Figure 3.23).  These results correlate with the cytotoxicity noted following 
treatment with these fatty acids (Figure 3.11).  Treatment with 89 µM LA did not 
cause any increase in apoptotic cells, while treatment with the t10,c12-CLA isomer 
caused an increase in apoptotic cells in comparison to the control, but this result was 
not significant (Figures 3.23 and 3.24).   
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Figure 3.23 Apoptosis analysis of cells following treatment for 3 days with 89 µM 
fatty acids.   
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Figure 3.24 Apoptosis analysis of 4T1 cells following treatment for 3 days with 54 
µM and 89 µM fatty acids.  Graph indicates percentage of annexin positive cells, 
including both early and late apoptotic cells. Treatment with 54 µM t10,c12-CLA, 89 
µM CLA and 89 µM c9,t11-CLA caused significant increases in annexin positive 
cells.  *p<0.05, Student’s t-test. 
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3.2.6  Effect of CLA and individual isomers on migration of the 4T1 cell line 
 
To determine the effect of LA, CLA, c9,t11-CLA and t10,c12-CLA on the 
migratory capabilities of 4T1 cells, in vitro migration assays were conducted and 
analysed as per section 2.2.5.  Results are from duplicate experiments, completed in 
triplicate.  Cells were initially pre-treated in 25 cm2 cell culture flasks with 18 µM of 
the fatty acids for 48 hours.  The cells were then trypsinised and seeded into FalconTM 
cell culture inserts, with treatment added, incubated for 24 hours and the level of 
migration quantified.  This concentration of fatty acid was chosen to ensure minimal 
toxicity for all fatty acids (≤ 10% cell death) in order to determine effects that were 
due to changes in migratory or invasive ability rather than being due to cell death.   
The results for migration assays are outlined in Figure 3.25.  Whole stained 
membranes are presented in Figure 3.26 and magnified at 200X under the microscope 
in Figure 3.27.  Treatment with LA and CLA had little effect on the level of migration 
of the 4T1 cell line in comparison to the control.  The c9,t11-CLA and the t10,c12-
CLA isomers caused an increase and decrease in migration of the 4T1 cells 
respectively.  The result following treatment with t10,c12-CLA was statistically 
significant in comparison to the control (p<0.05).   
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Figure 3.25 Effect of treatment with 18 µM LA, CLA, c9,t11-CLA and t10,c12-CLA 
for 3 days on migration of the 4T1 cell line. The t10,c12-CLA isomer caused a 
significant decrease in the migration of the 4T1 cells.  *p<0.05, Student’s t-test. 
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Figure 3.26 FalconTM cell culture inserts following fixing and staining of the 
membrane with crystal violet.  Chambers containing the t10,c12-CLA-treated cells 
had less stain.  
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Figure 3.27 FalconTM cell culture inserts following fixing and staining of the 
membrane with crystal violet.  A decrease in the number of migrated cells following 
treatment with t10,c12-CLA was clearly seen.  200X magnification of membranes. 
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3.2.7  Effect of CLA and individual isomers on invasion of the 4T1 cell line 
 
Invasion assays were set up in the same manner as migration assays.  Unlike 
the FalconTM cell culture inserts, the BD BioCoatTM MatrigelTM Invasion Chambers 
contained a layer of Matrigel on the top of the membrane, which must be degraded by 
the cells before they can move through the pores.  Results are from duplicate 
experiments, completed in triplicate.  The results for invasion assays are outlined in 
Figure 3.28.  Whole stained membranes are presented in Figure 3.29 and magnified at 
200X under the microscope in Figure 3.30.  Treatment with LA and t10,c12-CLA 
caused a decrease in invasion of the 4T1 cells, while CLA and c9,t11-CLA treatment 
resulted in an increase in the invasion of the cells.  However, these results were not 
statistically significant due to large standard deviations.   
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Figure 3.28 Effect of treatment with 18 µM LA, CLA, c9,t11-CLA and t10,c12-CLA 
for 3 days on invasion of the 4T1 cell line.  The c9,t11-CLA isomer caused an 
increase in the invasion of the 4T1 cells. 
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Figure 3.29 BD BioCoatTM MatrigelTM Invasion Chambers following fixing and 
staining of the membrane with crystal violet.  Darker staining of the chambers 
containing c9,t11-CLA treated cells were evident.   
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Figure 3.30 BD BioCoatTM MatrigelTM Invasion Chambers following fixing and 
staining of the membrane with crystal violet.  An increase in the number of invasive 
cells treated with c9,t11-CLA was clearly seen.  200X magnification of membranes. 
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3.2.8  Effect of CLA and individual isomers on adhesion of the 4T1 cell line 
 
Cell adhesion involving numerous cell adhesion molecules play an important 
role in invasion and metastasis (Hanahan and Weinberg, 2000).  Cells must be able to 
attach to and move through the ECM for intravasation and extravasation.  Loss of cell 
adhesion molecules like the cadherins and integrins can contribute to movement of 
the cells in this crucial step in metastasis (Cavallaro and Christofori, 2004).  Cell 
adhesion was examined following treatment with the fatty acids as outlined in section 
2.2.6.  Cells were pre-treated with 18 µM fatty acid for 3 days before being seeded 
into a 96-well plate and incubated at 37°C, 5% CO2 for 100 minutes.  Non-adhered 
cells were then removed from the plate and the adhered cells quantified using the 
MTS assay.  Figure 3.31 shows the results from the adhesion assay.  CLA treatment 
caused a decrease in adhesion of the 4T1 cells.  Treatment with the c9,t11-CLA and 
the t10,c12-CLA isomers resulted in an increase in adhesive cells in comparison to 
the control.  However, these results were not statistically significant.   
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Figure 3.31 Effect of treatment with 18 µM LA, CLA, c9,t11-CLA and t10,c12-CLA 
for 3 days on adhesion of 4T1 cells.  Percentage adhesion is in relation to the control 
plate, in which non-adhered cells were not removed from the wells.  No significant 
effect on adhesion of the cells was observed after incubation for 100 minutes. 
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3.2.9  Effect of CLA and individual isomers on colony formation of the 4T1 cell 
line in soft agar 
 
The anchorage-independent growth of cells in soft agar is generally regarded 
as an indication of tumourigenicity and can be used to assess the efficacy of 
anticancer compounds.  A compound is considered efficacious if treatment results in 
a reduction in the number of colonies to below 30% of that in the control sample 
(Fiebig et al., 2004).  Colony-forming efficiency has also been shown to be associated 
with experimental metastatic potential (Price et al., 1986).  This technique involved 
seeding cells in semi-solid medium containing agar and assessing the formation of 
colonies in this environment.  4T1 cells pre-treated with 18 µM fatty acids for 3 days 
were seeded in the soft agar and incubated for 10 days.  Live colonies were stained 
with p-iodonitrotetrazolium chloride solution and colonies with a diameter greater 
than 100 µm were counted.  Results are representative of duplicate experiments, 
completed in triplicate.  Figures 3.32 and 3.33 illustrate results from the soft agar 
assays.  All treatments caused an increase in the number of colonies formed with a 
significant increase in colonies formed from cells pre-treated with CLA (p<0.01), 
c9,t11-CLA (p<0.01) and t10,c12-CLA (p<0.00005).   
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Figure 3.32 Effect of treatment with 18 µM LA, CLA, c9,t11-CLA and t10,c12-CLA 
for 3 days on 4T1 cell colony formation in soft agar assay.  *p<0.01, **p<0.00005, 
Student’s t-test. 
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The increase in colonies formed following treatment with CLA, c9,t11-CLA 
and t10,c12-CLA can be clearly observed in the images of the wells in Figure 3.33.  
The change in pH of the medium in the wells due to the growth of the colonies of 
cells pre-treated with t10,c12-CLA was dramatic.   
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Figure 3.33 Effect of treatment with 18 µM LA, CLA, c9,t11-CLA and t10,c12-CLA 
for 3 days on 4T1 cell colony formation in soft agar assay.  An increase in the number 
of colonies formed following treatment with the t10,c12-CLA isomer is clear.  
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3.2.10  Effect of CLA and individual isomers on levels of MMP-2 and MMP-9 
mRNA 
 
In order to investigate further the possible effect of the fatty acids on invasion 
and metastasis, the expression of MMP-2 and MMP-9 was examined.  The 4T1 cell 
line was treated with 18 µM LA, CLA, c9,t11-CLA or t10,c12-CLA for 3 days.  RNA 
was extracted from the treated cells as outlined in sections 2.2.8 and 2.2.9.1, 
quantified and separated on a 1.2% agarose gel as described in section 2.2.9.2.  Figure 
3.34 shows a picture of the agarose gel used to confirm the integrity of the RNA.  The 
18S and 28S sub-units could be seen clearly in all samples.   
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Figure 3.34 1 µg RNA from 4T1 cells treated with LA, CLA, c9,t11-CLA and 
t10,c12-CLA separated on a 1.2% agarose gel.  The presence of the 28S and 18S sub-
units was indicative of RNA integrity. 
 
The RNA was used as a template to produce cDNA by reverse transcription as 
per section 2.2.9.3.  The cDNA was then used to amplify sections of the actin, MMP-
2 and MMP-9 genes as described in section 2.2.9.4.  Figure 3.35 shows the actin PCR 
products.  These products were used to normalise data from the densitometry of the 
following RT-PCR experiments.  Figure 3.36 shows PCR products and densitometry 
analysis for MMP-2 and MMP-9.  In comparison to the control, all fatty acid-
treatments resulted in a decrease in the level of MMP-2 mRNA.  Treatment with LA, 
CLA and t10,c12-CLA resulted in an increase in the levels of MMP-9 mRNA, while 
c9,t11-CLA caused a decrease in expression of MMP-9 mRNA (Figure 3.36).  
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Figure 3.35 Actin RT-PCR of samples from the 4T1 cell line.  The PCR product is 
visible at 554 bp.  Densitometry values for MMP and TIMP RT-PCR were 
normalized to these RT-PCR products.   
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Figure 3.36 MMP-2 (A) and MMP-9 (B) RT-PCR and densitometry analysis (C) of 
samples from fatty acid-treated 4T1 cells.  PCR products were separated on 1% 
agarose gels.  PCR products were 475 bp and 467 bp for MMP-2 and MMP-9 
respectively.   
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3.2.11  Effect of CLA and individual isomers on levels of MMP-9 protein in the 
4T1 cell line 
 
Following analysis of mRNA levels of MMP-2 and MMP-9 in the 4T1 cell 
line, protein levels were examined in conditioned medium collected from cells treated 
with 18 µM fatty acids for 3 days, as described in section 2.2.8.  Centrifugal filter 
devices were used to eliminate proteins under 10 kDa to concentrate the protein 
samples.  The total protein in the concentrated conditioned medium was quantified 
and an equal amount of protein was loaded for each sample and separated on a gelatin 
zymogram as outlined in sections 2.2.10.1 and 2.2.10.2.  Gelatin zymography is a 
technique used to analyse gelatinase enzymes.  Gelatin was incorporated into the SDS 
gel as a substrate for the gelatinases (MMP-2 and MMP-9).  Proteins were separated 
on the gel, incubated to allow the enzymes to degrade the gelatin and then stained 
with Coomassie Blue.  Upon de-staining, clear bands became visible against the blue 
background in the position of the gelatinases, where the gelatin had been degraded.  
Figure 3.37 shows a gelatin zymogram and densitometry analysis with conditioned 
medium samples from the 4T1 cell line, which contained 4.5 µg total protein.  Mouse 
MMP-9 is 105 kDa in comparison to human MMP-9 at 92 kDa, as in the BHK 
control.  MMP-9 protein levels in the 4T1 cell line were decreased following 
treatment with LA, and increased following treatment with CLA, c9,t11-CLA and 
t10,c12-CLA.  No bands were observed for MMP-2 in these samples, which indicated 
no protein was produced or levels were so low that they were undetectable.  A 
western blot was conducted with an antibody for MMP-9 but no bands were visible 
(data not shown).  The antibody used was directed against human MMP-9 but the 
data sheet stated reactivity with mouse MMP-9 so this result was disappointing.   
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Figure 3.37 Gelatin zymography (A) and densitometry analysis (B) using 
concentrated conditioned medium samples from the 4T1 cell line.  Conditioned 
medium from the BHK cell line was used as a control, as it constitutively expressed 
MMP-2 and was transfected with cDNA for human MMP-9.  4.5 µg total protein was 
loaded for the samples from the 4T1 cell line.  Bands are visible at 105 kDa for 
murine MMP-9 in the 4T1 cell line but no MMP-2 is evident.   
 
 
3.2.12  Effect of CLA and individual isomers on levels of MMP-2 protein in the 
Hs578T cell line 
 
In order to investigate the effect on the levels of MMP-2 protein, conditioned 
medium samples from the Hs578T cell line were separated on a gelatin zymogram.  
Figure 3.38 shows the gelatin zymogram and densitometric analysis using samples 
from the Hs578T cell line, containing 5.34 µg total protein.  A band for latent MMP-2 
can be observed at 72 kDa, with a weak band at 66 kDa for the active form.  MMP-2 
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protein levels in the Hs578T cell line were elevated in all fatty acid-treated cells in 
comparison to the control.  Western blot analysis was conducted using the samples 
from the Hs578T cell line as outlined in section 2.2.10.4.  Figure 3.39 shows the 
western blot and densitometric analysis using samples from the Hs578T cell line.  
Treatment of the Hs578T cell line with LA, CLA and the c9,t11-CLA isomer caused 
an increase in the protein level of MMP-2.   
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Figure 3.38 Gelatin zymography (A) and densitometry analysis (B) using 
concentrated conditioned medium samples from the Hs578T cell line.  Conditioned 
medium from the BHK cell line was used as a control, as it constitutively expressed 
MMP-2 and was transfected with cDNA for human MMP-9.  5.34 µg total protein 
was loaded for samples from the Hs578T cell line.  Bands were visible for latent and 
active MMP-2 at 66 kDa and 72 kDa respectively.  
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Figure 3.39 Western blot (A) and densitometry analysis (B) using conditioned 
medium samples from the Hs578T cell line.  Conditioned medium from the BHK cell 
line was used as a control, as it constitutively expresses MMP-2 and is transfected 
with cDNA for human MMP-9.  5.34 µg total protein was loaded for samples from 
the Hs578T cell line.  An increase in MMP-2 protein level was noted after treatment 
with LA, CLA and c9,t11-CLA in comparison to the control.  
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3.2.13 Effect of CLA and individual isomers on levels of TIMP-1 and TIMP-2 
mRNA 
 
TIMP mRNA levels were investigated by RT-PCR to determine any effect 
following treatment with the fatty acids.  RT-PCR products and densitometry analysis 
are outlined in Figure 3.40.  Bands were normalised to actin in Figure 3.35.  All 
treatments resulted in a decrease in the levels of TIMP-1 mRNA, with the t10,c12-
CLA isomer having the greatest effect.  TIMP-2 mRNA levels decreased following 
treatment with LA and increased following CLA and t10,c12-CLA treatment.   
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Figure 3.40 TIMP-1 RT-PCR (A), TIMP-2 RT-PCR (B) and densitometry analysis 
(C) of RNA extracted from fatty acid-treated 4T1 cells.  PCR products were separated 
on 1% agarose gels.  PCR products were 584 bp and 341 bp for TIMP-1 and TIMP-2 
respectively.   
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3.2.14 Effect of CLA and individual isomers on levels of TIMP-1 and TIMP-2 
protein 
 
Reverse zymograms are used to detect TIMP proteins.  They were prepared 
using a similar method to the gelatin zymogram, with the addition of BHK medium 
incorporated into the gel.  Protein samples were separated on the gel, which was then 
incubated in substrate buffer and stained with Coomassie Blue.  The BHK medium 
degraded the gelatin in the gel except in the region of the TIMPs, hence leaving blue 
bands against a white background.  A reverse zymogram was used to analyse 
conditioned medium samples from the 4T1 cell line to determine the effect of the 
fatty acids on levels of TIMP-1 and TIMP-2 proteins.  Unfortunately, no bands were 
evident in the samples from the 4T1 cell line despite a band visible for the TIMP-1 
and TIMP-2 recombinant controls (data not shown).   
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3.3  Discussion 
 
CLA and various isomers have been shown to have beneficial effects in 
relation to cancer, atherosclerosis, diabetes and obesity (Belury, 2002b).  There is 
considerable interest in using CLA as a component in functional foods.  Current 
levels of CLA intake in the UK are approximately 400-600 milligrams per day 
(Wahle et al., 2004).  Sources with increased CLA content are desirable and the level 
of CLA in cow’s milk can be manipulated by changes in the diet of the cows.  
Unsaturated fats, processed seeds, fish oils, marine algae and pasture feeding have all 
been shown to increase the level of CLA in milk fat (Bauman et al., 1999). 
The aim of this chapter was to investigate the effect of a mixture of CLA 
isomers and the two individual isomers, c9,t11-CLA and t10,c12-CLA, on 
proliferation, cell cycle and apoptosis.  In order to look at the modulation of 
metastasis, these fatty acids were investigated with regard to in vitro cell invasion, 
migration, adhesion and colony formation in soft agar.  MMP and TIMP mRNA and 
protein levels were also analysed following treatment with the fatty acids.  The CLA 
mixture of isomers contained c9,t11-CLA/t9,c11-CLA (~41%), t10,c12-CLA (~44%), 
c10,c12-CLA (~10%) and others (~5%).  In order to carry out this assessment, the 
4T1 cell line was chosen as it forms highly metastatic tumours in BALB/c mice.  This 
cell line would facilitate future animal studies investigating the effect of CLA on 
tumourigenesis and metastasis.  The Hs578T cell line was used to examine the effect 
of CLA in a human breast cancer cell line.  
Assays for quantification of cell death were initially investigated and the 
Promega MTS system chosen for cytotoxicity assays (Figure 3.7).  Cytotoxicity was 
analysed after treatment of cells for 1, 3 and 5 days.  Standard curves were optimised 
to ensure cells were in the logarithmic growth phase for experiments (Figure 3.8 and 
Table 3.2).  Concentrations of 18 µM (5 µg/ml) to 107 µM (30 µg/ml) were chosen 
for analysis.  Concentrations of 10-70 µM are the physiological levels found in 
human serum, thus the range tested included current and elevated physiological levels 
(Tanmahasamut et al., 2004).  After treatment of the 4T1 cell line for 1 day, toxicity 
was low except at the top concentration of CLA, at which nearly 100% cell death was 
exhibited (Figure 3.10).  The toxicity of CLA in the 4T1 cell line was also evident 
after 3 and 5 days treatment (Figures 3.11 and 3.12).  Despite the high toxicity of 
 100
CLA after treatment for 3 days with an IC50 value of 44 µM, the IC50 value after 5 
days treatment increased to 58 µM.  This did not completely reflect the toxicity of 
CLA over 5 days.  With the exception of the toxicity level at 54 µM, the toxicity at all 
other concentrations mirrored that observed after 3 days treatment. The increase in 
the IC50 value was due to this dip in toxicity at 54 µM.  The similarity between the 
toxicity of CLA after 3 and 5 days treatment was consistent with results noted in 
animal studies showing no increase in protection against development of mammary 
tumours above a certain dietary level of CLA (1%).  This would indicate a threshold 
in the anti-cancer activity of CLA, possibly due to a limit in the metabolism of CLA 
into the active products (Ip et al., 2001 and Ip et al., 1996).   
The c9,t11-CLA and t10,c12-CLA isomers also caused toxicity over 3 and 5 
days.  The c9,t11-CLA isomer had IC50 values of 82 µM and 78 µM over these two 
time points respectively (Figures 3.11, 3.12 and Table 3.3).  The t10,c12-CLA isomer 
was less toxic than c9,t11-CLA after 3 days treatment, with an IC50 value of 98 µM 
(Figure 3.11 and Table 3.3).  However, over 5 days, t10,c12-CLA was more toxic 
than c9,t11-CLA, with an IC50 of 62 µM (Figure 3.12 and Table 3.3).  Again, there 
may be a limit to the effect of c9,t11-CLA, with no increase in toxicity observed over 
the extended incubation period.  In experiments with the 4T1 cell line, there was no 
increase in cell growth following treatment with LA.  Cytotoxicity was noted only at 
the top concentration of 107 µM after 5 days treatment, with an IC50 value of 100 µM 
established (Figure 3.12 and Table 3.3).   
In the Hs578T cell line, cytotoxicity was low after treatment for 1 day and 3 
days (Figures 3.13 and 3.14).  IC50 values were not established over these time points 
for any treatment.  After 5 days treatment, CLA caused the highest toxicity levels 
with an IC50 value of 58 µM (Figure 3.15 and Table 3.4).  The c9,t11-CLA and 
t10,c12-CLA isomers exhibited toxicity at the highest concentration, with IC50 values 
established at 104 µM and 98 µM respectively.  Treatment with LA resulted in low 
toxicity even at the highest concentration of 107 µM after 5 days treatment.  LA 
caused an increase in cell growth after treatment with 71 µM for 1 day and 54 µM, 71 
µM and 89 µM for 3 days (Figures 3.13 and 3.14).  This correlates with published 
reports of increased growth up to a certain concentration, with cell death occurring at 
higher concentrations (Reyes et al., 2004). 
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While CLA had the same IC50 value in the 4T1 and Hs578T cell lines after 
treatment for 5 days, in general, the Hs578T cell line was more resistant to cell death 
than the 4T1 cells.  CLA was consistently more toxic to the 4T1 and Hs578T cell 
lines than the individual isomers over the time ranges tested.  The toxicity of c9,t11-
CLA and t10,c12-CLA varied, with c9,t11-CLA more toxic than t10,c12-CLA in the 
4T1 cell line after 3 days treatment, but t10,c12-CLA was more toxic after 5 days 
treatment in both cell lines.  The toxicity exhibited by CLA would indicate a 
synergistic effect of the isomers in the mix.  As this mixture contained 41% c9,t11-
CLA/t9,c11-CLA, without specifying the amount of each, it would be interesting to 
investigate the toxicity of t9,c11-CLA in the future, to determine its contribution to 
the cytotoxicity.   
Extensive studies have been conducted on the effect of CLA in the two breast 
cancer cell lines, MCF-7 and MDA-MB-231.  Majumder et al. (2002) found CLA to 
be more effective than the individual isomers at inhibiting proliferation of the MCF-7 
and MDA-MB-231 cell lines, supporting the results presented here, although the 
authors did not specify the concentrations tested.  Maggiora et al. (2004) saw no 
effect on MCF-7 and MDA-MB-231 cell proliferation after 24 hours treatment with 5 
µM, 50 µM or 200 µM CLA or LA.  A decrease was observed in cell numbers of both 
cell lines after treatment with 50 µM and 200 µM CLA for 48 hours in comparison to 
the control.  After 72 hours treatment, LA had no effect on cell growth in the MCF-7 
cell line, but caused a slight decrease in cell growth in the MDA-MB-231 cell line.  
CLA treatment at all three concentrations caused a decrease in cell growth after 72 
hours in the MCF-7 cell line but had a lower inhibitory effect in the MDA-MB-231 
cell line.  After incubation for 72 hours with CLA, the 50 µM treatment was more 
effective at inhibiting cell proliferation than the 200 µM treatment, indicating a limit 
in toxicity as observed with the results presented here.   
Using the same cell lines, MCF-7 and MDA-MB-231, Tanmahasamut et al. 
(2004) examined the effects of CLA over a concentration range of 25 – 200 µM for 
48 hours.  This group reported 80% inhibition of MCF-7 cell growth after treatment 
with 200 µM CLA for 48 hours, in comparison to the results from Maggiora et al. 
(2004), with less than 33% inhibition over the same time period.  Cell death was not 
reported in the MDA-MB-231 cell line after treatment with 200 µM CLA for 72 
hours (Tanmahasamut et al., 2004).  The individual isomers, c9,t11-CLA and 
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t10,c12-CLA, were also tested over 48 hours in the MCF-7 cell line.  At 100 µM and 
200 µM, t10,c12-CLA exhibited the highest inhibition of cell growth in comparison 
to CLA and c9,t11-CLA.  The c9,t11-CLA isomer had no effect on the growth of the 
MDA-MB-231 cell line after treatment for 48 hours, while the t10,c12-CLA isomer 
was not tested in this cell line.   
Treatment with 10 µM c9,t11-CLA isomer demonstrated the strongest 
inhibitory effect on growth of the MCF-7 cell line in comparison to the t10,c12-CLA 
isomer and CLA, after 2, 3 and 4 days (Chujo et al., 2003).  Miller et al. (2003) 
investigated the effect of CLA from milk fat and synthetic c9,t11-CLA in the MCF-7 
cell line.  Milk fat containing 80.6 µM CLA inhibited growth of the MCF-7 cell line 
by 61%, while the synthetic c9,t11-CLA caused growth inhibition of 49%.  Thus 
CLA and the individual isomers have caused varying toxicity to cells depending on 
time of incubation, concentration and cell line.  In general, the MDA-MB-231 cell 
line was less sensitive to treatment; a fact partially explained by the negative ER 
status of these cells (Tanmahasamut et al., 2004).  Both the 4T1 and Hs578T cell 
lines are ER negative (Banka et al., 2006 and ATCC), which could account for the 
low level of toxicity noted in the Hs578T cell line.  Toxicity in the 4T1 cell line was 
obviously effected through other mechanisms and so this was investigated further.  
The effect of CLA and the individual isomers on cell cycle kinetics was 
examined in the 4T1 cell line.  The Guava® PCA flow cytometry system was used for 
these experiments.  This machine has been designed for high-throughput, benchtop 
use with the required assays pre-programmed into the system.  The cell cycle is 
rigorously controlled by checkpoints throughout the process to ensure mutations 
cannot be passed on to daughter cells.  The main checkpoints occur at the latter stages 
of the G1 phase, during S phase and late in the G2 phase, before mitosis occurs.  The 
G1 checkpoint, called the restriction (R) point, halts cells moving into the S phase 
until all the necessary proteins are synthesised for DNA replication and the DNA is 
checked for damages.  During DNA synthesis in the S phase, replication can be halted 
due to depletion of nucleotide pools or misincorporation of nucleotides.  At the G2 
checkpoint, the DNA is once again checked to ensure replication is complete and all 
damage has been repaired before the cell moves into the mitosis phase (Sampath and 
Plunkett, 2001).   
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Two concentrations, 54 µM and 89 µM, were chosen to assess perturbations 
in the cell cycle.  In comparison to control-treated cells, all treatments at the lower 
concentration caused a G1 arrest, and a decrease in the S and G2 phase populations 
(Figures 3.17 and 3.18, Table 3.5).  The greatest arrests in the G1 phase were noted 
following treatment with 54 µM LA and c9,t11-CLA, with populations increased to 
74.4% and 71.7% respectively, in comparison to the control (37%).  In the control, 
39.7% of the cells were in the S phase.  The c9,t11-CLA isomer had the greatest 
effect on this phase, reducing the population to 8.2%.  LA, CLA and t10,c12-CLA 
caused a decrease in S phase population to 12.5%, 15.4% and 24.5% respectively.  
The t10,c12-CLA isomer had the greatest effect on the G2 population, reducing it to 
10.2%, in comparison to the control (23.2%).  The c9,t11-CLA isomer caused a small 
reduction in G2 phase population, to 20.1%, with LA and CLA decreasing the 
population to 13.2% and 17.1% respectively.  In the cytotoxicity experiments, 54 µM 
CLA caused approximately 60% cell death, while the other treatments were not toxic 
to the 4T1 cells.  Regardless of this, CLA did not have a dramatic effect on the cell 
cycle in comparison to the other fatty acids.   
At the higher concentration of 89 µM, an increase was also observed in the G1 
phase population (Figures 3.19 and 3.20, Table 3.6).  LA caused the greatest increase, 
with the G1 population rising to 69% compared to 35.3% for the control.  Treatment 
with CLA, c9,t11-CLA and t10,c12-CLA increased the G1 phase population to 
57.8%, 65.3% and 64% respectively.  The S and G2 phase populations decreased 
following all treatments at the higher concentration.  The S phase population dropped 
from 45.4% for the control to 13.5%, 29.5%, 22.8% and 20.7% following treatment 
with LA, CLA, c9,t11-CLA and t10,c12-CLA respectively.  The G2 phase population 
decreased to 17.5% and 15.3% following treatment with LA and t10,c12-CLA 
respectively, in comparison to the control (19.3%).  CLA and c9,t11-CLA caused 
greater decreases in G2 phase populations to 12.7% and 11.9% respectively.  In 
comparison to the effect at 54 µM, the arrest in G1 phase was not as pronounced and 
the S phase population was greater following treatment with 89 µM fatty acids.  This 
could suggest increased apoptosis from the G1 phase population at the higher 
concentration. 
Durgam and Fernandes (1997) also reported arrest of MCF-7 cells in the G1 
phase following treatment with 35 µM CLA for 3 days.  71% of the cell population 
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was in the G1 phase as compared to 53% of the control cells.  LA, however, did not 
cause an increase in the G1 phase population in their experiments.  In contrast, in the 
MDA-MB-231 cell line, no effect was noted in cell cycle kinetics following treatment 
with 60 µM CLA for 24 or 48 hours (Miglietta et al., 2006a).  After 72 hours 
treatment, a decrease was observed in the G1 phase population, with a corresponding 
increase in S phase population.  Our results, along with this data, would indicate that 
the effects of CLA on cell cycle kinetics are dependent on cell line and concentration 
of treatment.  However, research using non-breast cancer cell lines has also shown G1 
phase arrest following CLA treatment.  In the HT-29 colorectal cancer cell line, dose-
dependent increases in the G1 phase population were noted with increasing 
concentration of CLA (18/36/71 µM) following treatment for 3 days (Lim et al., 
2005).  The S and G2 phase populations decreased accordingly.  Cho et al. (2006) 
looked at the effect of the t10,c12-CLA isomer on the cell cycle kinetics of the HT-29 
cell line.  Treatment with just 4 µM t10,c12-CLA caused a G1 phase arrest and 
reduction in the percentage of cells in the S and G2 phases, although the authors did 
not specify the duration of treatment.  Liu et al. (2002) also saw a G1 phase arrest in 
the gastric adenocarcinoma cell line SGC-7901 following treatment with a range of 
concentrations of c9,t11-CLA over 24 and 48 hours.   
Analysis of the effect of the treatment with fatty acids on apoptosis in the 4T1 
cell line was conducted using an annexin V/7-AAD assay.  During early apoptosis, 
phosphatidylserine molecules on the inner surface of the cell membrane become 
translocated to the outer membrane where they can bind annexin V.  At later stages of 
apoptosis and during necrosis, the membrane integrity is compromised and the 7-
AAD stain can enter the cell.  Treatment of the 4T1 cells with 54 µM LA, CLA and 
c9,t11-CLA did not cause any significant change in the levels of apoptotic cells 
(Figure 3.24).  The treatment with 54 µM t10,c12-CLA caused a significant increase 
in apoptotic cells in comparison to the control.  The results for LA and c9,t11-CLA 
correlated with the low cytotoxicity observed following this treatment (Figure 3.11).  
The level of apoptosis noted in the cells treated with CLA was lower than the cell 
death noted in the cytotoxicity assays under the same conditions.   
Following treatment at the higher concentration of 89 µM, a significant 
increase in apoptotic cells was noted for CLA and the c9,t11-CLA isomer (Figure 
3.24).  CLA treatment resulted in an increase in apoptotic cells to approximately 75%, 
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which correlated with the cytotoxicity exhibited after the same treatment (Figure 
3.11).  The c9,t11-CLA isomer caused an increase in apoptotic cells to approximately 
59%, which was similar to the cell death observed in the cytotoxicity assays.  The 
apoptotic population of cells was not significantly increased following treatment with 
LA or t10,c12-CLA, correlating with the results from the cytotoxicity assays.   
Analysis of apoptosis following treatment with CLA has been examined by 
Maggiora et al. (2004) in the MCF-7 and MDA-MB-231 cell line.  This group 
reported an increase in apoptosis in the MCF-7 cell line following treatment with 50 
µM and 200 µM CLA for 48 hours, but little increase in the MDA-MB-231 cell line.  
Levels of apoptotic cells were 25% at the higher concentration of 200 µM in the 
MCF-7 cell line.  Majumder et al. (2002) reported induction of apoptosis in the MCF-
7 cell line following treatment with 50 µM and 100 µM CLA for 24 hours.  The effect 
in the MDA-MB-231 cell line was not as pronounced under the same conditions.  The 
effect of individual isomers on apoptosis has not been looked at in breast cancer cell 
lines.  The c9,t11-CLA isomer did not cause any induction of apoptosis in the 
HCT116 colorectal cancer cell line after treatment with 50 µM for 72 hours (Lee et 
al., 2006).  On the other hand, treatment with the t10,c12-CLA isomer doubled the 
percentage of apoptotic cells.  Cho et al. (2005) also saw a doubling in the apoptotic 
cell population following treatment of the HT-29 colorectal cancer cell line with 4 
µM t10,c12-CLA.  This group reported no induction of apoptosis following treatment 
with the c9,t11-CLA isomer.  These results, and the data presented here, confirm that 
CLA induced apoptosis in a number of different cell lines.  The results for the 
individual isomers presented here did not correlate with the literature and this would 
indicate that the effect may be species or cell line dependent. 
Metastasis of tumour cells to secondary sites of the body plays a significant 
role in the prognosis of the disease.  Numerous factors influence this action, including 
the ability of the tumour cell to migrate, to invade the ECM and also to grow and 
divide in a new organ (Bogenrieder and Herlyn, 2003).  Migration of the 4T1 cell line 
following treatment with CLA and the individual isomers was investigated using the 
FalconTM Cell Culture Inserts.  Cells were pre-treated for 48 hours with 18 µM fatty 
acids, then seeded into the chamber and incubated for 24 hours with treatment added.  
The effects on migration of this cell line are illustrated in Figures 3.25, 3.26 and 3.27.  
LA and CLA treatment did not result in a change in the migratory ability of the 4T1 
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cells.  The c9,t11-CLA isomer caused an increase in migration of the cells but due to 
large error bars this difference was not statistically significant.  Treatment with the 
t10,c12-CLA isomer resulted in a statistically significant decrease in migration of the 
4T1 cells (p<0.05).  These results are illustrated in the images in Figures 3.26 and 
3.27.   
For invasion assays, cells were treated in the same manner and seeded into BD 
BioCoatTM MatrigelTM Invasion Chambers.  Treatment of the cells with LA and 
t10,c12-CLA caused a decrease in invasion, while CLA and c9,t11-CLA treatment 
caused an increase but these results were not statistically significant due to large error 
bars (Figure 3.28).  The considerable standard deviations are due to inter-assay 
variability despite a general consistency in the results trend.  This has previously been 
noted in our laboratory with this assay and is probably due to variations in batches of 
Matrigel-coated membranes.  The chambers and invaded cells can be seen in the 
images in Figures 3.29 and 3.30.  The increase in invaded cells following treatment 
with c9,t11-CLA can be clearly seen in these pictures.   
In the ADF human glioblastoma cell line, pre-treatment with 25 µM CLA 
caused a decrease in cell migration and invasion after incubation for 6 hours in the 
chambers (Cimini et al., 2005).  Migration and invasion were reduced to 
approximately 40% and 20% of the control cells respectively.  Chen et al. (2003) 
looked at migration and invasion of the human gastric carcinoma cell line SGC-7901 
following treatment with the c9,t11-CLA isomer.  The authors pre-treated the cells for 
24 hours prior to seeding, and during the 4 hour incubation in the migration 
chambers, resulting in a dose-dependent decrease in migration of the cells.  The 
highest concentration of 200 µM caused inhibition of cell migration by 16% in 
comparison to the control.  Invasion results were similar, with a dose-dependent 
reduction of invading cells.  At the highest concentration, cell invasion was inhibited 
by 53.7%. 
Invasion of the human gastric cell line MKN28 and the human colon cancer 
cell line Colo320 was investigated following treatment with 0.5 nM and 1 nM CLA 
(Kunayasi et al., 2006).  Both treatments caused a decrease in invasion of the cells, 
with 1 nM CLA reducing invasion to 2% and 8% of the controls in the MKN28 and 
Colo320 cell lines respectively.  The authors did not specify the duration of treatment 
or incubation in the invasion chambers.  A recent publication looked at the effects of 
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the individual isomers c9,t11-CLA and t10,c12-CLA on phorbol 12-myristate 13-
acetate (PMA)-induced migration of the SW480 cell line (Soel et al., 2007).  
Treatment for the 16 hour incubation in the chambers with 1 µM, 2 µM and 4 µM of 
the c9,t11-CLA isomer, but not the t10,c12-CLA isomer, resulted in decreased 
migration of the cells.  Thus, all published reports to date documented a decrease in 
migration and invasion following fatty acids treatment, correlating with the result 
presented here for the t10,c12-CLA isomer.  Increases in migration following c9,t11-
CLA treatment and in invasion following CLA and c9,t11-CLA treatments have not 
previously been reported but the results detailed here were not statistically significant. 
Adhesion of cells plays a major role in invasion and metastasis (Hanahan and 
Weinberg, 2000).  Loss of adhesion to the surrounding cells and the ECM allows 
invasion and migration into the blood or lymph system, which facilitates cells in the 
process of metastasis.  Treatment of the 4T1 cell line with 18 µM fatty acids for 3 
days caused a decrease in adhesion of CLA-treated cells and an increase in adhesion 
of cells pre-treated with c9,t11-CLA and t10,c12-CLA (Figure 3.31).  However, these 
results were not statistically significant.  Adhesion of the ADF human glioblastoma 
cell line was investigated following treatment with 25 µM for 48 hours (Cimini  et al., 
2005).  The authors reported an increase in adhesion to plastic to approximately 200% 
of control cells.  Adhesion to gelatin and Matrigel was also increased.  In contrast, 
adhesion of the human gastric carcinoma cell line SGC-7901 to laminin, fibronectin 
and Matrigel decreased in a dose-dependent manner following treatment with a range 
of concentrations of c9,t11-CLA (Chen et al., 2003).   
Soft agar assays were used to test the effect of CLA and individual isomers on 
anchorage-independent growth of the 4T1 cell line.  Growth in soft agar is regarded 
as an indication of tumourigenicity and has been shown to be associated with 
experimental metastatic potential (Price et al., 1986).  A significant stimulatory effect 
on colony formation was noted following treatment with the t10,c12-CLA isomer for 
3 days (P<0.00005) (Figure 3.32).  Significant increases were also observed after 
CLA and c9,t11-CLA treatment (p<0.01).  Colonies can be seen in Figure 3.33, with 
the growth of colonies of cells pre-treated with t10,c12-CLA having an effect on the 
pH of the medium.  A thorough search through published literature did not reveal any 
reports on the effect of CLA on soft agar colony formation to date.  The effect of LA 
on soft agar colony formation was investigated in the MCF-7 cell line (Chamras et 
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al., 2002).  LA, at concentrations of 1 µM, 10 µM and 100 µM, did not have any 
significant effect on colony growth.  Cells were treated for the two week duration of 
the assay.  
The overall effect of the t10,c12-CLA isomer was to reduce migration and 
invasion of the 4T1 cell line and increase colony formation in soft agar.  The 
decreases in migration and invasion could suggest an effect on the role of adhesion 
molecules in this event.  CLA has been shown to modulate the activation of PPARs.  
The effect of CLA on PPARγ has recently been reported to influence β-catenin and 
E-cadherin expression in the MCF-7 cell line (Bocca et al., 2007).  An increase in 
both proteins was noted along with an increase in co-precipitation of the proteins, 
suggesting a role for CLA in stabilisation of the β-catenin:E-cadherin complex.  This 
could explain the migration and invasion results reported here with t10,c12-CLA and 
the 4T1 cell line.  An increase in cell-cell adhesion would decrease migration and 
invasion.  Further investigation along these lines is needed to confirm the mechanism 
of the decreased migration and invasion.  Although adhesion of pre-treated cells to 
plastic was not affected by the treatments, adhesion to Matrigel, fibronectin and 
laminin could be examined.   
The stimulatory effect of t10,c12-CLA on colony formation in soft agar could 
be further assessed using varied concentrations to determine if the effect on colony 
growth is dose-dependent.  Molecular interactions responsible for this result could be 
examined by analysing changes in the Ras/Raf/ERK protein kinase pathway, which is 
involved in cell proliferation.  Modulation by CLA of expression of proteins in this 
pathway has been reported in the literature (Miglietta et al., 2006b and Miller et al., 
2003).   
With the decrease in migration and invasion of cells following treatment with 
the t10,c12-CLA isomer and the increase caused by c9,t11-CLA treatment, we 
decided to investigate the roles of MMPs and TIMPs in these results.  MMPs play a 
major role in the process of metastasis and the combined activity of the whole family 
of enzymes can degrade the ECM (Lynch and Matrisian, 2002).  Following treatment 
of the 4T1 cells with 18 µM fatty acids, mRNA was extracted and subjected to RT-
PCR.  Primers for MMP-2 and MMP-9 were used to examine the levels of these 
gelatinase enzymes in the 4T1 cells by RT-PCR.  A decrease in MMP-2 was noted 
after all treatments with the fatty acids, although bands were faint even after 30 cycles 
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of PCR (Figure 3.36).  In contrast, MMP-9 levels varied in response.  Following 
treatment with LA, CLA and t10,c12-CLA there was an increase in the level of 
MMP-9 mRNA.  c9,t11-CLA treatment however caused a decrease in MMP-9 
mRNA levels (Figure 3.36).   
Gelatin zymography was used to examine the level of MMP-2 and MMP-9 
proteins secreted into the conditioned medium from the cells (Figure 3.37).  Bands for 
murine MMP-9 were observed at 105 kDa.  Densitometry showed increases in MMP-
9 protein in the samples from CLA, c9,t11-CLA and t10,c12-CLA-treated cells in 
comparison to the control.  Treatment with LA caused a decrease in the level of 
MMP-9 protein.  The effect of CLA and t10,c12-CLA treatments on MMP-9 protein 
levels correlated with the effect observed on mRNA levels.  The MMP-9 protein 
levels in cells treated with LA and c9,t11-CLA had opposing results to the mRNA 
findings.  This could indicate post-transcriptional regulation influencing the levels of 
protein being produced.  Western blotting was conducted to confirm the MMP-9 
protein levels but no bands were visible (data not shown), probably due to low 
affinity of the antibody for the murine protein, despite indications otherwise from the 
manufacturer’s data sheet.   
No bands were observed for MMP-2 on a gelatin zymogram, indicating that 
protein levels were too low for detection.  The MMP-2 RT-PCR bands present in 
Figure 3.36 were quite faint and thus low mRNA levels could account for the low 
protein levels.  The Hs578T cell line had previously been shown to express MMP-2 
(Hughes, 2006).  In order to look at the effect of the fatty acids on MMP-2 protein 
levels, the Hs578T cell line was treated and conditioned medium collected.  Gelatin 
zymography using these samples showed an increase in MMP-2 protein levels 
following all treatments, in comparison to the control (Figure 3.38).  A western blot 
using an anti-MMP-2 antibody confirmed the increase in protein following treatment 
with LA, CLA and c9,t11-CLA however, no increase was noted following treatment 
with t10,c12-CLA (Figure 3.39).  RNA levels were not investigated in this cell line.   
The TIMP molecules help to modulate MMP activity by binding non-
covalently to the active MMPs (Birkedal-Hansen et al., 1993).  Thus, the effect of 
CLA and the individual isomers on TIMP mRNA and protein expression was 
investigated.  RT-PCR analysis of TIMP-1 and TIMP-2 showed varied effects on the 
mRNA levels (Figure 3.40).  TIMP-1 mRNA levels were decreased after all 
treatments, with the greatest reduction observed following treatment with t10,c12-
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CLA.  TIMP-2 mRNA levels were reduced following treatment with LA but 
increased following CLA and t10,c12-CLA treatment.  The bands for TIMP-2 mRNA 
were weak, which would correlate with the MMP-2 result, as TIMP-2 plays a role in 
regulating MMP-2 (Birkedal-Hansen et al., 1993).  Unfortunately, the reverse 
zymogram with conditioned medium from the treated cells was not sensitive enough 
to detect bands for the TIMP proteins. 
Cimini et al. (2005) looked at the effect of 25 µM CLA on MMP-2 expression 
on the ADF human glioblastoma cell line.  Treatment for 48 hours down-regulated 
MMP-2 protein expression.  Modulation of both MMP-2 and MMP-9 protein levels 
in the SGC-7901 gastric carcinoma cell line by the c9,t11-CLA isomer were 
investigated by gelatin zymography (Chen et al., 2003).  A dose-dependent reduction 
of MMP-9 protein was noted following treatment with 25 µM, 50 µM, 100 µM and 
200 µM c9,t11-CLA for 24 hours.  No effect was observed on MMP-2 protein levels 
in the same samples.  The authors also investigated the effect of the c9,t11-CLA 
isomer on TIMP-1 and TIMP-2 mRNA levels by RT-PCR.  A dose-dependent 
increase in TIMP-1 and TIMP-2 mRNA was noted following treatment with 25 µM, 
50 µM, 100 µM and 200 µM c9,t11-CLA for 24 hours.   
A recent publication examined the effects of c9,t11-CLA and t10,c12-CLA on 
phorbol 12-myristate 13-acetate (PMA)-induced expression of MMP-9 protein in the 
SW480 cell line (Soel et al., 2007).  The c9,t11-CLA isomer caused a dose-dependent 
decrease in MMP-9 protein activity as assessed by gelatin zymography.  The t10,c12-
CLA isomer had no effect on the activity of MMP-9.  However, the isomers did not 
have any effect on the MMP-9 protein levels as analysed by western blot.  These 
results and the findings presented here suggest tissue-specific effects of CLA and the 
isomers on the levels of MMP-2 and MMP-9.  In our results, the increase in MMP-9 
protein following treatment with CLA, c9,t11-CLA and t10,c12-CLA correlated with 
the decrease in TIMP-1 mRNA levels, as the association of these two proteins 
regulates MMP-9 activity (Birkedal-Hansen et al., 1993).  Unfortunately, the reverse 
zymogram could not confirm the reduced protein levels of TIMP-1.  The invasion 
results following CLA treatment correlated with the increase in MMP-9 protein levels 
and the decrease in TIMP-1 mRNA levels.   
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3.4  Summary 
 
The effect of CLA and the individual isomers, c9,t11-CLA and t10,c12-CLA, 
produced interesting but varied results with regards to cytotoxicity, cell cycle 
kinetics, apoptosis, migration, invasion, adhesion, colony formation in soft agar and 
MMP/TIMP levels.  CLA was the most toxic to both the 4T1 murine mammary 
cancer cell line and the Hs578T human breast cancer cell line in comparison to the 
individual isomers.  Analysis of cell cycle kinetics revealed a predominant G1 phase 
arrest in the 4T1 cells following treatments.  Migration and invasion of the 4T1 cell 
line was increased after treatment with c9,t11-CLA and decreased after treatment 
with t10,c12-CLA (p<0.05).  Adhesion assays did not show any significant changes 
after treatment with the fatty acids.  The t10,c12-CLA isomer had a significant effect 
on colony formation of the 4T1 cells in soft agar, with a 25-fold increase in colonies 
formed in comparison to the control (P<0.00005).  The c9,t11-CLA isomer and CLA 
also increased the number of colonies formed (p<0.01).  MMP-2 mRNA levels were 
reduced in the 4T1 cell line following all treatments but MMP-2 protein expression 
was not observed using gelatin zymography.  MMP-2 protein levels in the Hs578T 
cell line were increased following treatment with c9,t11-CLA and t10,c12-CLA.  
MMP-9 mRNA and protein levels were increased following treatment with CLA and 
t10,c12-CLA, which correlated with decreased TIMP-1 mRNA levels.  Future work 
in this area would focus on the effect of the t10,c12-CLA isomer on migration, 
invasion, adhesion and colony growth in soft agar.  
  
 
 
Chapter 4 
 
Biological evaluation of a series of 5-Fluorouracil and 5-
Fluorouridine derivatives in breast and colorectal cancer 
cell lines 
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4.1  Introduction 
 
4.1.1  5-Fluorouracil: Metabolism and mechanisms of action 
 
5-Fluorouracil (5-FU) is an anti-metabolite agent, first synthesised in 1957 by 
replacing hydrogen with fluorine at position 5 of the uracil molecule.  It was designed 
following the discovery that rat hepatomas utilised uracil more rapidly than normal 
tissues (Longley et al., 2003).  5-FU and its deoxynucleoside, 5-Fluorouridine (5-
FUrd), are used extensively in the treatment of a wide range of solid tumours, 
including colorectal, breast and gastric cancers (Figure 4.1).  Treatment with 5-FU 
alone has response rates of only 10-15%, while combination treatments with 
irinotecan and oxaliplatin increase response rates to 40-50% (Longley et al., 2003 and 
Venook, 2005).   
 
N
N
O
O
F
5-FU
O
OH OH
OH N
N
O
F
O
5-FUrd  
 
Figure 4.1 The structure of 5-FU and 5-FUrd.  
 
Upon introduction into the body, there are two pathways which 5-FU can 
undertake (Figure 4.2).  Approximately 80% of injected 5-FU follows the catabolic 
route, which involves degradation of 5-FU by the enzyme dihydropyrimidine 
dehydrogenase (DPD) into dihydrofluorouracil (DHFU), then α-fluoro-β-
ureidopropionic acid and α-fluoro-β-alanine which are excreted from the body in the 
urine (Malet-Martino and Martino, 2002 and Heggie et al., 1987).  This primarily 
occurs in the liver but also in the plasma and gastrointestinal (GI) tract (Longley et 
al., 2003).  The remaining 5-FU is utilised by the anabolic route, which leads to three 
main mechanisms of action of toxicity; RNA misincorporation, thymidylate synthase 
(TS) inhibition and DNA misincorporation. 
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Firstly, 5-FU can be converted to 5-FUrd by uridine phosphorylase (UP), 
followed by conversion to 5-Fluorouridine monophosphate (5-FUMP) by uridine 
kinase (UK) (Xiong and Ajani, 2004).  5-FUMP is also derived directly from 5-FU 
via the action of orotate phosphoribosyltransferase (OPRT).  5-FUMP can then be 
phosphorylated by pyrimidine monophosphate kinase (PMK) to 5-Fluorouridine 
diphosphate (5-FUDP), which is further phosphorylated to 5-Fluorouridine 
triphosphate (5-FUTP) by pyrimidine diphosphate kinase (PDK).  5-FUTP is partially 
responsible for the anti-cancer effect of 5-FU through RNA misincorporation.  RNA 
polymerases (RP) insert 5-FUTP into all classes of RNA instead of uridine-5-
triphosphate (UTP).  Pre-ribosomal RNA (rRNA) processing to mature rRNA is 
inhibited, along with disruption of post-transcriptional modification of transfer RNAs 
(tRNAs).  Complexes of small nuclear RNA (snRNA) and proteins are affected and 
lead to inhibition of splicing of pre-messenger RNA (mRNA) (Longley et al., 2003 
and Malet-Martino and Martino, 2002). 
Thymidine phosphorylase (TP) is involved in converting 5-FU into 5-
Fluorodeoxyuridine (5-FdUrd) in the first step of the second mechanism of action, TS 
inhibition.  Thymidine kinase (TK) phosphorylates 5-FdUrd giving 5-
Fluorodeoxyuridine monophosphate (5-FdUMP).  5-FdUMP is the key molecule 
involved in the inhibition of TS which is the primary mode of action of 5-FU toxicity.  
The enzyme TS is usually involved in the conversion of deoxyuridine monophosphate 
(dUMP) to deoxythymidine monophosphate (dTMP), the precursor to 
deoxythymidine triphosphate (dTTP), which is incorporated into DNA during 
replication of the genome and during repair mechanisms.  The reduced folate 5,10-
methylenetetrahydrofolate (CH2THF) acts as methyl donor, transferring a methyl 
group to the carbon 5 of dUMP to form dTMP.  TS acts as a dimer, each subunit 
binding FdUMP and CH2THF.  The fluorine atom at position 5 of FdUMP is more 
tightly bound than the hydrogen of dUMP and so cannot be removed for replacement 
with the methyl group, thus forming a stable ternary complex of these molecules 
(Malet-Martino and Martino, 2002).  This action sequesters TS in the cell and thereby 
prevents binding of dUMP, thus cutting off production of dTMP.  This leads to 
disruption of DNA synthesis and repair, and subsequent cell death (Longley et al., 
2003 and Malet-Martino and Martino, 2002).  TS inhibition also results in dUMP 
accumulation in the cell, which leads to increased production of deoxyuridine 
triphosphate (dUTP).  dUTP can be integrated into DNA in place of dTTP, 
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contributing to cell damage by the third mechanism of action of 5-FU, DNA 
misincorporation.  This mechanism is also played out by the production of 5- 
Fluorodeoxyuridine triphosphate (5-FdUTP). By the action of enzymes 
ribonucleotide reductase (RR) and pyrimidine diphosphate kinase (PDK), 5-FUDP 
can be converted to 5-Fluorodeoxyuridine diphosphate (5-FdUDP) and then 5-
FdUTP.  Incorporation of uracil and 5-FdUTP into DNA causes DNA damage and 
cell death. 
 
4.1.2 5-Fluorouracil resistance 
 
Variations in expression of the numerous enzymes involved in the complex 
metabolism process play a major role in the efficacy of, and the resistance to, 5-FU 
treatment.  DPD activity primarily determines the level of 5-FU that is rapidly 
eliminated from the body before the drug can exert any effect on the tumour cells.  
Variability in activity of this enzyme has been observed between patients and also 
between normal and tumour tissue in the one patient (Malet-Martino and Martino, 
2002).  High levels of DPD mRNA have been noted in various tumours and cell lines 
with low sensitivity to 5-FU (Kakimoto et al., 2005).  Patients with low DPD levels 
can experience systemic toxicity following treatment with 5-FU while over-
expression of DPD has been shown to correlate with resistance to the treatment 
(Longley et al., 2003).   
TS activity and expression also has an effect on cellular sensitivity to 5-FU.  
The promoter of the TS gene is polymorphic, with variation in a 28 bp tandem repeat 
sequence.  TSER*2 and TSER*3 promoters have 2 or 3 tandem repeats in the 
enhancer region respectively.  TS promoters containing the TSER*3 sequence result 
in mRNA levels threefold higher than those with the TSER*2 sequence.  Individuals 
who are homozygous for TSER*3 have been shown to be less likely to respond to 5-
FU-based chemotherapy, due to the increased levels of TS (Relling and Dervieux, 
2001 and Longley et al., 2003).  TS expression is also induced following treatment 
with 5-FU due to a negative-feedback mechanism – free TS can bind to TS mRNA, 
preventing translation, thus when TS is sequestered into complexes with FdUMP, the 
mRNA is released to be translated, producing more TS protein (Longley et al., 2003).  
This is also a potential mechanism of resistance of cells to 5-FU.   
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Mutations or loss of the tumour suppressor p53 may also play a role in the 
development of resistance to 5-FU chemotherapy.  The normal function of p53 is to 
induce apoptosis in cells with DNA damage.  Following loss of function, these cells 
can avoid apoptosis and thus reduce the cellular sensitivity to 5-FU treatment 
(Longley et al., 2003).  DNA MMR function similarly has an effect on response to 5-
FU.  Cells with low levels of MMR proteins are less sensitive to 5-FU due to lack of 
detection of the DNA damaging chemotherapeutic agent intended to initiate cell death 
(Jover et al., 2006).   
 
4.1.3 Administration of 5-FU 
 
5-FU, as a small molecule with a pKA of 8.0, would be expected to have 
excellent absorption and bioavailability (Malet-Martino and Martino, 2002).  
However, it is rarely administered orally due to irregular absorption, possibly 
accounted for by the variation in levels of DPD in the GI tract.  It is usually 
administered intravenously, either by continuous infusion (CI) or bolus infusion.  The 
side effects or toxicities accompanying 5-FU chemotherapy vary between these two 
methods of administration.  Patients under the bolus regimen usually experience 
myelosuppression, oral mucositis, diarrhoea, nausea and vomiting.  These GI side-
effects are a result of the conversion of 5-FU into 5-FUMP by OPRT in the GI tract.  
Hand-foot syndrome affects patients administered 5-FU under CI without the 
hematologic or GI toxicities (Malet-Martino and Martino, 2002).  Prolonged exposure 
through CI results in TS-directed cell death while the RNA-mediated cell death is 
seen mainly following bolus administration of 5-FU (Xiong and Ajani, 2004, and 
Malet-Martino and Martino, 2002).  
While remaining one of the most widely used chemotherapeutic agents, the 
lack of selectivity of 5-FU for tumour tissue, the short half-life in plasma (5-20 
minutes), the low bioavailability due to DPD degradation and tumour cell resistance 
has led to numerous combination therapies and the introduction of 5-FU prodrugs in 
an attempt to overcome these short-comings (Malet-Martino and Martino, 2002). 
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4.1.4 Combination therapies of 5-FU 
 
To improve the response rates to 5-FU, a number of combination therapies 
have been developed for patients.  Leucovorin (5-formyltetrahydrofolate, LV) is the 
calcium salt of folinic acid and acts as an intracellular source of reduced folates, 
including CH2THF, which is required for the formation and stabilisation of the TS-
FdUMP-CH2THF complex, thereby increasing the inhibition of TS (Longley et al., 
2003 and Malet-Martino and Martino, 2002).  Clinical trials combining 5-FU with LV 
showed an increase in overall response rate from 11% to 23% (Xiong and Ajani, 
2004).  5-FU is now administered with LV as standard chemotherapy.  Oxaliplatin is 
often combined with 5-FU/LV for treatment of colorectal cancer, a regimen termed 
FOLFOX.  This drug is a platinum analog, which acts as a DNA-damaging agent 
(Xiong and Ajani, 2004).  Irinotecan is a synthetic analogue of camptothecan and is 
converted to SN38, a topoisomerase inhibitor.  Irinotecan treatment with 5-FU/LV is 
termed FOLFIRI.  Irinotecan prevents the religation of DNA following cleavage by 
topoisomerase I by stabilising the complex formed by the enzyme and the DNA, 
resulting in apoptosis (Xiong and Ajani, 2004).  The combination of 5-FU/LV with 
irinotecan and oxaliplatin has been termed FOLFOXIRI and has recently shown 
significant antitumour activity and allowed surgical resection of metastases in patients 
(Masi et al., 2006).  Eniluracil (EU), administered in combination with 5-FU, is an 
irreversible inhibitor of DPD that binds to its active site, resulting in increased oral 
bioavailability and a prolonged half-life of 5-FU (Xiong and Ajani, 2004 and Lamont 
and Schilsky, 1999).   
 
4.1.5  Prodrugs  
 
A prodrug is a pharmacologically inactive drug, which is only modified at the 
tumour site to a pharmacologically active species (Denny, 2001).  Prodrugs have been 
designed to enhance drug uptake or the pharmacokinetics.  Tumour-activated 
prodrugs (TAP) have also recently been investigated.  Prodrugs can be activated by 
conditions or enzymes within the cell (termed bioreductive prodrugs), by an enzyme 
delivered to the cell via antibody attachment (termed antibody directed enzyme 
prodrug therapy - ADEPT) or by an enzyme whose gene was delivered by gene 
therapy (termed gene directed enzyme prodrug therapy - GDEPT).   
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Bioreductive prodrugs can be activated by biological enzymes in the cell, with 
selectivity occurring due to the hypoxic conditions of tumours.  In normal tissues, the 
reaction is incomplete or reversed due to the presence of oxygen while in the hypoxic 
tumour cells, the reaction is allowed to commence and the active drug is produced 
(Sinhababu and Thakker, 1996).  ADEPT involves the delivery of a non-human 
enzyme to the tumour site by covalent linkage to a monoclonal antibody directed to 
tumour-specific antigens (Sinhababu and Thakker, 1996).  GDEPT, or suicide gene 
therapy, delivers the gene encoding a non-human enzyme to the tumour cell where 
the enzyme is produced.  Following targeting of the antibody-enzyme complex or the 
gene to the tumour cells in ADEPT and GDEPT, the prodrug is then administered to 
the patient.  Activation of the prodrug will thus occur specifically at the tumour site 
(Denny, 2001).   
Photodynamic therapy (PDT) is another method of activation of a prodrug.  In 
traditional PDT, a photosensitiser is delivered to the tumour cell and, upon 
application of visible light, converts molecular oxygen to highly reactive oxygen 
species (ROS), causing cell death (Castano et al., 2006).  Utilising this strategy with a 
prodrug attached to a photosensitiser would prolong the effect on the cells after 
exposure to the light therapy (Gray, 2005).   
 
4.1.6  Objectives of Chapter 4 
 
The aims and objectives of the work outlined in this chapter were to examine 
the biological activity of a panel of 5-FU and 5-FUrd derivatives, including five 
prodrugs.  The compounds were synthesised and analysed as part of a structure-
activity relationship (SAR) study to investigate the effect of varying components on 
these widely used chemotherapeutic agents.  Firstly, the effect was investigated by 
testing the compounds in a murine mammary and a human colorectal cancer cell line 
to determine the levels of toxicity.  The effect on proliferation of a 5-FU resistant 
colorectal cancer cell line was also investigated.  Modulation of the cell cycle kinetics 
and apoptosis following treatment with the compounds was examined, to determine 
the molecular mechanisms involved.  Assays were conducted to investigate the 
effects of the compounds on the migration, invasion and soft agar colony formation of 
the cells.   
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4.2  Results 
 
5-FU and 5-FUrd derivatives were synthesised and their cytotoxicity was 
assessed for a range of concentrations over 3 and 5 days using the 4T1 murine 
mammary cancer cell line, the SW480 human colorectal cancer cell line and the 
HCT116 human colorectal cancer cell line.  Cytotoxicity was expressed as percentage 
cell death in relation to cells treated with vehicle only.  IC50 values were extrapolated 
from the toxicity profiles.  The effect of the compounds on the cell cycle kinetics and 
apoptosis in the 4T1 cells was analysed using the Guava® Personal Cell Analysis 
(PCA) system.  Invasion and migration of the 4T1 cells following treatment with the 
compounds was assessed.  The ability of cells to form colonies in soft agar following 
treatment was also investigated. 
 
4.2.1  Synthesis of 5-FU and 5-FUrd derivatives 
  
Twelve derivatives of 5-FU and 5-FUrd were synthesised by Dr. Ian Gray and 
Dr. Kieran Nolan in the School of Chemical Sciences, Dublin City University (Lin et 
al., 1986 and Gray, 2005) (Table 4.1).  The compounds were analysed by nuclear 
magnetic resonance (NMR), and purity (>95%) confirmed.  The lipophilicity value 
(ClogP) and size (Å3) of each compound were calculated using Chem 3D Ultra 9.0 
(Cambridge Software) and are listed in Table 4.1.  The ClogP value gives an 
indication of the solubility of a compound in 1-octanol and water.  If the compound is 
more soluble in water than 1-octanol, it will have a negative ClogP value, whereas if 
the reverse is the case, the ClogP value will be positive.  The more negative the ClogP 
value, the more hydrophilic the compound and this may inhibit crossing of the 
cellular membranes.  The more lipophilic compounds, with larger ClogP values, will 
interact more with the membranes and may not cross to the aqueous phase 
(Silverman, 1992).  The size of the compounds are represented as Å3.   
Compounds 3-5 and 10-14 were derivatives of 5-FU while compounds 6-9 
were derivatives of 5-FUrd (Table 4.1).  There were 3 types of 5-FU derivatives: 
those with a nitro-benzyl side-chain, an ester side-chain or an acid derivative.  The 
side-chains were linked to either the N1 or N3 position of 5-FU, or both (Figure 4.3).  
Compounds 3, 13 and 14 contained nitro-benzyl side-chains.  The side-chain of 
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compounds 3 and 13 were joined to the N3 of 5-FU.  Compound 13 had a longer side-
chain, with the nitro-benzyl part separated by a carbonate segment.  Compounds 3 
and 14 contained the same side-chain, the side-chain attached to both the N1 and the 
N3 positions in compound 14.   
The ester group included compounds 4, 5, 10 and 11, of which, all except 
compound 10 contained a benzyl group.  Compound 4 was a long chain methoxy 
ester while compound 5 was a short chain methoxy ester, both bound at the N1 
position of the 5-FU molecule.  Compound 11 had the same short chain methoxy 
ester group as compound 5, but bound at both the N1 and the N3 position.  Compound 
10 was another short chain methoxy ester ending with a double bond between the 
final two carbons in the chain and without the benzyl group.  Compound 12 was an 
acid derivative, with no benzyl group (Table 4.1).   
 
 
N1O
O
N3
F
 
 
Figure 4.3 Structure of 5-Fluorouracil demonstrating positions of N1 and N3 where 
the side-chains were bound in the derivatives.  (Gray, 2005) 
 
The 5-FUrd derivatives contained nitro-benzyl side-chains and a taxol-derived 
side-chain.  Compounds 6 and 9 had the same nitro-benzyl side-chain as the 5-FU 
derivatives, compounds 3 and 14.  This nitro-benzyl group was at position N3 of 5-
FUrd with the sugar bound at the N1 position.  Compounds 7, 8 and 9 all had 
protected secondary hydroxyl groups C-2 and C-3 of the sugar.  This eliminated any 
possibility of unwanted side reactions with these hydroxyls.  Compound 7 contained a 
side chain which is a derivative of the side chain found in Taxol, (2R, 3S)-N-benzoyl-
3-phenylisoserine.   
Compounds 3, 6, 9, 13 and 14 were designed as prodrugs, pharmacologically 
inactive drugs which can be activated at the site of action.  Removal of the nitro-
benzyl side-chain releases the active 5-FU molecule.   
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Table 4.1 Names, molecular weights, lipophilicity values (ClogP), sizes (Å3) and 
structures of 5-FU and 5-FUrd derivatives. (ND=Not determined) 
 
547
397
294
378
265
262
130
MW
ND
-1.15
0.984
ND
1.62
-1.74
-0.577
ClogP
ND
283
190
ND
159
185
67.4
Å 3
5-Fluorouracil1
2’,3’-isopropylidene-5’-O-
((-4’’S,5’’R)-N-acetyl-
2’’,2’’-dimethyl-4’’-
phenyl-1’’,3’’-oxazolidine-
5’’-carboxylate)-
fluorouridine
7
N3-(p-nitrobenzyl)-5-
Fluorouridine
6
1-Benzyloxycarbonyl 
oxymethyl-5-Fluorouracil
5
Hexanedioic Acid 
Benzylester-5-Fluorouracil 
Methyl ester
4
3-(p-nitrobenzyl)-5-
Fluorouracil
3
5-Fluorouridine2
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Table 4.1 (Continued) Names, molecular weights, lipophilicity values (ClogP), sizes 
(Å3) and structures of 5-FU and 5-FUrd derivatives. (ND=Not determined) 
 
400
309
204
458
244
436
301
MW
2.87
0.658
-1.36
0.715
0.31
0.0287
-0.61
ClogP
283
182
112
ND
142
ND
231
Å 3 StructureChemical NameCmpd
No.
1,3-bis-(p-nitrobenzyl)-5-
Fluorouracil
14
3-(p-nitrobenzyloxy 
carbonyl)-5-Fluorouracil
13
Acid derivative of 5-FU12
1,3-benzyloxycarbonyl 
oxymethyl-5-Fluorouracil
11
1-Alloxycarbonyloxy 
methyl-5-Fluorouracil
10
2,3-Isopropylidene-N3-(p-
nitrobenzyl)-5-
Fluorouridine
9
2,3-isopropylidene-5-
Fluorouridine
8
OH O
N
N
O O
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4.2.2 Cytotoxicity of 5-FU and 5-FUrd derivatives in the 4T1 murine 
mammary cancer cell line 
 
Initial experiments were conducted in the 4T1 cell line.  Results are from a 
minimum of duplicate experiments, completed in triplicate.  Cytotoxicity assays were 
set up as described in Section 2.2.2.  Cells were seeded in triplicate and allowed to 
attach overnight before treatment was added.  Standard curves were set up for each 
assay to ensure cells were in the exponential phase of growth for the experiments.  
Cells for treatment were seeded at the second highest point on the standard curve.  
The x-axis of each cytotoxicity graph is on a logarithmic scale to show clearly the 
range of concentrations tested.  Figure 4.4 shows the cytotoxicity results for 5-FU and 
the nitro-benzyl derivatives of 5-FU, compounds 3, 13 and 14, after treatment for 3 
days.  The parent compound 5-FU showed dose-dependent cytotoxicity and was the 
most toxic to the 4T1 cells, with an IC50 value of 0.35 µM (Table 4.2).  Greater than 
80% cell death was seen from 4 µM and higher.  The toxicity profile of compound 3 
mirrored that of 5-FU but was less toxic, with an IC50 value of 0.71 µM.  Compound 
13 showed toxicity from approximately 11 µM upwards.  However, its IC50 value of 
40 µM was two orders of magnitude higher than 5-FU (Table 4.2).  Compound 14, on 
the other hand, showed low toxicity even up to 250 µM, the highest concentration 
tested.   
The cytotoxicity of the ester derivatives of 5-FU are shown in Figure 4.5.  
Compound 10, with the short chain methoxy ester ending with a double bond, showed 
dose-dependent cytotoxicity, with a low IC50 value of 0.037 µM, an order of 
magnitude lower than the parent 5-FU (Table 4.2).  Compound 11 showed increased 
toxicity in the 4T1 cells compared with 5-FU, with an IC50 value of 0.21 µM.  
Compounds 4 and 5 were also highly toxic, with IC50 values of 0.63 µM and 0.34 µM 
respectively.  Figure 4.6 shows toxicity for compound 12, the acid derivative of 5-FU, 
which mirrored very closely the toxicity profile of the parent compound, with the 
same IC50 value of 0.35 µM.   
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Figure 4.4 Cytotoxicity of the nitro-benzyl derivatives of 5-FU in the 4T1 cell line 
after treatment for 3 days.  5-FU showed the highest toxicity towards the cells with 
compound 3 marginally lower in toxicity.  Compound 13 showed toxicity only from 4 
µM upwards and low toxicity was seen for compound 14 up to the highest 
concentration tested, 250 µM.  
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Figure 4.5 Cytotoxicity of the ester derivatives of 5-FU in the 4T1 cell line after 
treatment for 3 days.  Compound 10 showed the highest toxicity towards the 4T1 
cells.  Compound 11 was also more toxic than 5-FU, with compounds 4 and 5 
marginally less toxic. 
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Figure 4.6 Cytotoxicity of the acid derivative of 5-FU in the 4T1 cell line after 
treatment for 3 days.  The toxicity profile of compound 12 mirrored that of 5-FU very 
closely, showing considerable toxicity from 0.04 µM upwards. 
 
 
The cytotoxicity results for the derivatives of the nucleoside, 5-FUrd, are 
shown in Figure 4.7.  5-FUrd was very toxic, with an IC50 value of 0.018 µM, 
revealing higher toxicity than 5-FU and also the 5-FU derivatives - compounds 10, 11 
and 12.  However, all of the 5-FUrd derivatives, compounds 6, 7, 8 and 9, showed 
low toxicity, and IC50 values were not established for these compounds at the range of 
concentrations tested.   
Figure 4.8 shows the cytotoxicity profiles of 5-FU compounds 3 and 14 and 5-
FUrd compounds 6 and 9, which all have the same nitro-benzyl side-chain.  Despite 
the similar side-chain, the only compound which showed a significant level of 
cytotoxicity was compound 3, the 5-FU derivative with the nitro-benzyl side-chain 
attached at the N3 position in the 5-FU molecule.   
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Figure 4.7 Cytotoxicity of the 5-FUrd derivatives in the 4T1 cell line after treatment 
for 3 days.  5-FUrd was toxic to the 4T1 cells from 0.004 µM upwards, compared to 
the derivatives, which showed low toxicity over the range of concentrations tested.   
 
-40
-20
0
20
40
60
80
100
0.
00
1
0.
01 0.
1 1 10 10
0
µM Treatment
%
 C
el
l D
ea
th
Cmpd 3
Cmpd 6
Cmpd 9
Cmpd 14
 
 
 
Figure 4.8 Cytotoxicity of the nitro-benzyl derivatives of 5-FU and 5-FUrd in the 
4T1 cell line after treatment for 3 days.  Despite having the same side-chain, 
compound 3 was the only derivative which showed toxicity in the 4T1 cells.   
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Cytotoxicity of the compounds was also tested in the 4T1 cell line over 5 
days.  For the sake of clarity, the individual graphs of cytotoxicity over 5 days are not 
shown but IC50 values were calculated and are listed in Table 4.2.  The 5 day 
cytotoxicity analysis showed similar patterns, with 5-FU, compounds 3, 4, 5, 10, 11 
and 12 all having low IC50 values.  Compounds 4, 5 and 10 showed the most toxicity 
with IC50 values of 0.02 µM, 0.022 µM and 0.014 µM respectively, all approximately 
one order of magnitude lower than the parent 5-FU (IC50: 0.17µM).  Compounds 3 
and 11 had similar toxicity to 5-FU, with IC50 values of 0.11 µM and 0.1 µM 
respectively, while compound 12 was less toxic with an IC50 value of 0.31 µM.  5-FU 
derivatives 13 and 14 showed low toxicity, with IC50 values two and three orders of 
magnitude higher than 5-FU respectively.  The IC50 value for 5-FUrd was not 
established in the range tested, with greater than 50% cell death seen from the lowest 
concentration tested, 0.004 µM (Table 4.2).  5-FUrd derivatives 6, 7, 8 and 9 again 
showed low toxicity.  IC50 values were not established for compounds 6, 8 and 9, over 
the range of concentrations tested.  The IC50 value for compound 7 was established at 
5.7 µM, considerably higher than the IC50 value for the parent 5-FUrd.   
 
Table 4.2 IC50 values of the 5-FU and 5-FUrd derivatives in the 4T1 murine 
mammary cancer cell line after treatment for 3 and 5 days. 
 
150±7>250bCmpd 14
16±740±7Cmpd 13
0.31±0.260.35±0.08Cmpd 12
0.1±0.080.21±0.1Cmpd 11
>16.1b>16.1bCmpd 90.014±0.0060.037±0.015Cmpd 10
>33b>33bCmpd 80.022±0.0060.34±0.1Cmpd 5
5.7±4.7>12.8bCmpd 70.02±0.0090.63±0.16Cmpd 4
>7.6b>7.6bCmpd 60.11±0.130.71±0.22Cmpd 3
<0.004a0.018±0.0045-FUrd0.17±0.060.35±0.035-FU
5 Days3 Days5 Days3 Days
IC50 Values 4T1 Cell Line (µM)
Mean ± SD
(a) IC50 value not established, lower than range of concentrations tested 
(b) IC50 value not reached up to highest concentration tested  
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4.2.3  Cytotoxicity of the 5-FU and 5-FUrd derivatives in the SW480 human 
colorectal cancer cell line 
 
The SW480 cell line was derived from a human colorectal adenocarcinoma.  
Cytotoxicity was assayed after treatment for 3 and 5 days, IC50 values were 
established and are listed in Table 4.3.  Results are from a minimum of duplicate 
experiments, completed in triplicate.  The nitro-benzyl derivatives of 5-FU caused a 
similar level of toxicity, after treatment for 3 days, to that observed in the 4T1 cell 
line (Figure 4.9).  Compound 3 was less toxic than 5-FU, with IC50 values of 11 µM 
and 4.9 µM respectively.  Compounds 13 and 14 showed no toxicity over the range of 
concentrations tested, however, due to limited availability of compounds, 
concentrations could not be tested to as high a concentration as with the 4T1 cell line.  
The ester derivatives, compounds 10 and 11, were again more toxic than the parent 5-
FU after treatment for 3 days (Figure 4.10).  The IC50 value of compound 10 (0.38 
µM) was greater than one order of magnitude less than that of the parent 5-FU (Table 
4.3).  Compounds 4 and 5 were slightly less toxic than 5-FU with IC50 values of 7.8 
µM and 7.1 µM respectively (Table 4.3).  The IC50 value of compound 12, the acid 
derivative, was 5.1 µM, again with a toxicity profile which mirrored 5-FU (Figure 
4.11). 
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Figure 4.9 Cytotoxicity of the nitro-benzyl derivatives of 5-FU in the SW480 cell 
line after treatment for 3 days.  5-FU and compound 3 showed toxicity from 1 µM 
upwards.  Compounds 13 and 14 showed low toxicity over the range of 
concentrations tested.  
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Figure 4.10 Cytotoxicity of the ester derivatives of 5-FU in the SW480 cell line after 
treatment for 3 days.  Compounds 10 and 11 showed the highest toxicity in the 
SW480 cells.  5-FU, compound 4 and compound 5 showed similar toxicity profiles.   
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Figure 4.11 Cytotoxicity of the acid derivative of 5-FU in the SW480 cell line after 
treatment for 3 days.  A similar cytotoxic response to the treatment was seen for both 
5-FU and compound 12. 
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The 5-FUrd derivatives, compounds 6, 7, 8 and 9 showed low toxicity over 
the range of concentrations tested over 3 days (Figure 4.12 and Table 4.3).  The IC50 
value for 5-FUrd after treatment for 3 days was 0.37 µM, more toxic than 5-FU or the 
5-FU derivatives, although compound 10 had a similar IC50 value of 0.38 µM.   
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Figure 4.12 Cytotoxicity of the 5-FUrd derivatives in the SW480 cell line after 
treatment for 3 days.  5-FUrd showed toxicity from 0.04 µM, reaching 100% cell 
death at approximately 3 µM.  The 5-FUrd derivatives showed low toxicity over the 
range of concentrations tested. 
 
After treatment for 5 days, similar results were seen with IC50 values for 
compounds 10 and 11 (0.22 µM and 1.2 µM) lower than the parent 5-FU (2.6 µM) 
(Table 4.3).  Compound 5 also had a lower IC50 value of 2.4 µM after treatment for 5 
days.  Compounds 3 (IC50: 3.5 µM), 4 (IC50: 4.3 µM) and 12 (IC50: 3 µM) were less 
toxic than 5-FU (Table 4.3).  After treatment for 5 days, 5-FUrd had an IC50 value of 
0.25 µM, with only the 5-FU derivative, compound 10, being more toxic.  The 5-
FUrd derivatives, compounds 6-9, had low toxicity over the range of concentrations 
tested.   
 
 
 132
Table 4.3 IC50 values of the 5-FU and 5-FUrd derivatives in the SW480 human 
colorectal cancer cell line after treatment for 3 and 5 days. 
  
>25a>25aCmpd 14
>32a>32aCmpd 13
3±0.455.1±0.2Cmpd 12
1.2±0.42.05±0.8Cmpd 11
>16.1a>16.1aCmpd 90.22±0.10.38±0.47Cmpd 10
>33a>33aCmpd 82.4±0.757.1±5.3Cmpd 5
>12.8a>12.8aCmpd 74.3±2.17.8±0.85Cmpd 4
>7.6a>7.6aCmpd 63.5±1.0411±12.4Cmpd 3
0.25±0.0050.37±0.285-FUrd2.6±0.54.9±1.25-FU
5 Days3 Days5 Days3 Days
IC50 Values SW480 Cell Line (µM)
Mean±SD
(a) IC50 value not reached up to highest concentration tested  
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4.2.4 Cytotoxicity of 5-FU derivatives in the HCT116 parental and 5-FU 
resistant cell lines 
 
The HCT116 parental and 5-FU resistant cell lines were kindly provided by 
Professor Patrick G. Johnston, Department of Oncology, Cancer Research Centre, 
Queen’s University Belfast, Belfast, Northern Ireland.  The HCT116 parental 
(HCT(P)) cell line was a human colorectal carcinoma cell line.  The HCT116 5-FU-
resistant (HCT(R)) cell line was established from the HCT(P) cell line by repeated 
exposure to stepwise increasing concentrations of 5-FU (Boyer et al., 2004).  The 
IC50 values for 5-FU after treatment for 3 days was increased 3-fold following this 
treatment, from 4.3 µM to 12.7 µM.  The 5-FU resistant cell line was sub-cultured in 
medium supplemented with 2 µM 5-FU to maintain this selection (Boyer et al., 
2004).  These cell lines were acquired to determine the toxicity of selected 5-FU 
derivatives.   
The cytotoxicity of 5-FU, 5-FUrd and selected 5-FU compounds was analysed 
over 3 and 5 days using the parental and resistant cell lines (Table 4.4).  The results 
are from triplicate treatments.  The IC50 value for HCT(P) after treatment for 3 days 
was 4.5 µM, similar to that established by Boyer et al. (2004).  The IC50 value for the 
5-FU resistant cell line was only 2-fold higher in our experiments, at 9 µM (Figure 
4.13 and Table 4.4).  A decrease in this ratio indicates increased sensitivity of the 
resistant cell line to the treatment.  If the ratio of IC50 values was less than 1, the 
resistant cell line was more sensitive to the treatment than the parental cell line.  Of 
the derivatives tested, treatment with compounds 4 and 10 resulted in the lowest ratio 
of IC50 values between the parental and resistant cell lines at 1.7 (Figure 4.13, 4.14 
and Table 4.4).  5-FUrd had a 1.44-fold difference while compounds 3 and 5 had fold 
differences of 1.83 and 2.33 respectively.  Compounds 11, 13 and 14 showed low 
toxicity and IC50 values were not established over the range of concentrations tested 
(Figure 4.14 and Table 4.4).   
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Figure 4.13 Cytotoxicity of 5-FU and compound 4 in the HCT(P) and HCT(R) cell 
lines after treatment for 3 days.  The IC50 value of 5-FU in the resistant cell line was 
2-fold higher than in the parental cell line.  Compound 4 had a ratio of 1.7 between 
the IC50 values for the parental and resistant cell line. 
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Figure 4.14 Cytotoxicity of compounds 10, 11 and 13 in the HCT(P) and HCT(R) 
cell lines after treatment for 3 days.  Compound 10 showed toxicity from 0.1 µM 
upwards, with IC50 values of 0.47 µM and 0.8 µM for the parental and resistant cell 
lines respectively.  Compounds 11 and 13 showed low toxicity over the range of 
concentrations tested. 
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After treatment for 5 days, there was a 4-fold difference in IC50 value between 
the parental and resistant cell line for 5-FU (Table 4.4).  5-FUrd was extremely toxic 
in both cell lines over 5 days.  The IC50 values of 0.062 µM and 0.053 µM for the 
parental and resistant cell lines respectively gave a ratio of 0.86.  This indicates that 
the resistant cell line was unexpectedly more sensitive to the 5-FUrd than the parental 
cell line (Table 4.4).  For the 5-FU derivatives, all four compounds that exhibited 
toxicity showed lower ratios than for the 5-FU treatment.  The ratio of IC50 values for 
compounds 3 and 10 were 1.13 and 0.89, again indicating the resistant cell line was 
relatively more sensitive to these derivatives than to 5-FU.  This would also suggest 
the HCT(R) cells were more sensitive to compound 10 than the HCT(P) cells.  
 
 
Table 4.4: IC50 values of the 5-FU derivatives and 5-FUrd in the HCT(P) and 
HCT(R) cell lines after treatment for 3 and 5 days.  
 
 
>6.3b>6.3b>6.3b>6.3bCmpd 14
>8.1b>8.1b>8.1b>8.1bCmpd 13
>5.5b>5.5b>5.5b>5.5bCmpd 11
0.890.42±0.030.47±0.021.700.8±0.010.47±0.03Cmpd 10
1.446.6±0.894.6±12.3310±0.154.3±1.5Cmpd 5
1.285±1.963.9±0.81.709±3.15.3±2Cmpd 4
1.137.9±0.957±0.381.8313±3.87.1±1.7Cmpd 3
0.860.053±0.040.062±0.0041.440.23±0.010.16±0.055-FUrd
4.004.8±0.91.2±0.152.009±2.34.5±2.35-FU
FoldaHCT(R)HCT(P)FoldaHCT(R)HCT(P)
5 Days3 Days
IC50 Values HCT116 Parental & Resistant Cell Lines (µM)
Mean ± SD
(a) Fold = fold increase in resistance
(b) IC50 value not reached up to highest concentration tested  
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4.2.5 Guava® cell cycle analysis of 4T1 cells following treatment with 5-FU and 
5-FU derivatives 
 
4T1 cells were treated with 0.1 µM and 1 µM 5-FU and 5-FU derivatives for 3 
days, and then assessed on the Guava® PCA.  These concentrations were chosen 
because the IC50 values for the majority of the compounds fell between these two 
points and would therefore, give a good indication of the effect on the cell cycle with 
increasing toxicity.  Results are representative of three independent experiments.  
Data was analysed using Multicycle software (Phoenix Flow Systems, CA) to 
determine the cell cycle stages.  Figure 4.15 shows the cell cycle analysis for 5-FU 
and compounds 3, 4, 5, 10, 11, 13 and 14 at 0.1 µM.  Figure 4.16 and Table 4.5 
summarise these results.  Control cells were treated with the equivalent amount of 
DMSO used in the treatments.  In the control sample, the majority of the cell 
population was in the G1 phase (44.1%), with 38.1% in S phase and 17.9% in G2 
phase (Figures 4.15 and 4.16).  Following treatment with 5-FU at 0.1 µM, an increase 
was seen in the percentage of cells in the G2 phase (35.4%), with a reduction of cells 
in G1 phase to 28.1% and S phase to 36.5%.   
Compounds 3 and 5 caused a decrease in G1 cell population and an increase 
in the G2 phase population after treatment with 0.1 µM (Figures 4.15 and 4.16).  
Compound 4 caused a decrease in the G1 and S phase populations and an increase in 
G2 phase population.  Compound 10 had a considerable effect on the cell cycle even 
after treatment with 0.1 µM, with the S phase increasing to 92.4%, G2 decreasing to 
0% and the G1 population to 7.6% (Figures 4.15 and 4.16).  Compound 11 also 
caused an increase in the cell population in the S and G2 phases following treatment 
with 0.1 µM (Figures 4.15 and 4.16).  Treatment with compounds 13 and 14 had little 
effect on the cell cycle.  For compound 13, 0.1 µM of treatment led to a slight 
decrease in G1 phase, with corresponding small increases in S and G2 phases.  
Compound 14 caused an increase in G1 and S phase cell populations with a decrease 
in G2 cell population following 0.1 µM treatment (Figures 4.15 and 4.16).   
Treatment with 5-FU at the higher concentration of 1 µM caused a complete 
reduction in the S phase cell population to 0% (Figures 4.17 and 4.18, Table 4.6).  
The G1 phase accounted for 62.4% of the cell population and G2 phase 37.6% 
(Figures 4.17 and 4.18, Table 4.6).  Treatment with 1 µM of compounds 3, 4 and 5 
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resulted in a dramatic decrease in S phase population.  Compounds 3, 4 and 5 caused 
a decrease in the S phase population to 0%, 3% and 0.7% respectively (Figures 4.17 
and 4.18, Table 4.6).  Upon treatment with 1 µM of compound 10, 28.8% of the cell 
population were in the G1 phase and 71.2% in the S phase (Figures 4.17 and 4.18, 
Table 4.6).  1 µM of treatment with compound 11 caused an increase in G1 cell 
population and a decrease in the S phase cell population (Figures 4.17 and 4.18, Table 
4.6).  Exposure to 1 µM of compound 13 and compound 14 resulted in an increase in 
the G2 population (Figures 4.17 and 4.18, Table 4.6).   
 
Control 5-FU Cmpd 3
Cmpd 4 Cmpd 5 Cmpd 10
Cmpd 11 Cmpd 13 Cmpd 14
 
 
Figure 4.15 Cell cycle analysis of 4T1 cells following treatment for 3 days with 0.1 
µM 5-FU and 5-FU derivatives.  X-axis shows DNA content, y-axis represents counts 
of cells.  G1 phase is in light blue, S phase in pink and G2 phase in dark blue. 
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Figure 4.16 Cell cycle analysis of 4T1 cells following treatment for 3 days with 0.1 
µM 5-FU and derivatives.  5-FU, compounds 3, 4, 5, 11 and 13 all caused an increase 
in the percentage of cells in the G2 phase.  Compound 10 treatment resulted in a 
complete reduction of cells in the G2 phase.  Compound 14 showed slight increase of 
cells in G1 phase.  
 
Table 4.5 Percentages of cell cycle populations following treatment with 0.1 µM 5-
FU and 5-FU derivatives for 3 days.  
 
9.542.747.7Cmpd 14
20.140.639.4Cmpd 13
25.144.630.3Cmpd 11
0.092.47.6Cmpd 10
43.038.918.1Cmpd 5
54.317.528.2Cmpd 4
27.340.032.6Cmpd 3
35.436.528.15-FU
17.938.144.1Control
G2 (%)S (%)G1 (%)
Cell Cycle Analysis: 0.1 µM
 
 
 139
Cmpd 10
Cmpd 11 Cmpd 13 Cmpd 14
5-FU Cmpd 3
Cmpd 4 Cmpd 5
Control
 
 
Figure 4.17 Cell cycle analysis of 4T1 cells following 3 days treatment with 1 µM 5-
FU and 5-FU derivatives.  X-axis shows DNA content, y-axis represents counts of 
cells.  G1 phase is in light blue, S phase in pink and G2 phase in dark blue. 
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Figure 4.18 Cell cycle analysis of 4T1 cells following treatment for 3 days with 1 
µM 5-FU and derivatives.  5-FU, compounds 3, 4, 5 and 11 caused a decrease in S 
phase population and an increase in the G1 and G2 populations.  Compound 10 
caused a complete reduction in G2 cell population.  Compounds 13 and 14 showed 
minimal effect on the cell cycle.  
 
Table 4.6 Percentages of cell cycle populations following treatment with 1 µM 5-FU 
and 5-FU derivatives for 3 days.   
 
28.838.932.4Cmpd 14
30.534.235.2Cmpd 13
22.720.856.4Cmpd 11
0.071.228.8Cmpd 10
53.20.746.1Cmpd 5
44.63.052.4Cmpd 4
26.90.073.1Cmpd 3
37.60.062.45-FU
19.640.539.9Control
G2 (%)S (%)G1 (%)
Cell Cycle Analysis: 1 µM
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4.2.6  Guava® apoptosis analysis of 4T1 cells following treatment with 5-FU and 
5-FU derivatives 
 
The 4T1 cell line was treated with 0.1 µM and 1 µM of 5-FU and 5-FU 
derivatives in order to investigate the effect on apoptosis.  Figures 4.19 and 4.20 
shows the apoptosis analysis results from cells treated for 3 days with 0.1 µM and 1 
µM of 5-FU and 5-FU derivatives.  Results are representative of three independent 
experiments.  Figure 4.21 summarises the data, illustrating the percentage of annexin 
V positive cells, which includes both early and late apoptotic cells and also necrotic 
cells.  The x-axis and y-axis represent Annexin V and 7-AAD staining respectively.  
Healthy cells without any dye are seen in the lower left quadrant of the dot-plots in 
Figure 4.19, while cells undergoing apoptosis move firstly into the lower right 
quadrant (following translocation of phosphatidylserine molecule from inner to outer 
surface to cell membrane) and then move to the upper right quadrant (following 
breach of the integrity of the membrane).  Cells undergoing necrosis move from the 
lower left quadrant to the upper right quadrant without moving into the lower right 
quadrant.  
The control-treated cells showed 8-9% annexin V-positive cells, with the bulk 
of the cell population evident in the lower left quadrant of the dot-plot (Figure 4.19).  
For the parent compound, 5-FU, approximately 12% apoptotic cells were noted 
following treatment with 0.1 µM, increasing to approximately 45% after treatment 
with 1 µM (p<0.05) (Figures 4.19 and 4.20).  The movement of the cell population 
from the lower left quadrant into the lower and upper right quadrants can be observed 
following treatment with 1 µM (Figure 4.20).  Compounds 3, 4 and 5 showed similar 
effects on the 4T1 cells, with 10-12% annexin V-positive cells after treatment with 
0.1 µM and 25-30% following treatment with 1 µM (p<0.05) (Figures 4.19 and 4.20).  
Treatment with compounds 10 and 11 resulted in the highest level of apoptotic cells 
following the 0.1 µM treatment, at 45% and 24% of the cell population respectively.  
This result for compound 10 was statistically significant in relation to the control cells 
and also in relation to the 5-FU-treated cells (p<0.01) (Figure 4.21).  After treatment 
with 1 µM of both these compounds only a small increase in apoptosis was seen, to 
46% and 29% (Figures 4.20 and 4.21).  Compounds 13 and 14 at 0.1 µM and 1 µM 
showed low levels of apoptosis, below 10%, similar to the control-treated cells.  This 
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result was statistically significant (p<0.01) in relation to the 5-FU treated cells at 1 
µM.  
 
 
5-FU Cmpd 3
Cmpd 4 Cmpd 5
Control
Cmpd 10
Cmpd 14Cmpd 11 Cmpd 13
 
 
Figure 4.19 Apoptosis analysis of 4T1 cells following treatment for 3 days with 0.1 
µM 5-FU and 5-FU derivatives.  Cells in the lower left quadrant are not stained with 
either dye.  Cells undergoing apoptosis move firstly into the lower right quadrant then 
move to the upper right quadrant. 
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Cmpd 10
Cmpd 11 Cmpd 13 Cmpd 14
Control 5-FU Cmpd 3
Cmpd 4 Cmpd 5
 
 
Figure 4.20 Apoptosis analysis of 4T1 cells following treatment for 3 days with 1 
µM 5-FU and 5-FU derivatives.  An increased number of cells can be seen in the 
lower and upper right quadrants following treatment with 5-FU and compounds 3, 4, 
5, 10 and 11.  
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Figure 4.21 Apoptosis analysis of 4T1 cells following treatment for 3 days with 0.1 
µM and 1 µM 5-FU and 5-FU derivatives.  Graph indicates the percentage of annexin 
positive cells, giving an indication of early and late apoptotic cell population and 
necrotic cell population.  * p-value<0.05 in relation to control, ** p-value<0.01 in 
relation to control, # p-value<0.01 in relation to 5-FU treated cells, Student’s t-test.  
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4.2.7  Effect of 5-FU and 5-FU derivatives on migration of the 4T1 cell line 
 
To determine the effect of 5-FU and derivatives on the migratory capabilities 
of 4T1 cells, in vitro migration assays were conducted and analysed as per section 
2.2.5.  Results are from duplicate experiments, completed in triplicate.  Cells were 
initially pre-treated in 25 cm2 cell culture flasks with 0.5 nM of the compound for 48 
hours, then trypsinised and seeded into FalconTM Cell Culture Inserts, with treatment 
added, incubated for 24 hours and the level of migration quantified.  This 
concentration of compound was chosen to ensure minimal toxicity for all compounds 
(<10% cell death) in order to determine effects that were due to changes in migratory 
or invasive ability rather than cell death.  Figure 4.22 shows the results for the 
migration assay.  In comparison to control-treated cells, the percentage of cells 
migrating through the membrane was increased following treatment with 5-FU and 
the derivatives.  5-FU and compounds 3, 4, 13 and 14 caused the largest increases in 
migration (Figure 4.22).  The increase seen for compounds 3 (82%), 4 (84%) and 14 
(51%) were significant in comparison to the control-treated cells (36%) (p<0.001, 
p<0.01, p<0.05 respectively) (Table 4.7).   
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Figure 4.22 Effect of treatment with 0.5 nM 5-FU and 5-FU derivatives for 3 days on 
migration of the 4T1 cell line.  Treatment with 5-FU, compounds 3, 4, 13 and 14 
resulted in increased invasion of the cells.  *p<0.05, *p<0.01, ***p<0.001, Student’s 
t-test. 
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Figure 4.23 shows photographs of the migratory cells which have been fixed 
and stained on the underside of the membrane.  A clear increase can be seen in the 
cells treated with 5-FU and compounds 3, 4, 13 and 14, in comparison to the control-
treated cells. 
 
 
Control 5-FU Cmpd 3
Cmpd 4 Cmpd 13 Cmpd 14
 
 
 
Figure 4.23 FalconTM cell culture inserts following fixing and staining of the 
membrane with crystal violet.  A clear increase in the number of cells that have 
migrated can be seen for the populations treated with 5-FU and 5-FU derivatives in 
comparison to the control-treated cells. 
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4.2.8  Effect of 5-FU and 5-FU derivatives on invasion of the 4T1 cell line 
 
Invasion assays were set up in the same manner as migration assays.  Unlike 
the FalconTM Cell Culture Inserts, the BD BioCoatTM MatrigelTM Invasion Chambers 
contained a layer of Matrigel on the top of the membrane, which must be degraded by 
the cells before they can move through the pores.  Results are from duplicate 
experiments, completed in triplicate.  Figure 4.24 illustrates the effect of 5-FU and 5-
FU derivatives on invasion of the 4T1 cell line.  The control-treated cells showed 
15% invasion after 24 hours (Table 4.7).  Treatment with 0.5 nM of 5-FU and 5-FU 
derivatives caused an increase in invasion in comparison to the control.  Compounds 
3 and 4 resulted in the greatest increases in invasion of the cells, with a statistically 
significant result for compound 4 (51%, p<0.05).  Figure 4.25 shows pictures of the 
membranes with a clear increase in the number of cells that had invaded following 
treatment with 5-FU and compounds 3 and 4.  Table 4.7 summarises the migration 
and invasion data.  
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Figure 4.24 Effect of treatment with 0.5 nM 5-FU and 5-FU derivatives for 3 days on 
invasion of the 4T1 cell line. Invasion of cells increased following treatment with 5-
FU, compounds 3 and 4.  *p<0.05, Student’s t-test. 
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Control 5-FU
Cmpd 4Cmpd 3
 
 
Figure 4.25 BD BioCoatTM MatrigelTM Invasion Chambers following fixing and 
staining of the membrane with crystal violet.  A clear increase in the number of cells 
that have invaded can be seen for the populations treated with 5-FU and compounds 3 
and 4 in comparison to the control-treated cells. 
 
 
Table 4.7 Migration and invasion data for 4T1 cell line following treatment with 5-
FU and 5-FU derivatives for 3 days.   
 
26 ± 751 ± 2*Cmpd 14
26 ± 774 ± 30Cmpd 13
22 ± 742 ± 0.5Cmpd 11
22 ± 242 ± 7Cmpd 10
23 ± 442 ± 3Cmpd 5
51 ± 9*84 ± 8**Cmpd 4
40 ± 1182 ± 5***Cmpd 3
22 ± 1762 ± 225-FU
15 ± 436 ± 2Control
Invasion (%)Migration (%)
*p<0.05, **p<0.01, ***p<0.001, Student’s t-test  
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4.2.9  Effect of 5-FU and 5-FU derivatives on colony formation of the 4T1 cell 
line in soft agar 
 
Soft agar assays are used to test the anchorage-independent growth of cells 
which is a possible indication of tumourigenicity and is used to assess the efficacy of 
anticancer compounds.  A compound is considered efficacious if treatment results in 
a reduction in the number of colonies to below 30% of that in the control sample 
(Fiebig et al., 2004).  This technique involved seeding cells in semi-solid medium 
containing agar and assessing the formation of colonies in this environment.  4T1 
cells pre-treated with 0.5 nM 5-FU derivatives for 3 days were seeded in the soft agar 
and incubated for 10 days.  Live colonies were stained with p-Iodonitrotetrazolium 
chloride solution and colonies with a diameter greater than 100 µm were counted.  
Results are from duplicate experiments, completed in triplicate.  Cells pre-treated 
with compounds 5 and 14 led to an increase in the number of colonies formed, while 
cells pre-treated with compounds 11 and 13 showed a decrease in the number of 
colonies formed, in comparison to the control-treated cells (Figure 4.26).  However, 
none of these results were found to be statistically significant and none of the 
compounds showed a reduction to below 30% of the control.  
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Figure 4.26 Effect of treatment with 0.5 nM 5-FU and 5-FU derivatives for 3 days on 
4T1 cell colony formation in soft agar assay.  In comparison to the control, treatment 
with compounds 11 and 13 resulted in a decrease in the number of colonies formed.  
Compounds 5 and 14 caused the largest increase in number of colonies formed.   
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4.3  Discussion 
 
5-FU has been used extensively in chemotherapy for the treatment of a range 
of cancers over several decades.  Despite its widespread use, response rates are still 
only 40-50% following combination treatments (Longley et al., 2003 and Venook, 
2005).  More efficacious drugs are required to increase patient survival.  Drugs that 
specifically target the tumour would reduce side-effects of therapy, improving the 
quality of life of patients, and allow higher doses to be administered.  Toward this 
end, a number of derivatives of 5-FU and its nucleoside, 5-FUrd, were synthesised 
and examined for their effect on proliferation, cell cycle kinetics, apoptosis, 
migration, invasion and the ability to form colonies in soft agar.  The aim of the 
design and synthesis of these compounds was to gain insight into the effect of various 
additions and modifications to 5-FU and 5-FUrd on toxicity and mechanisms of 
action of the drugs.  As such, this work was part of a SAR study to refine structural 
requirements for biological activity of the compounds.  
Eight derivatives of 5-FU and 4 derivatives of 5-FUrd were synthesised, 
including nitro-benzyl, ester and acid derivatives.  The nitro-benzyl derivatives, 
compounds 3, 6, 9, 13 and 14 were designed as prodrugs, with the nitro-benzyl side-
chain to be cleaved by reductases within the cell, yielding 5-FU and quinone methide, 
which would also be toxic to the cells, via formation of DNA adducts (Wang et al., 
2005).  The prodrug aspect will be further investigated in chapter 5.  Initial 
cytotoxicity testing of all compounds was conducted in the 4T1 murine mammary 
cancer cell line.  The nitro-benzyl derivatives of 5-FU showed different toxicities 
towards the cells, with compound 3 marginally less toxic than 5-FU, compound 13 
considerably less toxic and compound 14 showing low toxicity over the range of 
concentrations tested (Figure 4.4 and Table 4.2).  Unfortunately, compound 14 could 
not be tested to higher concentrations as this would have resulted in a final 
concentration of greater than 0.1% DMSO.  As these three compounds were designed 
as prodrugs, the lower toxicity of compounds 13 and 14 was not surprising.  Low 
toxicity, below 20%, was seen for compound 14 up to 254 µM, due to the presence of 
two nitro-benzyl side-chains attached at both the N1 and N3 positions of 5-FU.  
Addition of these two side-chains increased the lipophilicity (ClogP value) and size of 
this compound in comparison to 5-FU (Table 4.1). Attachment of a side-chain to the 
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N1 position interferes with formation of the corresponding nucleoside, preventing 
bonding with the sugar (Figure 4.27).  For 5-FU, this meant the toxicity via 
production of 5-FUTP, 5-FdUTP and 5-FdUMP was prevented, hence the lack of 
effect of compound 14 on the cells.   
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Figure 4.27 Formation of nucleosides from 5-FU and compound 14.  The nitro-
benzyl side-chain attached to the N1 position in compound 14 blocks addition of the 
sugar. 
 
 
Compound 3 had considerable toxicity despite the nitro-benzyl side chain at 
the N3 position.  Addition of this side-chain resulted in a lipophilicity value and size 
of 1.62 and 159 Å3 respectively (Table 4.1).  As the N1 position of this compound 
was not bound by a side-chain, the compound was still be able to form the 
corresponding nucleoside, as depicted in Figure 4.28.  Thymidylate synthase attacks 
the carbon atom next to the N1 position, and the nitro-benzyl side-chain would not 
hinder this process, thus this molecule is most likely exhibiting its toxicity via 
thymidylate synthase inhibition, like the parent 5-FU (Figure 4.28).  Since it may 
form the nucleoside, this compound may also cause cytotoxicity via misincorporation 
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into DNA and RNA.  The addition of the nitrobenzyloxycarbonyl side-chain to the N3 
position in compound 13 suppressed toxicity of 5-FU up to approximately 10 µM 
after 3 days.  The ClogP value and size of this compound was 0.658 and 182 Å3 
respectively (Table 4.1).  The side-chain would not hinder the formation of the 
nucleoside but would affect the reaction with the thymidylate synthase complex 
(Figure 4.28).  This compound would be less reactive to attack by the enzyme 
complex due to the extended conjugation of the carbamate linkage (Figure 4.29).   
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Figure 4.28 Formation of nucleosides from compounds 3 and 13.  E-S- represents 
thymidylate synthase enzyme.   
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Figure 4.29 Extended conjugation due to carbamate linkage of compound 13 would 
hinder reaction with the thymidylate synthase enzyme, in comparison to compound 3.  
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The ester derivatives of 5-FU, compounds 4, 5, 10 and 11, were all toxic to 
the 4T1 cells, with similar, if not lower, IC50 values to 5-FU (Figure 4.5 and Table 
4.2).  The ester side-chains were introduced to increase the lipophilicity of the drug, 
resulting in increased absorption by the cells.  As can be seen from Table 4.1, the 
ClogP values have were increased in compounds 5, 10 and 11 with a corresponding 
increase in size.  The ClogP value and size of compound 4 were unfortunately not 
determined.  Compound 10, with an allyloxycarbonylmethyl group attached at the N3 
position, was extremely toxic to the cells with an IC50 value one order of magnitude 
lower than 5-FU.  Compound 11 had a benzyloxycarbonylmethyl side-chain attached 
at both the N1 and N3 positions and was also more toxic than 5-FU, with an IC50 value 
after 3 days treatment of 0.21 µM.  Compound 5 had this same side-chain attached at 
just the N1 position and had an IC50 value of 0.34 µM after 3 days treatment.  
Compound 4 had a longer methoxy ester chain attached to the N1 position, and 
exhibited toxicity marginally less than 5-FU, with an IC50 value of 0.63 µM after 
treatment for 3 days.   
The toxic nature of these compounds indicated increased uptake of the drug 
and also rapid cleavage of the side-chains following addition to the cells.  Inclusion of 
the ester side-chain allowed the bond between the N1 of 5-FU and the first carbon of 
the side-chain to become more labile to chemical/enzyme hydrolysis, as illustrated in 
Figure 4.30 with compounds 11 and 5.  Compounds 4 and 10 underwent the same 
hydrolysis reaction.  The increased lipophilicity would have caused greater absorption 
of the compounds, resulting in the increased toxicity observed with compounds 10 
and 11 in comparison to the parent 5-FU molecule.  The free side-chains of these 
compounds may also have contributed to the toxicity seen in the cells.  The double 
bond at the end of the side-chain of compound 10 would increase the toxicity of this 
side-chain (Thomas, 2000).  The acid derivative, compound 12, exhibited toxicity in 
the 4T1 cells which strikingly mirrored that of the parent 5-FU.  Again, for this 
molecule, rapid hydrolysis of the side-chain to release 5-FU would account for the 
toxicity seen in the cells. 
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Figure 4.30 Hydrolysis of the carbamate bridge of side-chains in compounds 11 and 
5.   
 
 
5-FUrd proved to be very toxic to the cells, with an IC50 value of 0.018 µM 
after treatment for 3 days, in comparison to 0.35 µM for 5-FU (Table 4.2).  This was 
due to the fact that 5-FUrd in effect skips a step in the anabolism of 5-FU, and was 
available to be immediately utilised by UK for conversion to 5-FUMP, followed by 
further phosphorylation to 5-FUDP and 5-FUTP, leading to RNA misincorporation.  
5-FUDP can also be reduced to 5-FdUDP and from there can follow the pathways to 
effect DNA misincorporation and TS inhibition (Figure 4.1).  All of the derivatives of 
5-FUrd showed low toxicity (Figure 4.7 and Table 4.2).  Addition of the side-chains 
increased the ClogP values and size of compounds 6, 8 and 9.  These values could not 
be determined for compound 7.  Compound 8 had the C-2 and C-3 hydroxyl groups 
of the sugar protected in comparison to the parent 5-FUrd (Table 4.1).  This 
modification alone prevented the toxicity of the molecule.  Compound 6 had the 
nitro-benzyl group attached to the N3 of the 5-FUrd and again this modification 
caused the reduction of toxicity of this molecule.  Compound 9 was a combination of 
compounds 8 and 6 – with both the protected C-2 and C-3 hydroxyl groups and the 
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nitro-benzyl group at the N3 position, and showed minimal toxicity to the 4T1 cell 
line, due to a combination of the two modifications.  Compounds 8 and 9, despite the 
protection of the C-2 and C-3 hydroxyl groups, would still be able to form the 
triphosphate molecule, as the C-5 hydroxyl is still available to form bonds with the 
phosphate groups.  However, upon incorporation into RNA, the strand could not be 
elongated as the C-2 hydroxyl group would not be free to bind to the next nucleotide 
in the chain.  They would also be unable to form 5-FdUMP, 5-FdUDP or 5-FdUTP as 
the C-3 hydroxyl group could not be removed by RR.  Thus the mechanisms of action 
of 5-FU were prevented by the protection of the hydroxyl groups.  Compound 7 had 
the protected C-2 and C-3 hydroxyl groups and had a Taxol-derived side-chain 
attached to the C-5 of the sugar.  This side-chain should enhance diffusion of the 
compound into the cell but would also prevent binding of the phosphate groups to the 
sugar, thus having a negative effect on formation of the nucleotides, 5-FUMP, 5-
FUDP or 5-FUTP.   
The lack of toxicity of compound 6 was interesting but puzzling at the same 
time, as compound 6 was in fact the nucleoside of compound 3.  Compound 3 had an 
IC50 value of 0.71 µM in the 4T1 cell line after treatment for 3 days, while compound 
6 exhibited no toxicity up to 7.6 µM, the highest concentration available for testing.  
One possibility for the difference in toxicity is the lipophilicity and size of the 
compounds.  Compound 3 had a ClogP value of 1.62 and a size of 159 Å3,  whereas 
compound 6 had a ClogP value of -1.15 and a size of 283 Å3.  The decrease in 
lipophilicity and increase in the size of compound 6 could affect the uptake of the 
compound and consequently the toxicity.   
The cytotoxicity of these compounds was also tested in the SW480 human 
colorectal cancer cell line.  Toxicity profiles were similar to those in the 4T1 cell line 
with IC50 values being generally higher.  Of the nitro-benzyl derivatives, compound 3 
had an IC50 value of 11 µM after treatment for 3 days, in comparison to 4.9 µM for 5-
FU.  Compounds 13 and 14 showed low toxicity with no IC50 values established over 
the ranges tested.  Compounds 10 and 11, the ester derivatives, were again more toxic 
than 5-FU and compounds 4 and 5 were slightly lower in toxicity than 5-FU.  This 
would indicate that the rapid hydrolysis of the side-chain was also occurring in this 
cell line.  The acid derivative, compound 12, and the 5-FUrd derivatives all had 
similar effects on the SW480 cell line as in the 4T1 cell line.   
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Resistance of tumour cells to 5-FU is a major factor influencing response rates 
following treatment.  Numerous different enzymes are involved in the anabolism and 
catabolism of 5-FU in the body and varying levels and activity of these enzymes can 
affect resistance to therapy (Longley et al., 2003 and Boyer et al., 2004).  Selected 
compounds were tested on the HCT(P) and HCT(R) cell lines.  The HCT(R) cell line 
was established following repeated exposure to stepwise increasing concentrations of 
5-FU, resulting in a 3-fold increase in the IC50 value observed (Boyer et al., 2004).  
Analysis of the cytotoxicity of the 5-FU derivatives in the resistant cell line could 
possibly identify if any of the compounds could overcome resistance due to an 
alternative mechanism of cytotoxicity towards the cells, and could possibly highlight 
strategies to do so.  Molecular analysis of the 5-FU resistant cell line revealed a 
reduction in the levels of TP mRNA, the enzyme which processes 5-FU to 5-FdUrd, 
and an increase in TK mRNA (Boyer et al., 2004).  TK salvages thymidylate from 
exogenous thymidine when the intracellular supplies are low.  There was no 
difference in the levels of DPD, TS, UK, or UP mRNA between the parental and 
resistant cell lines (Boyer et al., 2004).   
After treatment for 3 days, the IC50 value of 5-FU in the parental cell line was 
4.5 µM and two-fold higher, 9 µM, in the resistant cell line (Table 4.4).  The IC50 
value in the HCT(R) cell line was lower than the IC50 of 12.7 µM reported by Boyer 
et al. (2004).  After treatment for 5 days, the ratio of IC50 values had increased to 4-
fold.  5-FUrd exhibited the most toxicity towards the parental and resistant cell lines, 
with 3 day IC50 values of 0.16 µM and 0.23 µM respectively, giving a ratio of 1.44.  
After 5 days treatment, the ratio of IC50 values had decreased to 0.86 for 5-FUrd 
(Table 4.4).  A decreased ratio would indicate an increase in sensitivity of the 
resistant cell line to the treatment.  IC50 values were not established for compounds 
11, 13 and 14 after treatment for 3 or 5 days.  This was surprising for compound 11 as 
the IC50 values in the SW480 colorectal cancer cell line had been established as 2.05 
µM and 1.2 µM after treatment for 3 and 5 days respectively.   
The nitro-benzyl derivative, compound 3, showed toxicity after treatment for 
3 and 5 days, with ratios of IC50 values of 1.83 and 1.13 respectively.  Compound 10 
had an IC50 value of 0.47 µM in the HCT(P) cell line, and 0.8 µM in the HCT(R) cell 
line after treatment for 3 days.  These values are greater than one order of magnitude 
lower than the IC50 values for 5-FU.  The ratio of the IC50 values for compound 10 
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was 1.7.  After treatment for 5 days, however, the IC50 value had not decreased in the 
HCT(P) cell line, while the IC50 value for the HCT(R) cell line was established as 
0.42 µM, and the ratio had consequently decreased to 0.89.  This indicates increased 
sensitivity of HCT(R) cell line to this compound and could reflect a different 
mechanism of action of toxicity.  Compound 4 had ratios of IC50 values of 1.7 and 
1.28 after 3 and 5 days treatment respectively, while compound 5 had a ratio of 2.33 
after treatment for 3 days and 1.44 after treatment for 5 days.  The derivatives with 
the ester side-chains, compounds 4, 5 and 10, were seen to have high toxicity in the 
4T1 and SW480 cell lines.  The decrease in ratio may be due to the increased uptake 
of the compounds and toxicity exhibited by the side-chains of these compounds.  
Also, it is a possibility that the compounds are not deactivated as efficiently by the 
catabolic enzyme DPD, resulting in increased toxicity in the resistant cell lines. 
Following analysis of the cytotoxicity of the derivatives, we wanted to 
investigate the mechanisms involved in this process and also to look at the effect on 
migration, invasion and colony formation in soft agar.  The 5-FU nitro-benzyl and 
ester derivatives were chosen for the remaining experiments, due to availability of 
larger quantities of these compounds.  Firstly, the effect of the derivatives on cell 
cycle kinetics and apoptosis was investigated.  The Guava® PCA system was used for 
these experiments.  This machine has been designed for high-throughput, benchtop 
use with the required assays pre-programmed into the system.  For the cell cycle 
analysis, the Multicycle software uses a more accurate method than the Guava® 
software for deciphering the populations in the different stages.  This software uses an 
algorithm which assumes the G1/G0 and G2/M phases have normal distribution and 
subsequently calculates the S phase population accordingly.   
The effect of 5-FU on the cell cycle has been investigated by a number of 
groups.  Marchal et al. (2004) looked at the effect of 5-FU on the breast cancer cell 
line, MCF-7.  Following treatment with 2.75 µM 5-FU for 48 hours, a decrease in the 
number of cells in G0/G1 phase (68% to 58%) and in G2/M phase (12% to 2%), and a 
corresponding increase in S phase population (20% to 39%) was observed in 
comparison to the control cells.  Boyer et al. (2004) investigated the effect of 1 µM, 5 
µM and 10 µM 5-FU on the colorectal cancer cell line HCT116, after treatment for 3 
days.  They noted an S phase arrest after treatment with 1 µM and a G2/M phase 
arrest after treatment with 5 µM and 10 µM.  Upon cell cycle analysis with the DLD-
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1, LoVo and SW620 colorectal cancer cell lines, Tokunaga et al. (2000) concluded 
three modes of cell growth modulation following treatment with 5-FU.  The drug was 
seen to cause both a loss of, and an accumulation in, the S phase population; a G2/M 
block; and arrest in the G1/S border; depending on the cell line and the concentration 
of treatment.  Li et al. (2004) treated the NA and HSC-4 oral cancer cell lines with 1 
mg/ml and 10 mg/ml of 5-FU (7.7 mM and 77 mM) and observed late G1/early-S 
phase accumulation over 8-24 hours.  The effect of 5-FU on DNA synthesis, through 
the inhibition of TS and misincorporation into DNA, will manifest itself in the S 
phase while RNA misincorporation of 5-FU occurs in the G1 phase (Li et al., 2004).  
The different regimens of administration of 5-FU to patients may even have an effect 
on the perturbation of the cell cycle, with continuous infusion exhibiting toxicity 
through TS inhibition while bolus administration resulted in RNA inhibition (Xiong 
and Ajani, 2004). 
In the work presented here, 5-FU treatment at 0.1 µM showed mainly an 
increase in the number of cells in G2 phase and a decrease in the G1 cell population 
(Figures 4.15 and 4.16, Table 4.5).  Following treatment with 1 µM 5-FU, 62% of 
cells were in G1 phase and the remaining were in G2 phase, with no cells in S phase 
(Figures 4.17 and 4.18, Table 4.6).  These results would indicate that following 
treatment with the lower concentration of 5-FU, cells were still moving into the S 
phase for DNA replication but there was a pause before mitosis due to the cell 
damage, causing a build-up of cells in G2 phase.  At the higher concentration, cells 
were no longer moving into the S phase, possibly due to RNA misincorporation, and 
were arrested in G1 and G2 phases.  Compounds 3, 4 and 5 had similar effects on the 
cell cycle kinetics.  Treatment with compound 11 at 0.1 µM resulted in a decrease in 
G1 phase and increases in S and G2 phases, indicating S phase and G2 phase arrest.  
The higher concentration of 1µM caused an accumulation of cells in G1 (56.4%), 
possibly due to RNA misincorporation of 5-FU.   
Compound 10 had the most dramatic effect on the cells, with 92.4% of cells in 
S phase and 7.6% cells in G1 phase after treatment with 0.1 µM.  After treatment with 
1 µM of compound 10, 71.2% of the cell population were in S phase with 28.8% in 
G1 phase (Figures 4.17 and 4.18, Table 4.6).  This indicated inhibition of replication 
of DNA in the S phase due to extensive DNA damage, with the cells unable to 
proceed to the G2 phase due to their arrest and subsequent death.  Hence, it would 
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appear that compounds 3, 4, 5 and 11 were having more of an effect on both RNA 
misincorporation and DNA synthesis, as the cells were arresting in G1 phase but also 
appeared to be pausing before mitosis, probably due to errors in DNA replication 
which would have occurred during S phase.  Compound 10 appeared to be affecting 
mainly DNA synthesis in the S phase, with damaged cells accumulating in this phase.  
Treatment with 0.1 µM and 1 µM of compounds 13 and 14 had little effect on the cell 
cycle.  This would correlate with the cytotoxicity data, with low levels of cell death 
seen at these two concentrations.   
This analysis showed that the 5-FU derivatives were affecting different 
aspects of the cell cycle.  Arrest in G1, S and G2 phases was seen depending on the 
concentration and compound.  Numerous molecules play a role in the complex 
process of regulation of the cell cycle, including the cyclins and cyclin-dependent 
kinases (CDKs).  The G1 checkpoint is regulated by cyclins D and E, and Cdk2 and 
Cdk4, with p21, Rb and p53 also playing roles in determining cell cycle progression 
or arrest (Sampath, 2001).  Progression through S phase checkpoints is determined by 
cyclin A, Chk1, Chk2, Cdc25A and Cdk2.  Cyclin B, Cdk1, Chk1, Chk2 and Cdc25C 
play a role in G2 checkpoint regulation (Sampath, 2001).  Had time and resources 
allowed, further investigation into the effect of the 5-FU derivatives on the levels of 
these key players of cell cycle progression would have been an interesting topic.   
Apoptosis of the cell is accompanied by many morphological changes, 
including nuclear chromatin condensation, fragmentation of DNA, cell shrinkage, 
collapse of the mitochondrial membrane potential and changes at the cell surface.  
This is a controlled process, hence also known as programmed-cell death.  In contrast, 
necrosis results in uncontrolled swelling, followed by rupture of the plasma 
membrane, and non-specific DNA degradation (Brown and Attardi, 2005).  Changes 
at the cell surface of apoptotic cells allow the annexin V assay to monitor this 
occurrence.  Early in apoptosis, the phosphatidylserine molecule moves from the 
inner membrane to the outer membrane of the cell surface.  Annexin V binds to this 
molecule on the outer membrane.  When used in conjunction with 7-AAD, which 
enters cells late in apoptosis or during necrosis, an indication of the populations of 
cells going through early and late apoptosis and necrosis can be monitored.   
Marchal et al. (2004) subjected MCF-7 breast cancer cells to 2.75 µM 5-FU 
and monitored the effect on apoptosis after treatment for 6, 12 and 24 hours.  After 6 
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hours of treatment, 66% of cells were undergoing apoptosis, with 38% in the early 
stage and 28% in the late stage.  Following 12 and 24 hours treatment, the percentage 
of cells undergoing apoptosis was still 66%, with varying amounts in early and late 
stages.  Espinosa et al. (2005), using the same cell line, observed 57% and 53% 
apoptotic cells following treatment with 2.75 µM for 24 and 48 hours.  In our work, 
the control cells showed approximately 10% apoptotic cells, with 5-FU treatment 
increasing this to 12% and 37% for 0.1 µM and 1 µM, respectively (Figures 4.19-
4.21).  Treatment with 0.1 µM compound 10 caused an increase in cells undergoing 
apoptosis (45%), with compound 11 increasing the apoptotic population to 24%.  The 
result for compound 10 was statistically significant in relation to both the control cells 
and the 5-FU treated cells (p<0.01).  The remaining compounds, at 0.1 µM, showed 
minimal effect on apoptosis of the cells.   
Treatment with 1 µM of the derivatives resulted in a more dramatic effect on 
apoptosis (Figure 4.20).  Compounds 3, 4 and 5 showed an increase in apoptotic cells 
to 26-29%.  Treatment with compounds 10 and 11 resulted in increases to 46% and 
29% respectively.  These results were all statistically significant in relation to the 
result for the control cells (p<0.05).  Treatment with compounds 13 and 14 had 
minimal effect in comparison to the control-treated cells, however their results were 
statistically significant in relation to the 5-FU treated cells (p<0.01).  These results 
reflected those seen in the cytotoxicity data, although the percentage of apoptotic 
cells does not seem to reach the corresponding percentage cell death values across the 
spectrum of results.  The levels of apoptosis were higher in the work of Marchal et al. 
(2004) than seen in our work, which could be explained by the different 
concentrations used.   
There are two different apoptotic pathways that cells undergo following death-
inducing signals.  The extrinsic pathway is mediated by receptors on the cell 
membrane including CD95 and TNF-related apoptosis-inducing ligand (TRAIL) 
receptors, which interact with intracellular proteins such as Fas-associated death 
domain (FADD) and caspase-8 to induce the caspase cascade (Fulda and Debatin, 
2006).  Intrinsic pathway activation occurs following disruption of the mitochondrial 
membrane, releasing cytochrome c, apoptosis inducing factor (AIF) and 
Smac/DIABLO into the cytosol.  Subsequent caspase activation leads to apoptosis of 
the cell.  These two pathways may also run concurrently and have an accumulative 
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effect on the progress to cell death.  p53 protein plays a role in both pathways, with 
p53-inducible elements in the promoter region of the gene encoding the CD95 
protein, involved in the extrinsic pathway.  In the intrinsic pathway, p53 can play a 
role in relaying DNA damage signals to the mitochondria and can also activate the 
expression of pro-apoptotic Bcl-2 proteins (Fulda and Debatin, 2006).  Considering 
the fact that the 4T1 cell line is p53-null, this would be an interesting area of 
investigation to pursue in future work – to elucidate the proteins involved in apoptosis 
induced by the 5-FU derivatives.  
Metastasis of tumour cells to secondary sites of the body plays a significant 
role in the prognosis of the disease.  Numerous factors influence this action, including 
the ability of the tumour cell to migrate, to invade the ECM and also to grow and 
divide in a new organ (Bogenrieder and Herlyn, 2003).  5-FU is used in 
chemotherapy for metastatic cancers, thus we wanted to investigate the possible 
effects of these new compounds on migration, invasion and colony formation in soft 
agar.  Cells were pre-treated with 0.5 nM 5-FU and 5-FU derivatives for 48 hours 
before being seeded into FalconTM cell culture inserts (migration) or BD BioCoatTM 
MatrigelTM Invasion Chambers, with further treatment, and incubated for 24 hours.  
Cells that succeeded in migrating or invading through the pores of the membrane 
were fixed, stained with crystal violet and the stain eluted out with glacial acetic acid 
and absorbance read.   
Surprisingly, given the fact that 5-FU was already used extensively in 
chemotherapy for primary and metastatic tumours, the literature regarding its effect 
on in vitro migration and invasion was not extensive.  5-FU has been shown to have a 
varied effect on the migration of cells, with no effect seen at lower concentrations 
(<1 µg/ml/<7.7 µM) and inhibition noted at concentrations of 1 µg/ml (7.7 µM) and 
higher (Gordon et al., 2005).  Warusavitarne et al. (2006) observed no significant 
difference in the rate of invasion of HCT116, LoVo, LIM1215 and KM12C cell lines 
which were seeded into the chambers in media containing 50 µM 5-FU and incubated 
for 24 hours.  Liang et al. (2004) established a 5-FU resistant variant from the human 
squamous cell line DLKP by pulse selection with 2 ng/ml (15.4 nM) over 4 months.  
This cell line was shown to be significantly more invasive after 48 hours than the 
parental cell line (p<0.001).   
In this work, the sub-lethal dose of 0.5 nM caused only increases in cell 
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migration in comparison to the control-treated cells (Figures 4.22 and 4.23).  5-FU 
and compounds 3, 4, 13 and 14 showed an increase in the number of cells that 
migrated through the membrane, with the results for compounds 3, 4 and 14 being 
statistically significant.  For the invasion assay, all the treatments of 0.5 nM resulted 
in an increase in the number of cells that invaded (Figures 4.24 and 4.25).  
Compounds 3 and 4 had the greatest effect on invasion, with the result for compound 
4 being statistically significant (p<0.05).  There are numerous players that have a role 
in the processes of migration, invasion and anchorage-independent growth, including 
enzymes such as the MMPs and cell adhesion molecules such as integrins and 
cadherins (Egeblad and Werb, 2002 and Cavallaro and Christofori, 2004).  However, 
as there was no significant reduction observed in the migration or invasion of the 4T1 
cells following treatment with the 5-FU derivatives, this area of investigation was not 
pursued. 
Colony formation in soft agar is used to investigate possible anticancer agents 
and their effect on the proliferative capacity of cancer cells.  Fiebig et al. (2004) 
looked at the effect of a number of chemotherapeutic agents, including 5-FU, on the 
growth of human tumour xenografts in soft agar.  The colon carcinoma xenograft was 
not affected by treatment with 0.2 µg/ml (1.5 µM) or 0.6 µg/ml (4.6 µM) 5-FU while 
the lung carcinoma xenograft showed a reduction of colony counts to between 30 and 
50% of the control after 0.2 µg/ml and below 10% after 0.6 µg/ml treatment.  Our 
results showed a decrease in the numbers of colonies formed after treatment with 
compounds 11 and 13, although the results were not significant and the colony counts 
were not below 30% of the control (Figure 4.26).  5-FU and compounds 4, 5 and 14, 
however, caused an increase in the number of colonies formed in the soft agar, 
although these results were not significant.  The work of Fiebig et al. (2004) was to 
test the resistance of the xenografts to treatments in comparison to the response of the 
patient and so they used a higher concentration than in our experiments.  Further 
investigation in this area could have examined the effect of different concentrations of 
the 5-FU derivatives.  Alternatively, the assay could be changed to allow the 
formation of the colonies in the soft agar followed by treatment with the derivatives, 
rather than the pre-treatment method used in this work. 
Investigation of the cytotoxicity of the 5-FU and 5-FUrd derivatives generated 
interesting results, with compound 10 proving the most toxic of the compounds, even 
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more toxic than the parent 5-FU.  The remaining ester derivatives, compounds 4, 5 
and 11, were found to be highly toxic compounds also, with increased lipophilicity 
due to the side-chains.  Analogues of compound 10 are currently being synthesised to 
investigate further the structural components underlying its toxicity.  Conversely, the 
lack of toxicity seen with the prodrugs of 5-FU (compounds 13 and 14) and 5-FUrd 
(compounds 6 and 9) towards the 4T1 and SW480 cell lines showed promise as 
activation of these prodrugs could lead to toxicity in the tumour cell environment.  
Thus, this avenue of investigation was followed – methods of activation and toxicity 
of the activated prodrugs (Chapter 5).  
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4.4  Summary 
 
Twelve derivatives of 5-FU and 5-FUrd were synthesised and tested for 
cytotoxic properties using the 4T1 and SW480 cell lines.  Varying responses were 
noted, from low toxicity (compounds 6-9, 13 and 14) to increased toxicity 
(compounds 10 and 11) compared to the parent compounds.  Cytotoxicity results 
using the HCT116 parental and resistant cell lines showed an increase in sensitivity of 
the resistant cell line to the 5-FU derivatives (compounds 3, 4 and 10).  Cell cycle 
analysis of the 4T1 cell line revealed two different modes of action – arrest during the 
S phase (compound 10) or arrest in G1 and G2 phases (compounds 3, 4, 5 and 11).  
Apoptosis analysis showed a significant increase following treatment with 1 µM 5-
FU, compounds 3, 4, 5, 10 and 11, and correlated with the cytotoxicity data.  
Investigation of the effect of the derivatives on migration of the 4T1 cell line resulted 
in a significant increase following treatment with compounds 3, 4 and 14.  Invasion 
assays also showed compound 4 caused a significant increase in invasion of the 4T1 
cells.  There was no significant effect on growth of colonies of treated 4T1 cells in 
soft agar assays.  This aspect of analysis of the compounds was not pursued following 
these results.  Having identified a number of prodrug-designed compounds with low 
toxicity (compounds 6, 9, 13 and 14) this area was focused on for further study.  
  
 
 
Chapter 5 
 
Prodrug derivatives of 5-Fluorouracil and 5-Fluorouridine: 
Analysis of activation and cytotoxicity 
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5.1 Introduction 
 
5.1.1 Tumour-activated prodrugs  
 
Prodrugs are pharmacologically inactive drugs that are transformed into an 
active metabolite which exhibits pharmacological effects.  They were first described 
by Albert (1958) and can be designed to overcome inadequate pharmacokinetic or 
pharmacodynamic properties such as chemical instability, poor solubility or poor 
absorption, but also to target the drug to the site of action (Ettmayer et al., 2004).  
The latter type, termed tumour-activated prodrugs (TAP) in relation to cancer 
therapy, will be concentrated on here.  TAPs come in the form of bioreductive or 
enzyme targeted prodrugs.  Bioreductive prodrugs can be activated by specific 
intracellular conditions including hypoxia or increased tissue- or cell-specific 
enzymes.  Prodrugs can also be activated by enzymes in enzyme prodrug therapy 
(EPT), in which case the enzymes are delivered to the cell via three different 
mechanisms: antibody-directed (ADEPT), gene-directed (GDEPT) or virus-directed 
(VDEPT) (Denny, 2001).   
In general, there are three domains present in a TAP referred to as a trigger, a 
linker and an effector (Figure 5.1).  The trigger undergoes selective metabolism at the 
site of action.  The linker deactivates the drug until metabolism of the trigger.  The 
effector is the active drug and exerts the cytotoxic effect on the tissue when released.  
The effector should have a suitable half-life to cause sufficient cell death, while it 
should also be capable of diffusion to neighbouring cells to exhibit a bystander effect 
i.e. the death of neighbouring cells which have not activated the prodrug themselves 
(Denny, 2001).   
 
 
 
 
Figure 5.1 Structure of tumour-activated prodrug, with three domains; trigger, linker 
and effector.   
TRIGGER LINKER EFFECTOR
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General properties of a prodrug are as follows: (a) it must distribute efficiently 
to the tumour site, (b) it must be selectively metabolised to a cytotoxic agent in the 
tumour only, and (c) it should be able to exhibit a bystander effect but without 
toxicity to neighbouring tissues or diffusion into the circulatory system (Denny, 2001 
and Xu and McLeod, 2001).  The released drug should be at least 100-fold more toxic 
than the prodrug in order to result in significant therapeutic gain (Greco and Dachs, 
2001). 
 
 
5.1.2 Bioreductive prodrugs 
 
Bioreductive prodrugs are activated by intracellular conditions such as 
selective enzyme expression, hypoxia and pH differences.  Increased gene expression 
of specific enzymes in tumour tissue as well as low extracellular pH conditions have 
been examined in relation to prodrugs.  Hypoxia, however, has been the main area of 
research for bioreductive prodrugs.  Hypoxia, or low oxygen tension, occurs within a 
tumour when oxygen demand exceeds oxygen supply (Airley et al., 2000).  Oxygen 
levels in normal cells can vary between 3.1 and 8.7% while tumours can have oxygen 
levels as low as 0.01% (Kizaka-Kondoh et al., 2003).  Breast cancer tumours 
reportedly have a median oxygen level of 1.4% (Brown and Wilson, 2004).  If a cell 
in a tumour is greater than 50 µm from a capillary, it is hypoxic.  A complete lack of 
oxygen, anoxia, occurs if a cell is greater than 145 µm from a blood supply (Airley et 
al., 2000).  Hypoxic regions occur as a tumour increases in size but also due to the 
poorly developed vascular system in solid tumours.  Two types of hypoxia exist 
within a tumour: chronic and acute.  Chronic hypoxia occurs due to the distance of 
the cell from the nearest blood vessel, although these cells can still survive and 
proliferate (Kizaka-Kondoh et al., 2003).  Acute or transient hypoxia is a result of 
temporary shut down of blood vessels (Kizaka-Kondoh et al., 2003 and Denny, 
2001).  Hypoxic conditions in a tumour are associated with resistance to 
chemotherapeutic and radiation treatment, and a metastatic phenotype (Sinhababu and 
Thakker, 1996 and Brown and Wilson, 2004).   
Hypoxia-selective prodrugs are generally substrates for enzymes present in all 
cells of the body.  However, in normal tissues the reaction is incomplete or reversed 
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due to the presence of oxygen while in the hypoxic tumour cells the reaction is 
allowed to commence and the active drug is produced (Figure 5.2) (Sinhababu and 
Thakker, 1996).  The prodrugs need to have effective extracellular distribution in 
order to reach the hypoxic cells distant from the blood vessels.  After activation 
however, the drugs should have a short half-life so that they do not diffuse into 
neighbouring tissues or into the circulatory system.   
The enzymes involved in activation of prodrugs include cytosolic reductases 
(carbonyl reductase, DT-diaphorase, xanthine oxidase, aldehyde oxidase), 
mitochondrial reductases (dihydrolipoamide dehydrogenase, cytochrome b5 
reductase, succinate dehydrogenase) and microsomal reductases (NADPH-
cytochrome reductase, cytochrome P450) (Smyth and Orsi, 1989).  The majority of 
these enzymes are one-electron reductases.  DT-diaphorase (also known as NQO1 – 
NAD(P)H-quinone oxidoreductase) and cytochrome P450 are two-electron reductases 
and carbonyl reductase can act as both a one-electron and two-electron reductase 
(Patterson, 2002 and Williams et al., 2001). 
 
 
 
 
 
Figure 5.2 Mechanism of prodrug activation under hypoxia.  Adapted from Denny, 
2001 and Airley et al., 2000.  
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There are four types of bioreductive drugs activated under hypoxia: quinones, 
aromatic N-oxides, aliphatic N-oxides and nitroaromatics/nitroheterocyclics (Denny, 
2001 and Airley et al., 2000).  Cytochrome P450 reductase activates quinones by one-
electron reduction to the semi-quinone radical anion.  Following reduction, 
subsequent fragmentation to a DNA cross-linking species generates toxicity in cells 
(Denny, 2001).  Tirapazamine (TPZ, 3-aminobenzotriazine-1,4-di-N-oxide) is an 
aromatic N-oxide which has shown promising results in conjunction with cisplatin in 
phase II and III trials in head and neck cancer and non-small cell lung cancer (Figure 
5.3A) (Brown and Wilson, 2004).  Under hypoxic conditions, TPZ undergoes a one-
electron reduction to an oxidising radical that leads to DNA double-strand breaks, 
single-strand breaks and base damage (Kizaka-Kondoh et al., 2003 and Maluf et al., 
2006).  Cytochrome P450 and cytochrome P450 reductase are the enzymes 
responsible for this activation (Denny, 2001).  AQ4N (1,4-bis-{[2-(dimethyl-amino-
N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione), an aliphatic N-oxide, is 
also a promising bioreductive agent.  AQ4N is activated to AQ4 (1,4-bis-{[2-
(dimethyl-amino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione) under hypoxic 
conditions.  AQ4 intercalates with DNA and blocks Topoisomerase II action (Figure 
5.3B) (Kizaka-Kondoh et al., 2003).  AQ4N is activated by two-electron reduction by 
the CYP3A isoenzyme of the cytochrome P450 family (Patterson, 2002).  
Nitroaromatics undergo six-electron reduction in cells by flavin-containing enzymes 
(Figure 5.3C) (Sinhababu and Thakker, 1996).   
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Figure 5.3 Structure and metabolism of prodrugs Tirapazamine (A) and AQ4N (B).  
From Brown and Wilson, 2004. (C) Nitroaromatic six-electron reduction. Adapted 
from Sinhababu and Thakker, 1996. 
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5.1.3  Antibody-Directed, Gene-Directed and Virus-Directed Enzyme Prodrug 
Therapy 
 
ADEPT involves covalent linkage of a non-human enzyme to a monoclonal 
antibody that is directed against a tumour antigen.  The prodrug must not be a 
substrate of any other human enzyme to avoid activation and toxicity in alternative 
sites of the body.  The enzyme-antibody conjugate must be allowed to localise to the 
tumour and clear from normal tissue before the prodrug is administered.  Following 
administration, the prodrug is activated by the enzyme at the site of the tumour only 
(Figure 5.4A) (Sinhababu and Thakker, 1996).  There are a number of criteria to be 
fulfilled in order to maximise this therapy.  Specificity of the antibody to the tumour 
cells is crucial and the enzyme-antibody conjugate must not be immunogenic 
(Sinhababu and Thakker, 1996).  The prodrug should be limited in its ability to enter 
cells before activation, this maximises the pool of prodrug to be acted on 
extracellularly (Denny, 2001).  The active drug must be able to diffuse into the 
tumour cells to exhibit its cytotoxic action.  This would also result in a bystander 
effect as the prodrug is activated extracellularly and the active drug may then diffuse 
to neighbouring cells, without the need for each individual cell to express the antigen 
or to attract the antibody-enzyme conjugate.  Conversely, limited diffusion to within 
the tumour is vital to avoid toxicity of neighbouring tissues.  The half-life of the 
active drug would have an impact on this (Sinhababu and Thakker, 1996 and Denny, 
2001).   
GDEPT and VDEPT both focus on delivering a gene encoding a non-human 
enzyme into the tumour cell wherein the enzyme is produced (Figure 5.4B) (Ettmayer 
et al., 2004 and Rooseboom et al., 2004).  In VDEPT, gene targeting is achieved by 
using viral vectors, most commonly retroviruses or adenoviruses, while in GDEPT, or 
suicide gene therapy, a non-viral vector is used for delivery of the gene (Rooseboom 
et al., 2004).  For both systems, the vector delivering the gene must be taken up by 
the cells and subsequent stable expression of the enzyme is essential.  The enzyme 
itself should not exhibit toxicity towards the cells (Kizaka-Kondoh et al., 2003).   
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Figure 5.4 Diagrammatical illustrations of ADEPT (A) and GDEPT/VDEPT (B).  
 
 
In GDEPT and VDEPT, it is necessary for the prodrug to enter the cell in 
order to undergo activation.  The active drug must be able to diffuse to neighbouring 
cells to exhibit a bystander effect as gene delivery will not have occurred in 100% of 
cells (Rooseboom et al., 2004).  Challenges to this system include selective delivery 
of the gene to the tumour tissue, immunogenic reaction to the DNA, and insertional 
mutagenesis (Ettmayer et al., 2004).  A problem for VDEPT is that retroviral vectors 
only target dividing cells, and within a tumour, this constitutes only approximately 6-
20% of the cells (Ettmayer et al., 2004).  One advantage of the GDEPT/VDEPT 
system over ADEPT, however, is the requirement of the majority of enzymes for a 
co-factor, which are generally available intracellularly (Xu and McLeod, 2001).  The 
literature at times refers to GDEPT even when viral vectors are used for delivery, 
hence VDEPT could in fact be considered a form of GDEPT.  
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5.1.4  CB1954 and Nitroreductase 
 
CB1954 (5-aziridinyl-2,4-dinitrobenzamide) is an example of a prodrug 
activated by the Escherichia coli nitroreductase (NTR) enzyme.  Initially, CB1954 
was noted to be effective in the treatment of tumours in rats.  CB1954 was activated 
by high levels of the DT-diaphorase enzyme present in the rat cells.  However, this 
unfortunately did not translate to humans, as CB1954 was a considerably poorer 
substrate for the human form of the DT-diaphorase enzyme (Denny, 2001).  The 
difference in reactivity between the enzymes from the two species was found to be 
caused by a one amino acid change at position 104 of the protein sequence (Denny, 
2003).  A related form, NQ02, which has no known physiological function, was 
found to have latent activity but only in the presence of the co-factor, 
dihydronicotinamide riboside (NRH) (Knox et al., 2003).  This co-factor was 
expensive and time-consuming to make, making this an unattractive combination.  An 
NRH substitute, EP-0152R has been selected for development with NQ02 (Denny, 
2003).   
CB1954 is, however, efficiently reduced by the E. coli NTR, a 24 kDa 
enzyme that uses NADH or NADPH as substrate and catalyses the reduction of nitro 
groups to hydroxylamine groups (Denny, 2003 and Rooseboom et al., 2004).  This 
enzyme is a product of the nfsB gene in E. coli and is an oxygen-insensitive flavin 
mononucleotide (FMN)-containing NTR.  NTR functions as a homodimer, with a 
FMN molecule attached to each monomer (Denny, 2003).  Reduction by NTR occurs 
by a substituted enzyme (ping-pong) mechanism – firstly, reduction of FMN occurs 
by NADH or NADPH, followed by reduction of the CB1954 substrate by the FMN 
(Searle et al., 2004).  CB1954 is a weak monofunctional alkylator but reduction 
produces a potent DNA cross-linking agent (Greco and Dachs, 2001).  Reduction can 
occur at either the 2- or 4-nitro group, giving a mixture of hydroxylamines.  The 4-
hydroxylamine is converted by cellular thioesters, such as acetyl coenzyme A, to the 
active metabolite which cross-links with DNA, exerting the main cytotoxic effect 
(Figure 5.5) (Denny, 2001 and 2003).  This cross-link is unique, with the 4-
hydroxylamine reacting with the C8 position of deoxyguanosine, while the aziridine 
group reacts with the opposing strand of DNA (Denny et al., 2003).  The 2-
hydroxylamine also exhibits some toxicity through formation of DNA adducts 
(Brown and Wilson, 2004).  A major advantage of CB1954 is that the activated drug 
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is able to kill proliferating and non-proliferating cells (Greco and Dachs, 2001).  Also, 
the hydroxylamine metabolites of CB1954 have been shown to be able to cross cell 
membranes freely and thus a bystander effect is possible for this drug (Xu and 
McLeod, 2001). 
 
 
 
 
Figure 5.5 Structure of prodrug CB1954 (left), used in enzyme prodrug therapy with 
NTR enzyme, and activation to 2-hydroxylamine (top pathway) and 4-hydroxylamine 
(bottom pathway).  (From Brown and Wilson, 2004.) 
 
The CB1954/NTR combination has been tested with various approaches to 
GDEPT and VDEPT.  In vitro testing of the CB1954/NTR system showed a dramatic 
increase in toxicity in NTR-expressing cell lines, with up to 2000-fold increase in 
IC50 values (Weedon et al., 2000).  Phase I trials have been completed testing the 
individual components of a VDEPT system (Chung-Faye et al., 2001 and Palmer et 
al., 2004).  Chung-Faye et al. (2001) administered intravenously (i.v.) varying 
concentrations of CB1954 as a single agent, to thirty patients with gastrointestinal 
malignancies.  This was to determine toxicity and pharmacokinetics of the prodrug 
alone before administration with the NTR.  The highest dose level was 37.5 mg/m2 
and all three patients in this treatment group experienced dose-limiting toxicities 
(DLTs).  It was concluded from this trial that a lower i.v. dose of 24 mg/m2 at 3-
weekly intervals was the safest regimen (Chung-Faye et al., 2001).  Palmer et al. 
(2004) constructed CTL102, a replication-deficient adenovirus vector, containing the 
E. coli nfsB gene.  This was administered to patients with liver cancer to determine 
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primarily toxicity, and secondly, expression of the NTR, immune response and 
pharmacokinetics.  A maximum dose of 5 x 1011 virus particles, administered 
intratumourally, was well tolerated with no DLTs observed.  Immunohistochemical 
staining of resected tumour sections showed expression of the NTR in the tumour 
cells (Palmer et al., 2004).  The authors have now moved on to test these two 
components together, with intratumoural CTL102 administration 48 hours prior to i.v. 
administration of CB1954.  To date no further publications or results from this 
clinical trial have been published. 
A phase I clinical trial in prostate cancer was also conducted using CTL102 
and CB1954 (James et al., 2004).  Intraprostatic injection of CTL102 has been 
reported as feasible and safe in the 16 patients treated.  Expression of the NTR was 
seen in tumour and stroma using immunohistochemistry staining of resected tissue.  
One patient was injected with the virus and administered i.v. CB1954, and exhibited 
no significant toxicities and a fall in PSA levels by >50% after one month.  No further 
results have been published to date.  
 
 
5.1.5  Current 5-FU prodrugs 
 
There are a number of prodrugs of 5-FU in use today, with an emphasis on 
oral administration in order to improve quality of life for patients.  These include 
Capecitabine and Ftorafur.  Capecitabine (N4-pentyloxycarbonyl-5-deoxy-5-
fluorocytidine) is a prodrug of 5-FU which is taken orally without degradation by 
DPD in the GI tract (Figure 5.6) (Xiong and Ajani, 2004).  It is acted on in the liver 
by carboxylesterase to produce 5-deoxy-5-fluorocytidine (5-DFCR).  Cytosine 
deaminase (CD) is highly expressed in the liver and solid tumours.  CD converts 5-
DFCR to 5-deoxy-5-fluorouridine (5-DFUR) which is then converted to 5-FU by TP 
and/or UP.  TP and UP are generally more active in tumour tissue than in normal 
tissue, thus resulting in an increased level of 5-FU being released in the tumour cells 
(Longley et al., 2003 and Xiong and Ajani, 2004).  Capecitabine is indicated for 
patients whose cancer progresses after anthracycline and taxane therapy (Kakimoto et 
al., 2005 and Awada et al., 2003).   
Ftorafur (FT, 1-(2-tetrahydrofuryl)-5-Fluorouracil) is a mixture of two 
stereoisomers (Figure 5.6).  FT is converted to 5-FU by two mechanisms, cleavage of 
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the C2’-N1’ bond which occurs in the cytosol by thymidine phosphorylase, or hepatic 
microsomal oxidation at the C5’ position by cytochrome P450 enzymes (Xiong and 
Ajani, 2004 and Rooseboom et al., 2004).  It is generally administered as a 
Uracil/Ftorafur (UFT) formulation, combining a 4:1 molar ratio of uracil with 
Ftorafur.  The uracil in this combination saturates DPD, thus allowing 5-FU to avoid 
degradation (Longley et al., 2003).  This combination has fewer side-effects than 5-
FU during clinical use, is reliably absorbed and, with a half-life of 5-12 hours in 
circulation, produces sustained high plasma levels of 5-FU (Lamont and Schilsky, 
1999).  The term S1 is used for another combination therapy with the prodrug FT, in 
conjunction with 5-chloro-2,4-dihydroxypyrimidine (CDHP) and potassium oxonate 
(OXO).  CDHP is an inhibitor of DPD, 180 times more potent than uracil, enhancing 
the efficacy of 5-FU by limiting degradation by DPD.  OXO inhibits phosphorylation 
of 5-FU by OPRT in the GI tract, which is one of the main causes of toxicity (Malet-
Martino and Martino, 2002).   
 
 
 
 
Figure 5.6 Structure of N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine 
(Capecitabine, left) and 1-(2-tetrahydrofuryl)-5-Fluorouracil (Ftorafur, right), 
prodrugs of 5-FU. 
 
 
 177
5.1.6  Chemistry of prodrugs 3, 6, 9, 13 and 14 
 
Compounds 3, 6, 9, 13 and 14 were designed as prodrugs, with a nitro-benzyl 
side-chain attached to the parent 5-FU or 5-FUrd.  These prodrugs have three 
components essential to their function: trigger, linker and effector.  In the case of 
these compounds, the nitro group acts as the trigger, the benzyl group is the linker 
and the effector is 5-FU or 5-FUrd, as illustrated in Figure 5.7 with a diagram of 
compound 3.  Activation of these prodrugs involves reduction of the nitro group, 
which causes conformational changes in the benzyl group and subsequent cleavage of 
the bond between the parent 5-FU or 5-FUrd and the linker/trigger section.  Figure 
5.8 demonstrates the activation of compound 3, with the final result showing free 5-
FU and quinone methide, another toxic molecule which forms DNA adducts (Wang 
et al., 2005).   
 
 
 
 
 
Figure 5.7 Structure of compound 3.  The nitro group acts as trigger, the benzyl 
group is a linker and 5-FU is the effector component.   
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Figure 5.8 Activation of compound 3.  Reduction of the nitro group to –NHOH 
results in cleavage of the bond between the benzyl linker group and 5-FU, releasing 
5-FU and quinone methide.   
 
 
5.1.7  Objectives of Chapter 5 
 
The possibility of using targeted therapies for cancer patients could improve 
the outcome of the disease.  Prodrugs may decrease side-effects in patients and offer 
more efficacious treatments.  Activation of the 5-FU and 5-FUrd prodrugs 3, 6, 9, 13 
and 14 and their corresponding toxicity was the focus of this chapter.  Hypoxia-
induced activation was initially analysed using the 4T1 and SW480 cell lines to 
investigate activation by endogenous one-electron reductases.  Enzyme activation 
using E. coli NTR was then tested, firstly by using recombinant protein in a multi-
well enzyme assay.  These assays allowed investigation of the enzyme kinetics using 
NTR.  Following this, a cell line expressing NTR was tested with the prodrugs and a 
known substrate.  Liquid chromatography in conjunction with mass spectrometry was 
used to analyse activation of the prodrugs in the NTR-expressing cells.  The cDNA 
for NTR was amplified in bacteria and used to transfect a human colorectal cancer 
cell line.  Establishment of a transfected cell line allowed testing of the compounds in 
human tumour cells.   
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5.2  Results 
 
5.2.1  Activation of prodrugs by hypoxia in the 4T1 cell line 
 
Prodrugs can be activated under hypoxic conditions by reduction to an 
intermediate molecule which is further modified to produce the pharmacologically 
active drug.  The selectivity to hypoxic cells occurs due to back-oxidation of the 
intermediate molecule to the original compound in the presence of oxygen (Brown 
and Wilson, 2004).  In order to investigate activation of the 5-FU and 5-FUrd 
prodrugs, cytotoxicity experiments were set up and then incubated under hypoxic 
conditions (2% O2).  The first step in this series of experiments was to determine any 
detrimental effect of the hypoxic conditions on the cell line.  The growth of the 4T1 
cell line was monitored after 24, 48 and 72 hours incubation at 5% CO2, 2% O2.  
Experiments were carried out in triplicate.  Figure 5.9 shows that there was minimal 
detrimental effect on the growth of this cell line over the three time points examined 
when compared to growth of the cells under normoxic conditions (20% O2).   
 
 
 
 
 
Figure 5.9 4T1 cell growth profile under hypoxic (2% O2) and normoxic (20% O2) 
conditions over 24, 48 and 72 hours to assess toxicity to the cells.  
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Compounds 13 and 14 were chosen for the initial investigation of toxicity in 
the 4T1 cell line.  Cells were seeded in 96-well plates as per section 2.2.3 and allowed 
to attach overnight in normoxic conditions.  The compounds were then added to the 
cells and incubated for 3 days.  Assays were incubated in hypoxic conditions for 3 or 
24 hours and then transferred to normoxic conditions for the remaining time, or they 
were incubated in the hypoxic conditions for 72 hours.  Assays incubated in normoxic 
conditions were placed in a standard 37°C, 5% CO2 incubator for 3 days.  The level 
of cell death caused by the compounds was quantified using the MTS assay.  Assays 
were carried out in triplicate.  Figure 5.10 shows the results for compound 13.  Over 
the full range of concentrations, 0.0003 µM to 323 µM, the cells under the four 
different conditions corresponded closely to one another.  Low toxicity was observed 
up to approximately 10 µM  for the cells in normoxia and 3 and 24 hours hypoxia, 
with the cell death rising up to approximately 80% at the top concentration of 323 
µM.  The cells incubated in hypoxic conditions for 72 hours showed no toxicity up to 
approximately 50 µM.  
 
 
 
 
Figure 5.10 Cytotoxicity of compound 13 in the 4T1 cell line after treatment for 3 
days, under normoxic conditions and following exposure to 3, 24 and 72 hours 
hypoxia (2% O2).   
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Compound 14 caused low toxicity over the range of concentrations tested, 
0.00025 µM to 250 µM, with no difference noted between the different conditions 
(Figure 5.11).   
 
 
 
 
Figure 5.11 Cytotoxicity of compound 14 in the 4T1 cell line after treatment for 3 
days, under normoxic conditions and following exposure to 3, 24 and 72 hours 
hypoxia (2% O2). 
 
 
Although no activation appeared to be occurring with compounds 13 and 14, 
compounds 3, 6 and 9 were then tested under hypoxic conditions for 72 hours.  
Compound 3 had shown toxicity previously against the 4T1 and SW480 cell lines 
(Sections 4.2.2 and 4.2.3).  However, the possibility of increased toxicity under 
hypoxic conditions was examined.  Figure 5.12 shows the results for this compound, 
with no difference in toxicity seen between the cells incubated in normoxic conditions 
and those exposed to hypoxia for 72 hours.  Compounds 6 and 9, both 5-FUrd 
derivatives, caused low toxicity in the 4T1 and SW480 cell lines (Sections 4.2.2 and 
4.2.3).  Exposure of cells to these compounds while incubated under hypoxia for 72 
hours did not cause an increase in cytotoxicity in the 4T1 cell line (Figure 5.13).   
-20
0
20
40
60
80
100
0.
00
01
0.
00
1
0.
01 0.
1 1 10 10
0
10
00
µM Treatment
%
 C
el
l D
ea
th
Normoxia
3Hr Hypoxia
24Hr Hypoxia
72Hr Hypoxia
 182
 
 
Figure 5.12 Cytotoxicity of compound 3 in the 4T1 cell line after treatment for 3 
days, under normoxic conditions and following exposure to 72 hours hypoxia (2% 
O2). 
 
 
Figure 5.13 Cytotoxicity of compounds 6 and 9 in the 4T1 cell line after treatment 
for 3 days, under normoxic conditions and following exposure to 72 hours hypoxia 
(2% O2). 
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5.2.1.2 Activation of prodrugs by hypoxia in the SW480 cell line 
 
Activation and cytotoxicity of these prodrugs was examined in the SW480 
colorectal cancer cell line following 72 hours exposure to hypoxic conditions.  This 
cell line was initially tested to ensure the hypoxia alone did not cause cell death 
(Figure 5.14).  Assays were carried out in triplicate.  Incubation for 48 and 72 hours 
caused an increase in the growth of the SW480 cells, but no decrease in cell growth 
was seen.  No significant difference was seen in the toxicity of these compounds 
under hypoxic conditions over 72 hours.  Figure 5.15 shows the toxicity profile for 
compound 3 which showed toxicity towards the cells but no increase in toxicity under 
hypoxic conditions.  Figure 5.16 shows the toxicity of compounds 6 and 9 after 
exposure to hypoxia for 72 hours.  No increase in toxicity was exhibited after 
incubation for 72 hours with compounds 6 and 9 under hypoxic conditions.  
Compounds 13 and 14 did not exhibit an increase in toxicity after incubation under 
hypoxic conditions for 72 hours (data not shown).  Hence, no activation was evident 
for prodrugs 3, 6, 9, 13 and 14 following exposure to hypoxic conditions over 3 days.  
This was possibly due to the fact that the majority of reductase enzymes in cells are 
one-electron reductases and these compounds appear to require two-electron 
reductases for activation.  Since the two-electron reductases in mammalian cells are 
unlikely to reach the reduction potential required to reduce the nitro trigger, a known 
reductase with the ability to reach low reduction potentials was examined. 
 
 
 
Figure 5.14 SW480 cell growth profile under hypoxic (2% O2) and normoxic (20% 
O2) conditions over 24, 48 and 72 hours to assess toxicity to the cells. 
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Figure 5.15 Cytotoxicity of compound 3 in the SW480 cell line after treatment for 3 
days, under normoxic conditions and following exposure to 72 hours hypoxia (2% 
O2). 
 
 
Figure 5.16 Cytotoxicity of compounds 6 and 9 in the SW480 cell line after 
treatment for 3 days, under normoxic conditions and following exposure to 72 hours 
hypoxia (2% O2). 
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5.2.2 Analysis of prodrug compounds as substrates for Escherichia coli 
nitroreductase 
 
E. coli NTR is a two-electron reductase which is known to activate 
nitroaromatic compounds including CB1954 (Parkinson et al., 2000).  In order to test 
if the prodrugs 3, 6, 9, 13 and 14 were substrates for this enzyme, the recombinant 
enzyme was purchased in powder form from Sigma Aldrich for use in a simple 
enzyme assay with NADH as co-factor.  CB1954 was also purchased from Sigma 
Aldrich and used as a control substrate.  Following optimisation experiments with 
CB1954, concentrations of 500 µM NADH, 3 µg/ml NTR and 200 µM substrate were 
chosen (data not shown).  The reaction with the substrate was set up and monitored 
by the decrease in absorbance of NADH at 340 nm over a period of 60 minutes, as 
per section 2.2.11.1.  Figure 5.17 shows the results from the enzyme assays.  A 
reduction in the absorbance at 340 nm was seen for all compounds.  CB1954 and 
compound 9 showed the most dramatic change in absorbance over the 60 minutes.   
 
 
 
Figure 5.17 Enzyme assay to determine if prodrugs were substrates for E. coli NTR.  
CB1954 was used as a control, as it is a known substrate for NTR.  Absorbance of 
NADH at 340 nm was monitored over a period of 60 minutes.  
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Although compound 9 looked the most promising in the enzyme assay 
outlined in Figure 5.17 there was a limited amount of this compound available for 
kinetic analysis therefore the more abundant compounds 13 and 14 were used.  
Assays were conducted using a range of substrate concentrations and the absorbance 
of NADH measured after 1 hour.  A plot of substrate concentration [S] versus rate 
(velocity, v) yields the Michaelis-Menton curve.  The Lineweaver-Burk, Hanes-
Woolf, Eadie-Hofstee plots as well as the non-linear regression software Enzfitter 
(Elsevier Biosoft) were used to calculate the Michaelis constant (Km), Vmax and 
catalytic constant (kcat) from this data.  The Km value is the concentration required to 
reach half the maximum velocity (Vmax) of the enzyme or the concentration at which 
half of the active sites are filled.  Km is related to how well the substrate binds the 
enzyme - the lower the Km value, the greater the affinity for the enzyme (Matthews 
and van Holde, 1990).  However, the greater the affinity for the enzyme, the slower 
the reaction will proceed and this will affect the kcat value.  kcat, or the turnover 
number, measures the number of molecules of substrate that are converted to product 
by one enzyme site per second.  The Km and Vmax (maximum velocity) are 
determined from the plots as described in Table 5.1.  
 
Table 5.1 Details of the Lineweaver-Burk, Hanes-Wolf and Eadie-Hofstee plots for 
determination of Km and Vmax.  
 
 
 
 
Determination of kcat was then calculated from the equation:  
 
  kcat = Vmax / Et 
 
where Et was the total enzyme, and was calculated as follows: 
 
x=Vmax/Kmy=Vmaxvv/[S]Eadie-Hofstee
x=-Kmy=Km/Vmax[S]/v[S]Hanes-Wolf
x=-1/Kmy=1/Vmax1/v1/[S]Lineweaver-Burk
y=0x=0y-axisx-axisPlot
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Concentration used in reaction (g.ml-1) / Molecular weight (g.mole-1) = Et (mole.ml-1) 
 
For these experiments, 3µg/ml enzyme was used, with molecular weight of 24,000 
g.mole-1.  Thus: 
 
Et (mole.ml-1) = 3 x 10-6 g.ml-1/ 24,000 g.mole-1 = 1.25 x 10-10 mole.ml-1  
 
Compound 13 showed excellent correlation between the substrate 
concentrations and velocity in the plots.  Figure 5.18 shows the Michaelis-Menton 
curve for compound 13 when substrate concentration was plotted against the velocity 
of the reaction.  The Lineweaver-Burk plot of 1/[S] versus 1/v gave a straight line 
with a correlation co-efficient (R2 value) of 1 (Figure 5.19).  The correlation co-
efficient for the Hanes-Woolf plot of [S] versus [S]/v was 0.998 (Figure 5.20).  Figure 
5.21 shows the Eadie-Hofstee plot of v/[S] versus v, giving a straight line with 
correlation co-efficient of 0.9828.  The Hanes-Woolf plots for compound 14 and 
CB1954 gave straight lines with correlation co-efficients of 0.9951 and 0.9973 
respectively (Figures 5.22 and 5.23).   
The values for Km and kcat calculated from the plots and using the Enzfitter 
software are shown in Table 5.2.  The Km values for compounds 13, 14 and CB1954 
were 48.17 µM, 13.47 µM and 9.66 µM respectively.  This would indicate that the 
nitroreductase enzyme has the highest affinity for CB1954, followed closely by 
compound 14.  The kcat value of 76427 sec-1 for compound 13 means that this 
substrate is converted to product at a faster rate than compound 14 or CB1954, with 
kcat values of 29857 sec-1 and 52195 sec-1 respectively.  The kcat/Km ratio indicates the 
catalytic efficiency of the reaction, taking into account both the affinity of the 
substrate for the enzyme and the rate of reaction.  The more efficient the reaction, the 
greater the value of kcat/Km.  In this case, the efficiency of reactions appears to be in 
the order CB1954>compound 14>compound 13.  This is due to a combination of high 
affinity but also moderate turnover for CB1954, whereas compound 13 had lower 
affinity with high turnover, and compound 14 had high affinity and low turnover.   
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Figure 5.18 Substrate concentration versus velocity for compound 13 yielded the 
Michaelis-Menton hyperbola.  
 
 
 
 
Figure 5.19 Lineweaver-Burk plot for compound 13 with 1/[S] versus 1/v.  The 
correlation co-efficient (R2) value was 1.   
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Figure 5.20 Hanes-Woolf plot for compound 13 with [S] versus [S]/v.  The 
correlation co-efficient (R2) value was 0.998. 
 
 
 
 
Figure 5.21 Eadie-Hofstee plot for compound 13 with v/[S] versus v.  The correlation 
co-efficient (R2) value was 0.9828. 
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Figure 5.22 Hanes-Woolf plot for compound 14 with [S] versus [S]/v.  The 
correlation co-efficient (R2) value was 0.9951. 
 
 
 
 
 
Figure 5.23 Hanes-Woolf plot for CB1954 with [S] versus [S]/v.  The correlation co-
efficient (R2) value was 0.9973. 
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Despite the fact that CB1954 reacts more efficiently with the enzyme in 
comparison to compounds 13 and 14, these results were still encouraging.  CB1954 is 
a known substrate with great potential for therapeutic purposes in conjunction with 
the nitroreductase enzyme.  Compounds 13 and 14 showed enough activity with the 
enzyme to warrant moving forward to activation within cells.   
 
 
Table 5.2 Km and kcat values for compounds 13, 14 and CB1954, calculated using the 
Lineweaver-Burk, Hanes-Woolf, Eadie-Hofstee graphs and the Enzfitter program. 
 
 
 
 
 
5.2.3  NTR activity in V79 Chinese hamster lung fibroblast cell line lysates 
 
Following analysis of the compounds with the E. coli NTR enzyme, a cell line 
expressing this protein, and a control cell line, were obtained from Morvus 
Technologies.  The V79 Chinese hamster lung fibroblast cell line had been 
transfected with the cDNA for the NTR enzyme and was designated V79-NTR 
(Friedlos et al., 1998).  The control cell line was transfected with the control vector 
and was designated V79-C.  These two cell lines were maintained in the selection 
agent, puromycin.  To firstly confirm activity of the NTR enzyme in this cell line, an 
enzyme assay was conducted using cell lysates as per section 2.2.11.2.  Cells were 
trypsinised, centrifuged and lysed by a freeze-thaw method.  The cell lysate was 
added to a mixture of the substrate CB1954 and the co-factor NADH and the 
Lineweaver-Burk Hanes-Woolf Eadie-Hofstee Enzfitter Average Std Dev kcat/KM (sec
-1M-1)
Cmpd 13
KM (µM) 47.87 45.88 50.04 48.88 48.17 1.76 1.59E+09
kcat (sec
-1) 76593 73411 80000 75702 76427 2733
Cmpd 14
KM (µM) 13.92 1.15 16.97 21.85 13.47 8.84 2.22E+09
kcat (sec
-1) 27841 26952 32000 32636 29857 2876
CB1954
KM (µM) 5.09 6.65 10.43 16.49 9.66 5.07 5.40E+09
kcat (sec
-1) 40733 53165 56000 58883 52195 7990
 192
absorbance of NADH monitored at 340 nm over 60 minutes.  Figure 5.24 shows the 
results from the enzyme assay using the cell lysates.  The total protein added to the 
reaction was 15.33 µg, 18 µg and 8.8 µg for the V79-NTR, V79-C and 4T1 cell lines 
respectively.  The lysate from the V79-NTR cell line caused an obvious decrease in 
the absorbance of NADH as the reaction proceeded.  The lysate from theV79-C cell 
line caused a small decrease in absorbance over the 60 minutes (Figure 5.24).  The 
4T1 cell line was used as a control as it did not express the NTR enzyme and 
accordingly, the lysate caused a small decrease in absorbance.  The specific activity 
was calculated from these assays, using the molar absorption coefficient of NADH 
(6.3 x 103 mole-1 cm-1).  The specific activity of the NTR enzyme was 0.1578 
Units/mg for the V79-NTR cell line.  For the V79-C and 4T1 cell lines, the specific 
activity was significantly lower, at 0.0013 Units/mg and 0.0037 Units/mg 
respectively.  Thus, NTR enzyme activity in the V79-NTR cell line was confirmed 
and the activation of the prodrugs was next tested using cytotoxicity assays. 
 
 
 
Figure 5.24 Enzyme assay using lysates from the V79-NTR, V79-C and 4T1 cell 
lines to test activity of NTR with known substrate CB1954.  The quantity of total 
protein in the lysates was 15.33 µg, 18 µg and 8.8 µg respectively. 
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5.2.4 Cytotoxicity of prodrugs in the V79 Chinese hamster lung fibroblast cell 
line 
 
Cytotoxicity of the known substrate, CB1954, and the prodrugs, 3, 6, 9, 13 
and 14 was investigated in the V79-C and V79-NTR cell lines.  Results are from a 
minimum of duplicate experiments, carried out in triplicate.  Figure 5.25 shows the 
cytotoxicity of CB1954 over 3 days.  The difference in toxicity in the two cell lines 
was extremely dramatic.  In the V79-C cell line, no toxicity was observed up to 40 
µM, with toxicity then rising to approximately 80% cell death at 397 µM.  In contrast, 
at the lowest concentration tested, 0.00397 µM, approximately 40% cell death was 
noted in the V79-NTR cell line.  The IC50 value of the V79-C cell line was 190 µM, 
over 27,000-fold higher than the IC50 value of 0.007 µM for the V79-NTR cell line 
(Table 5.3). 
 
 
 
 
Figure 5.25 Cytotoxicity of CB1954 in the V79-C and V79-NTR cell lines after 
treatment for 3 days. 
 
Treatment with compound 3 did not cause a difference in toxicity between the 
two cell lines, V79-C and V79-NTR.  Figure 5.26 shows the cytotoxicity profile over 
3 days, with compound 3 exhibiting cell death from a concentration of approximately 
0.4 µM and higher in both cell lines.  The IC50 values over 3 days for V79-C and 
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V79-NTR were 9 µM and 7.5 µM respectively, giving a ratio of 1.2 (Table 5.3).  The 
ratio of IC50 values increased slightly to 1.9 after 5 days treatment (Table 5.3).  
Compound 6 showed promising results after 3 days treatment, with greater toxicity in 
the V79-NTR cell line in comparison to the V79-C cell line at a concentration of 25 
µM (Figure 5.27).  However, this was not maintained at the higher concentration of 
252 µM or after 5 days treatment (Figures 5.27 and 5.28).  The ratio of IC50 values 
was 10.63 and 0.97 for 3 and 5 days respectively (Table 5.3). 
 
 
Figure 5.26 Cytotoxicity of compound 3 in the V79-C and V79-NTR cell lines after 
treatment for 3 days. 
 
 
 
Figure 5.27 Cytotoxicity of compound 6 in the V79-C and V79-NTR cell lines after 
treatment for 3 days. 
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Figure 5.28 Cytotoxicity of compound 6 in the V79-C and V79-NTR cell lines after 
treatment for 5 days. 
 
Compound 9 showed low toxicity in the V79-C cell line, with a maximum of 
35% cell death observed over 3 days (Figure 5.29).  In contrast, the V79-NTR cell 
line showed no toxicity over this time scale.  IC50 values were not reached after 
treatment for 3 and 5 days.   
 
 
Figure 5.29 Cytotoxicity of compound 9 in the V79-C and V79-NTR cell lines after 
treatment for 3 days. 
-40
-20
0
20
40
60
80
100
120
1 10 10
0
10
00
µM Treatment
%
 C
el
l D
ea
th V79-C
V79-NTR
-60
-40
-20
0
20
40
60
80
100
0.
00
1
0.
01 0.
1 1 10 10
0
µM Treatment
%
 C
el
l D
ea
th
V79-C
V79-NTR
 196
Figure 5.30 and 5.31 shows the results for compound 13 over 3 and 5 days 
respectively.  Treatment with compound 13 for 3 days caused more toxicity in the 
V79-NTR cell line than the control cell line, with 100% cell death seen in the V79-
NTR cells after treatment with 323 µM (Figure 5.30).  The maximum cell death 
observed for the V79-C cell line was approximately 50% at 323 µM, the top 
concentration tested.  The ratio of IC50 values for 3 days treatment was 4.89.  Over 5 
days, a more dramatic difference was seen between the two cell lines, with no toxicity 
seen in the V79-C cell line, up to 323 µM (Figure 5.31).  An IC50 value of 54 µM was 
established for the V79-NTR cell line but the IC50 value was not reached for the V79-
C cell line.  The ratio of IC50 values was thus greater than 5.98 (Table 5.3).  These 
results appear to indicate activation of the prodrug 13 by the NTR enzyme in the 
V79-NTR cell line.  
 
 
 
Figure 5.30 Cytotoxicity of compound 13 in the V79-C and V79-NTR cell lines after 
treatment for 3 days. 
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Figure 5.31 Cytotoxicity of compound 13 in the V79-C and V79-NTR cell lines after 
treatment for 5 days. 
 
 
Compound 14 showed a dramatic difference in cytotoxicity over 3 days 
(Figure 5.32).  No toxicity was seen in the V79-C cell line over the range of 
concentrations tested (0.25-250 µM).  Toxicity in the V79-NTR cell line was evident 
from 2.5 µM, with approximately 40% cell death occurring.  At 25 µM and 250 µM, 
100% cell death was observed.  The IC50 value in the V79-NTR cell line was 
established as 3.4 µM over 3 days.  The ratio of IC50 values was greater than 73.5, but 
a more accurate ratio could not be calculated as the IC50 value was not reached for the 
V79-C cell line.  Similar toxicity was observed over 5 days for the V79-NTR cell line 
(Figure 5.33).  Over 50% cell death was noted at 2.5 µM and 100% cell death was 
again evident after treatment with 25µM and 250 µM.  However, there was also an 
increase in toxicity in the control cell line, with approximately 40-50% cell death 
occurring after treatment with 25 µM and 250 µM.  The IC50 values were established 
as 33 µM and 1.8 µM for the V79-C and V79-NTR cell lines respectively, giving a 
ratio of 18.33 (Table 5.3).  
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Figure 5.32 Cytotoxicity of compound 14 in the V79-C and V79-NTR cell lines after 
treatment for 3 days. 
 
 
 
Figure 5.33 Cytotoxicity of compound 14 in the V79-C and V79-NTR cell lines after 
treatment for 5 days. 
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Table 5.3 IC50 values and ratios for prodrugs 3, 6, 9, 13, 14 and CB1954 in the V79-
C and V79-NTR cell lines after treatment for 3 and 5 days.  
 
 
 
 
Following cytotoxicity analysis with the V79-C and V79-NTR cell lines, 
compounds 13 and 14 showed the most promise as activated prodrugs in the presence 
of the nitroreductase-expressing cell line.  The next step was to confirm the activation 
of the prodrug as being the cause of this increased toxicity.   
 
 
271430.007±0.002190±25CB1954
18.331.8±0.233±3>73.5b3.4±1.27>250aCmpd 14
>5.98b54±7.07>323a4.8966±30323±54Cmpd 13
->16.1a>16.1a->16.1a>16.1aCmpd 9
0.9791±8.5488±7.810.638±2.8385±6.2Cmpd 6
1.95.8±1.0111±1.21.27.5±1.499±1.05Cmpd 3
FoldV79-NTRV79-CFoldV79-NTRV79-C
5 Days3 Days
IC50 Values V79-C & V79-NTR Cell Lines (µM)
Mean ± SD
(a) IC50 value not reached up to highest concentration tested
(b) Undetermined IC50, therefore highest concentration tested was used to calculate ratio and
thus was an underestimate.
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5.2.5  Liquid Chromatography-Mass Spectrometry Analysis 
 
In order to confirm the activation of the prodrugs, samples were analysed by 
liquid chromatography-mass spectrometry (LC-MS).  Dr. Rachel Wall and Dr. Robert 
O’Connor of the National Institute for Cellular Biotechnology (NICB) developed the 
method and ran the samples.  Media was collected from cells exposed to 75 µM 
prodrug 13 as described in section 2.2.12.1.  Analysis was carried out as described in 
section 2.2.12.2.  Figure 5.34 shows the mass spectrometric analysis of 5-FU and 
compound 13 in their pure forms, with peaks of 130 and 310 m/z at 4.1 and 9.5 
minutes respectively.  Two controls were used, the first was a sample of compound 
13 that was added to media and immediately frozen until analysis, the second was a 
sample of compound 13 that was added to media, incubated at 37°C for 5 days and 
then frozen for analysis.  Figure 5.35 shows the mass spectrometric analysis of these 
two control samples.  Figure 5.35 A and C show background noise, with the absence 
of a peak for 5-FU and B and D show peaks for compound 13 at 9.5 minutes.  This 
proves activation of compound 13 was not occurring in the media alone.  
 
 
 
 
Figure 5.34 Mass spectrometric analysis of 5-FU (A) and compound 13 (B), 
appearing as peaks at m/z 130 and 310. 
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Figure 5.35 Mass spectrometric analysis of controls, A and B – compound 13 added 
to media and frozen immediately, C and D – compound 13 added to media, incubated 
at 37°C for 5 days and then frozen. 
 
 
Figure 5.36 shows mass spectrometric analysis of samples from the V79-C 
(top) and V79-NTR (bottom) cells.  Compound 13 was added to cells at 75 µM and 
incubated at 37°C for 5 days.  The media was then removed and frozen for analysis.  
There was no 5-FU peak in the sample from the V79-C cells (Figure 5.36 A) while 
there was a peak for compound 13 evident at 9.5/9.7 minutes (Figure 5.36 B).  For the 
V79-NTR cells, however, there was a peak of 5-FU at 4.4 minutes (Figure 5.36 C), 
with a clear absence of the peak for compound 13 at 9.5 minutes (Figure 5.36 D).  
This would indicate activation of compound 13 to 5-FU after incubation with the 
V79-NTR cell line for 5 days.   
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Figure 5.36 Mass spectrometric analysis of 5-FU and compound 13 after incubation 
with the V79-C (A and B) and V79-NTR (C and D) cell lines for 5 days.  A peak of 
5-FU is evident in graph C while in the same sample, the peak for compound 13 (D) 
has disappeared. 
 
Unfortunately, mass spectrometric analysis of the cell pellets was not possible 
due to lack of sensitivity and rapid metabolism of 5-FU in the cells.  Had time and 
resources allowed, mass spectrometric analysis of all the prodrugs would have been 
interesting to examine.  However, from the data above confirming the release of 5-FU 
from the prodrug 13, it was decided to pursue the activation of the compounds by the 
NTR enzyme in the cancer cell environment.  
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5.2.6  Plasmid Preparations 
 
The F179 and F184 plasmids were kindly provided by Dr Steve Hobbs, 
CRUK Centre for Cancer Therapeutics, UK.  The F179 plasmid, 5.7 kb in size, was 
the control plasmid and contained an ampicillin resistance gene for selection in E.coli 
and the puromycin resistance gene for selection in mammalian cells (See Appendix A 
for plasmid map).  The F184 plasmid, 6.3 kb in size, contained the cDNA for the 
NTR enzyme under the control of a cytomegalovirus (CMV) promoter, along with the 
resistance genes previously mentioned for the F179 plasmid (See Appendix A for 
plasmid map).  The plasmids were provided on sterile discs of filter paper and thus 
the DNA had to be extracted and transformed into competent bacteria which were 
cultured to obtain working volumes of the plasmid DNA, as per section 2.2.13.  
Following preparations of the plasmid DNA, restriction digests were carried out as 
per section 2.2.13.3.  F179 plasmid was digested with Eco RI, which cleaves at two 
sites in the plasmid, giving two DNA segments of 2.5 kb and 3.2 kb (Figure 5.37).  
F184 plasmid was digested with Bam HI and Xho I enzymes.  Bam HI cleaves at one 
site and Xho I cleaves at two sites in the plasmid, in combination giving 3 fragments 
of DNA of 0.7 kb, 2.5 kb and 3.2 kb (Figure 5.38).  
 
 
 
 
Figure 5.37 Restriction digest of F179 plasmid using Eco RI enzyme, showing two 
bands of 2.5 kb and 3.2 kb for three separate preparations. 
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Figure 5.38 Restriction digest of F184 plasmid using Bam HI and Xho I enzymes, 
showing three bands of 0.7 kb, 2.5 kb and 3.2 kb for two separate preparations. 
 
 
5.2.7  Transfection of the NTR gene into colon cancer cell lines 
 
The SW480 cell line was the obvious choice for transfection of the plasmids, 
as the toxicity had previously been examined in this cell line and previous 
transfections of this cell line in our group had been successful (Murray et al., 2004).  
However, despite numerous attempts at transfection using varying cell numbers and 
ratios of plasmid DNA to transfection reagent, a stable cell line could not be 
established.  The stocks of this cell line in the lab had tested positive for mycoplasma 
and new stocks had been purchased from the ATCC prior to the transfection attempt.  
Despite having fresh, mycoplasma-negative stocks, the transfection was not 
successful and another avenue was pursued.  The HCT116 colorectal carcinoma cell 
line was chosen for transfection of the F179 and F184 plasmids.  Firstly, transfection 
efficiency of this cell line was investigated using the pCH110 plasmid (See Appendix 
A for plasmid map), which contained the lac Z gene encoding the β-galactosidase 
protein.  This plasmid was transfected into the HCT116 cell line and activity 
determined using X-gal (as per Section 2.2.14.1), which reacts with β-galactosidase 
to turn the transfected cells blue (Figure 5.39).  Transfection efficiency (percentage of 
blue cells of total cells) was calculated as 9.7% from the 200X photograph (Figure 
5.39). 
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Figure 5.39 Transfection efficiency of the HCT116 cell line as illustrated by the blue 
staining of cells due to the interaction of β-galactosidase in transfected cells with X-
gal.  Photographs were taken at different magnifications using an Olympus DP70 
camera. 
 
 
Following confirmation of the transfection efficiency of the HCT116 cell line, 
the F179 and F184 plasmids were transfected into the cells successfully on the first 
attempt.  Puromycin was used to select the cells containing the plasmids, as per 
section 2.2.14.2.  Two different populations containing each plasmid were 
established.  The presence of the plasmids in the cells was confirmed by PCR using 
DNA extracted from the cells as per section 2.2.14.3 (Figure 5.40). RT-PCR using 
mRNA extracted from the cells confirmed the production of NTR mRNA (Figure 
5.41).  The levels of NTR mRNA were similar in the HCT116 cells transfected with 
the F184 plasmid and the V79-NTR cells (Figure 5.41).  Once cell populations were 
established and the presence of the plasmid confirmed, the cells were used for testing 
the prodrugs.  The transfected cell lines were designated HCT-C (containing F179) 
and HCT-NTR (containing F184). 
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Figure 5.40 PCR products from F179 and F184 plasmids from transfected HCT116 
cell lines for ampicillin (top) and NTR (bottom).  M: Marker, Lane 1: F179(A), Lane 
2: F179(B), Lane 3: F184(A), Lane 4: F184(B), Lane 5: Control (H2O). 
 
 
 
 
Figure 5.41 RT-PCR products from F179 and F184 plasmids for actin and NTR.  M: 
Marker, Lane 1: F179(A), Lane 2: F179(B), Lane 3: F184(A), Lane 4: F184(B), Lane 
5: V79-NTR, Lane 6: RT negative control, Lane 7: control (H2O).  
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5.2.8  Cytotoxicity of prodrugs in the HCT-C and HCT-NTR cell lines 
 
The prodrugs, 3, 6, 9, 13 and 14 were tested on the established cell lines HCT-
C and HCT-NTR.  Cytotoxicity was assayed three times, in triplicate.  Figure 5.42 
shows the toxicity of compound 3 in these two cell lines after treatment for 3 and 5 
days.  No significant difference in toxicity was seen between the HCT-C and HCT-
NTR cell lines.  The IC50 values and ratios are listed in Table 5.4.  The ratio of IC50 
values for compound 3 was 0.92 and 0.6 for 3 and 5 days respectively.  Treatment 
with compound 6 only showed toxicity at the highest concentration used but caused 
no difference in toxicity between the two cell lines (Figure 5.43).  The IC50 value was 
not reached in the HCT-NTR cell line after 3 days treatment and thus the fold 
difference was less than 0.6 but an exact ratio could not be established.  After 5 days 
treatment, a ratio 1.3 was calculated between the two IC50 values (Table 5.4).   
 
 
 
 
Figure 5.42 Cytotoxicity of compound 3 in the HCT-C and HCT-NTR cell lines after 
treatment for 3 days (3D) and 5 days (5D). 
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Figure 5.43 Cytotoxicity of compound 6 in the HCT-C and HCT-NTR cell lines after 
treatment for 3 days (3D) and 5 days (5D). 
 
Compound 9 showed low toxicity over the range of concentrations tested, 
with IC50 values not reached for either treatment times (Figure 5.44).  After treatment 
for 3 days, compound 13 showed low toxicity in both cell lines, with no increased 
toxicity in the HCT-NTR cell line, and IC50 values were not reached for this time 
point (Figure 5.45 and Table 5.4).  After treatment for 5 days, a small increase in 
toxicity in the HCT-NTR cell line was noted in comparison to the control, at the top 
concentration of 323 µM.  The IC50 values were 320 µM and 200 µM for the HCT-C 
and HCT-NTR cell lines, giving a ratio of 1.6.  Low toxicity was observed after 
treatment with compound 14 (Figure 5.46).  There was no significant increase in the 
toxicity exhibited in the HCT-NTR cell line.  After treatment for 3 days, IC50 values 
of 200 µM and 248 µM were established, giving a ratio of 0.8, but the IC50 values 
were not reached for the 5 day treatment (Table 5.4).  Cytotoxicity of CB1954 was 
examined with the HCT-C and HCT-NTR cell lines (Figure 5.47).  There was an 
increase in toxicity in the HCT-NTR cell line at one concentration for each time 
point, but this was not consistent over the range of concentrations tested.  The ratio of 
IC50 values was 0.98 and 2.22 for 3 and 5 days respectively (Table 5.4).   
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Figure 5.44 Cytotoxicity of compound 9 in the HCT-C and HCT-NTR cell lines after 
treatment for 3 days (3D) and 5 days (5D). 
 
 
 
 
Figure 5.45 Cytotoxicity of compound 13 in the HCT-C and HCT-NTR cell lines 
after treatment for 3 days (3D) and 5 days (5D). 
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Figure 5.46 Cytotoxicity of compound 14 in the HCT-C and HCT-NTR cell lines 
after treatment for 3 days (3D) and 5 days (5D). 
 
 
 
 
Figure 5.47 Cytotoxicity of CB1954 in the HCT-C and HCT-NTR cell lines after 
treatment for 3 days (3D) and 5 days (5D). 
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Table 5.4 IC50 values and ratios for prodrugs 3, 6, 9, 13, 14 and known substrate 
CB1954 in the HCT-C and HCT-NTR cell lines after treatment for 3 and 5 days. 
 
 
 
 
 
5.2.9  HCT-C and HCT-NTR Enzyme Assays 
 
Activity of the NTR enzyme in the newly established cell line, HCT-NTR, 
was investigated using cell lysates as described in section 2.2.11.2.  Lysates from 
HCT-NTR and HCT-C cell pellets were tested with CB1954 for activity.  Figure 5.48 
shows an enzyme assay using 100 µg total protein, with no activity evident in the 
HCT-NTR cell line (Table 5.5: Experiment A).  The amount of total protein was 
increased to approximately 300 µg but still little activity was seen in the NTR-
expressing HCT cell line, and was mirrored by the HCT-C cell line (Table 5.5: 
Experiment B).  Table 5.5 contains the specific activity values calculated in the cell 
lysates used in these assays.  In experiment A, the V79-NTR cell line showed greater 
than 20 times more specific activity than the HCT cell lines.  The HCT-C cell line 
surprisingly showed higher specific activity than the HCT-NTR cell line but the 
values for both were low.  The V79-NTR cell line had lower specific activity in 
experiment B.  The specific activity for the HCT-NTR and HCT-C cell lines were 
Mean ± SD
(a) IC50 value not reached up to highest concentration tested
(b) Undetermined IC50, therefore highest concentration tested was used to calculate ratio and
thus was an overestimate.
2.2218±1240±240.98197±15.28194±3.6CB1954
->250a>250a0.8248±1200±50Cmpd 14
1.6200±70320±107->323a>323aCmpd 13
->16.1a>16.1a->16.1a>16.1aCmpd 9
1.33105±7140±81<0.6b>252a150±14.14Cmpd 6
0.606.2±1.043.7±1.780.9210.3±2.39.5±4.5Cmpd 3
FoldHCT-NTRHCT-CFoldHCT-NTRHCT-C
5 Days3 Days
IC50 Values HCT-C & HCT-NTR Cell Lines (µM)
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approximately half that of the V79-NTR cell line, with the control cell line again 
having slightly more activity than the NTR cell line. 
 
 
 
 
Figure 5.48 Enzyme assay using cell lysates from the V79-C, V79-NTR, HCT-C and 
HCT-NTR cell lines to test activity of NTR with CB1954.  100 µg protein from the 
cell pellets was used in this assay (Experiment A). 
 
 
Table 5.5 Specific activity of nitroreductase enzyme in lysates in experiments A and 
B.   
 
 
0.0
0.5
1.0
1.5
2.0
2.5
0 10 20 30 40 50 60
Time (Mins)
A
bs
 @
 3
40
nm
V79-C
V79-NTR
HCT-C
HCT-NTR
0.0003260.000310HCT-NTR
0.0004610.000588HCT-C
0.0008510.010252V79-NTR
-0.000035V79-C
Experiment BExperiment A
Specific Activity (Units/mg)
 213
In order to examine the levels of NTR protein being produced in the HCT-
NTR cell line, extracts were run on an SDS gel (Figure 5.49).  A positive control 
showed a band at 24 kDa for NTR protein (Lane 2, Figure 5.49).  However, no bands 
were seen in any other samples run.  V79-NTR (Lane 3) and V79-C (Lane 4) samples 
appeared to be slightly degraded, with no distinct protein bands visible.  Samples 
from the HCT-NTR cell lines (Lanes 5 and 6) unfortunately did not show a band for 
the NTR protein.   
 
 
 
 
 
Figure 5.49 SDS gel with protein samples from V79 and HCT cell lines.  Lane 1: 
SigmaMarkerTM, Lane 2: Positive control for NTR, band visible at 24 kDa, Lane 3: 
V79-NTR, Lane 4: V79-C, Lanes 5 and 6: HCT-NTR, Lanes 7 and 8: HCT-C.  35 µg 
total protein was loaded for each sample.   
36kDa
29kDa
24kDa
20kDa
1 2 3 4 5 6 7 8
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5.3  Discussion 
 
The aim of this chapter was to examine the activation of the 5-FU and 5-FUrd 
prodrugs.  These compounds were designed as bioreductive prodrugs so activation by 
hypoxia was first investigated.  Prodrugs 3, 6, 9, 13 and 14 were tested under hypoxic 
conditions (2% O2) and compared to control conditions of normoxia (20% O2).  Both 
the 4T1 and the SW480 cell line showed little negative effect when cultured in 
hypoxia for up to 72 hours (Figures 5.9 and 5.14).  The SW480 cell line in fact 
showed an increase in cell growth, probably due to activation of anti-apoptotic 
proteins in response to the hypoxia (Kizaka-Kondoh et al., 2003).  Incubation of the 
4T1 cell line with varying concentrations of the prodrugs under hypoxic conditions 
for up to 72 hours showed no increase in toxicity in comparison to cells in normoxic 
conditions (Figures 5.10-5.13).  Compound 13 showed toxicity towards the 4T1 cells 
at the higher concentrations but this was also exhibited under normoxia (Figure 5.10).  
Compound 14 showed low toxicity over the range of concentrations tested under both 
hypoxic and normoxic conditions (Figure 5.11).  Compound 3, as seen previously in 
chapter 4, was toxic to the cells from concentrations greater than 1 µM, but showed 
no difference under the normoxic and hypoxic conditions (Figure 5.12).  Low toxicity 
was seen after treatment with compounds 6 and 9 over 3 days (Figure 5.13).   
Cytotoxicity assays under hypoxic conditions with the SW480 cell line also 
showed no difference in toxicity after treatment with the prodrugs (Figures 5.15 and 
5.16).  These combined results led to the conclusion that the prodrugs were not being 
activated under hypoxic conditions.  A known hypoxia-activated prodrug, for 
example Tirapazamine, could have been used as a control to confirm that hypoxic 
levels were actually reached within the cells (Brown and Wilson, 2004).  Activation 
at a lower percentage of oxygen (1% or 0.1%) could have been examined, however 
these facilities were not available for these experiments.  These in vitro results were 
not necessarily an indication of the possible efficacy in vivo.  Initial investigations in 
the case of AQ4N showed no activation in cultured tumour cells (Patterson and 
McKeown, 2000).  Activation in culture was only achieved when experiments were 
supplemented with liver microsomal fractions (Patterson and McKeown, 2000).  
Freshly excised tumour tissue could also activate AQ4N under hypoxic conditions, 
but only up to 24 hours after excision (Hejmadi  et al., 1996 and Patterson et al., 
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2000).  This was due to the down-regulation of cytochrome P450 in cell culture 
conditions (Patterson and McKeown, 2000).   
The reductase enzymes responsible for the activation of prodrugs under 
hypoxic conditions are predominantly one-electron reductases (Williams et al., 2001).  
Thus, the lack of activation of the 5-FU and 5-FUrd prodrugs could be due to the 
requirement of two electron reductases, of which, cytochrome P450 has previously 
been shown to be down-regulated in culture.  Further investigation along this avenue 
would have required supplementation of assays with cytochrome P450.  However, 
activation by NTR and a GDEPT approach was also attractive.   
NTR, an E.coli enzyme of 24 kDa, is a two-electron reductase which has 
previously been used to activate prodrugs such as CB1954 (Denny, 2001).  This 
enzyme was tested with the nitrobenzyl prodrugs using an enzyme assay which 
monitored the rate of reaction by the decrease in absorbance of NADH at 340 nm.  
Compounds 9 and 13 appeared to be good substrates of the enzyme (Figure 5.17).  
Non-linear regression software Enzfitter and the linear plots, Lineweaver-Burk, 
Hanes-Woolf and Eadie-Hofstee, were used to calculate kcat and Km values using data 
from a range of assays varying substrate concentration and reaction time (Figures 
5.18-5.23).  The Km values decreased in order, compound 13 (48.17 µM)>compound 
14 (13.47 µM)>CB1954 (9.66 µM).  CB1954 thus had the highest affinity for this 
enzyme.  The kcat values showed compound 13 had the highest turnover (76,427 sec-1) 
followed by CB1954 (52,195 sec-1) and compound 14 (29,857 sec-1).   
kcat/Km ratios incorporate both of these values and give an indication of the 
overall efficiency of the reaction.  CB1954 and NTR proved to be the most efficient 
combination, with kcat/Km ratio of 5.4 x 109 sec-1M-1 (Table 5.2).  This was not 
surprising considering the fact that CB1954 is in clinical trials with this enzyme.  The 
kcat/Km values for compounds 13 and 14 were 1.59 x 109 and 2.22 x 109 sec-1M-1 
respectively, approximately 30% and 40% of the efficiency of the CB1954/NTR 
system.  Reported Km and kcat values for CB1954 were 862 µM and 6 sec-1 
respectively (Rooseboom et al., 2004).  These are considerably different values 
compared to the results obtained here.  The published results for CB1954/NTR are 
from a 1992 paper (Anlezark et al., 1992).  The authors used CB1954 provided by the 
Institute of Cancer Research and extracted NTR from E. coli B cell paste, as opposed 
to the CB1954 and NTR from Sigma-Aldrich used in the experiments presented here.  
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They also used a lower enzyme concentration (2 µg/ml), substrate concentration (100 
µM) and a different buffer. These differences in the experimental system would have 
an impact on the calculations of these values.  While our enzyme assay was a crude 
system, it allowed comparison between the known substrate CB1954 and our 
prodrugs, compounds 13 and 14. 
Activity of the prodrugs in cell lines expressing the E. coli NTR enzyme was 
investigated next.  A Chinese hamster lung fibroblast cell line transfected with the 
cDNA for NTR (V79-NTR) and the control cell line (V79-C) were obtained from 
Morvus Technologies.  Total protein extracts from the V79 cell lines were first used 
to assess activity of the cellular enzyme.  Activity in the V79-NTR cell line was 
evident with a sharp decrease in the absorbance of NADH in comparison to the 
control cell line and the 4T1 cell line (Figure 5.24).  Specific activity for the V-79 cell 
line was 0.1578 Units/mg in comparison to 0.0013 Units/mg for the control cell line.  
According to Morvus Technologies product information, specific activity should be 
0.02 Units/mg cell protein for the V79-NTR cell line and <0.0001 Units/mg cell 
protein for the V79-C cell line.  Our calculations differed by one order of magnitude 
for both, however there was still a greater than 100-fold difference in the specific 
activities so activity in the V79-NTR cell line was confirmed.   
Following this confirmation of the activity of the cellular enzyme, cytotoxicity 
in the V79-NTR and V79-C cell lines was examined.  The cytotoxicity profile of 
CB1954 illustrated the considerable difference in response to this prodrug in the two 
cell lines (Figure 5.25).  The ratio of IC50 values in the V79-C and V79-NTR cell 
lines for CB1954 was 27,143 (Table 5.3).  According to Morvus Technologies, a 
greater than 7,000-fold difference can be seen between the two IC50 values.  Higher 
ratios have previously been reported for this system, with up to 100,000-fold increase 
in toxicity (Knox et al., 1992).  Compound 3 showed toxicity in both the V79-C and 
V79-NTR cell lines, indicating that this prodrug was not activated by the NTR 
enzyme (Figure 5.26).  Considering the toxicity noted previously with compound 3, 
this was not a surprising result; however, the possibility of increased toxicity in the 
presence of NTR had to be examined.  Figure 5.27 illustrates the toxicity seen 
following treatment for 3 days with compound 6.  There was a difference in toxicity 
at 25 µM, with no cell death observed in the V79-C cell line and approximately 90% 
cell death in the V79-NTR cell line.  Despite this, at the top concentration of 252 µM, 
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compound 3 caused a higher percentage of cell death in the V79-C cell line than in 
the V79-NTR cell line.  Also, no increase in toxicity was observed in the V79-NTR 
cell line after 5 days treatment with the same compound (Figure 5.28).  
Compound 9, despite appearing to be a good substrate for the NTR enzyme 
(Figure 5.17), exhibited low toxicity over 3 and 5 days and IC50 values were not 
reached (Figure 5.29).  However, considering the structure of compound 9, if the 
nitroreductase cleaved the nitro-benzyl side-chain, the structure of compound 8 would 
remain, with the protected C-2 and C-3 in the sugar (Figure 5.50).  This component 
has been shown in chapter 4 to block activity of 5-FU.  Thus, cleavage may be 
occurring but the 5-FUrd product was not toxic.  Compound 13 caused an increase in 
toxicity in the V79-NTR cell line after treatment for both 3 and 5 days, with the ratio 
of IC50 values of 4.89 and greater than 5.98 respectively (Figures 5.30 and 5.31).  
Compound 14 showed promising results, causing 100% cell death in the V79-NTR 
cell line after treatment with 25 µM for 3 days (Figure 5.32).  In the V79-C cell line, 
low toxicity was observed up to the top concentration of 250 µM.  The ratio of IC50 
values over 3 days was greater than 73.5, a considerable ratio between the two cell 
lines (Table 5.3).  Over 5 days, compound 14 was more toxic to the V79-NTR cell 
line, with an IC50 value of 1.8 µM.  However, the V79-C cell line also showed some 
toxicity, with an IC50 value of 33 µM, giving a ratio of 18.33 (Figure 5.33).   
 
 
 
 
Figure 5.50 Nitroreductase activation of compound 9 would give rise to compound 8.  
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cytotoxicity assays using the V79 cell lines were for compound 14, with greater than 
73.5-fold increase in IC50 values over 3 days in the NTR-expressing cell line.  
Compound 13 also showed encouraging results, with an increase in toxicity over both 
3 and 5 days in the V79-NTR cell line.  Compound 3 had shown toxicity towards all 
cell lines tested to date and the results with the V79-C and V79-NTR cell lines were 
not surprising.  Compound 6 had a ratio of IC50 values of 10.63 after 3 days treatment 
however; this was only 0.97 after 5 days.  IC50 values were not reached for compound 
9, which had proven to be a good substrate for the NTR enzyme in the enzyme 
assays.  However, as illustrated in Figure 5.50, the reaction of compound 9 with NTR 
would produce compound 8 which has previously shown low toxicity, thus, 
compound 9 may be a good substrate but the resulting toxicity is not occurring.   
Mass spectrometry is a powerful analytical technique that can be used to 
elucidate the structure and chemical properties of molecules.  Mass spectrometers 
measure the mass-to-charge (m/z) ratio of ionised molecules.  Liquid chromatography 
mass spectrometry (LC-MS) separates compounds chromatographically before they 
are introduced to the ion source and mass spectrometer.  In order to confirm 
activation of compound 13 with the release of 5-FU, mass spectrometry was 
conducted using compound 13 as it was the most abundant compound.  The assay 
was developed and optimised in the NICB, DCU.  Samples of media from the V79-C 
and V79-NTR cell lines were analysed after treatment with 75 µM of compound 13 
for 5 days.  Controls mixing compound 13 with media with and without 5 day 
incubation showed no 5-FU peaks (Figure 5.35).  The media removed from the V79-
C cells showed a peak for compound 13 (Figure 5.36 B), with no peak appearing for 
5-FU (Figure 5.36 A).  The sample taken from the V79-NTR cell line had no peak for 
compound 13 (Figure 5.36 D), with a peak at 4.4 minutes for 5-FU (Figure 5.36 C), 
indicating release of the free 5-FU from the prodrug 13.  Figure 5.51 illustrates this 
activation of compound 13 by nitroreductase, releasing 5-FU, CO2 and quinone 
methide.  These results confirm the activation of compound 13 in the V79-NTR cell 
line and supported the basis of these compounds as NTR-activated prodrugs.  The 
nitroreductase inhibitor, dicoumarol, could be used in experiments as further 
confirmation that the nitroreductase activation was causing the increased cytotoxicity.  
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Figure 5.51 Activation of compound 13.  Reduction of the nitro group to –NHOH 
results in cleavage of the bond between the benzyl linker group and the 5-FU, 
releasing 5-FU, CO2 and quinone methide. 
 
Once we had successfully shown activation of the prodrugs, we wanted to test 
the compounds in human cancer cell lines.  The cDNA for E. coli NTR was obtained 
and transfected into the HCT116 colorectal cancer cell line.  Development of the 
HCT-C and HCT-NTR cell lines enabled cytotoxicity testing of the prodrugs using a 
colorectal cancer cell line over-expressing the NTR enzyme.  Despite problems in 
attempts to transfect the plasmids into the SW480 cell line, transfection using the 
HCT116 cell line was very successful.  Transfection efficiency in this cell line was 
established as 9.7% using the β-galactosidase reporter gene (Figure 5.39).  Two 
pooled populations were established containing each plasmid.  The presence of the 
plasmid and production of the NTR mRNA in these populations was confirmed by 
PCR and RT-PCR respectively (Figures 5.40 and 5.41).  Bands for NTR RT-PCR 
products in the V79-NTR (lane 5, Figure 5.41) and the HCT-NTR cell lines (lanes 3 
and 4, Figure 5.41) were similar, confirming production of the NTR mRNA.  
However, cytotoxicity of the prodrugs with the HCT-C and HCT-NTR cell lines did 
not achieve the results anticipated.  No increase in toxicity was observed in either of 
the duplicate HCT-NTR cell lines.  Compound 3 showed toxicity over 3 and 5 days in 
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both the HCT-C and HCT-NTR cell lines (Figure 5.42).  This was not surprising as 
the same result was seen with the V79 cell lines.  Compound 6 showed toxicity over 3 
and 5 days at the highest concentration tested but this was in both cell lines, so no 
increase was seen in the HCT-NTR cell line (Figure 5.43).  Compound 9 showed no 
toxicity over the range of concentrations tested (Figure 5.44).   
Compound 13 and 14 showed the most promising results in the V79 toxicity 
experiments.  However, the results using the HCT cell lines were disappointing with 
no increase in toxicity in the HCT-NTR cell line.  Compound 13 exhibited lower 
toxicity than in the V79-NTR cell line, with IC50 values not reached over 5 days, and 
IC50 values of 320 µM and 200 µM established over 5 days for the HCT-C and HCT-
NTR cell lines respectively (Figure 5.45).  Compound 14 also showed low toxicity; 
with IC50 values of 200 µM and 248 µM established over 3 days for the control and 
NTR-expressing cell lines respectively (Figure 5.46).  These results indicated that no 
activation of the prodrugs was occurring in the HCT-NTR cell lines.  To investigate 
this further, CB1954 was tested with the HCT-C and HCT-NTR cell lines.  Toxicity 
was noted in both HCT cell lines at the highest concentration, 397 µM, after 3 days 
treatment, the equivalent to that seen in the V79-C cell line (Figures 5.47 and 5.25).  
No increase in the level of cell death was seen in the HCT-NTR cell line.  Higher 
toxicity levels were observed after treatment for 5 days but no increase was evident in 
the HCT-NTR cell line (Figure 5.47).  These results unfortunately supported the 
suggestion that activation of the prodrugs by the NTR enzyme was not occurring in 
the HCT-NTR cell lines.   
To confirm this, enzyme assays were carried out using cell extracts from each 
of the cell lines.  Experiments with 100 µg total cell protein showed no activity in the 
HCT-NTR cell line (Figure 5.48).  V79-NTR cell extracts were used as a control and 
showed specific activity of 0.01 Units/mg, while the HCT-C and HCT-NTR showed 
specific activity of 5.88 x 10-4 and 3.1 x 10-4 Units/mg respectively (Table 5.5 
Experiment A).  Increasing the amount of total protein added to the reaction mixture 
did not increase the specific activity of V79-NTR (data not shown and Table 5.5 
Experiment B).  Specific activity was higher in the HCT-C cell line than the HCT-
NTR cell line but both values were very low, at 4.61 x 10-4 Units/mg and 3.26 x 10-4 
Units/mg respectively.  The values for specific activity for the V79-NTR cell line 
were considerably lower than in previous experiments (Figure 5.24).  The lack of 
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activity in the V79-NTR cell pellet was probably due to their storage at -20°C for a 
number of months.  The enzyme could thus have been inactivated, accounting for the 
loss of activity. 
Unfortunately, the overall conclusion from the HCT-C/HCT-NTR 
cytotoxicity and the enzyme assays using cell lysates was that, despite confirmation 
of production of the NTR mRNA in the HCT-NTR cell line, active enzyme was not 
being produced.  There are two possible reasons for this, firstly, translation of the 
mRNA was not taking place or secondly, the NTR protein was being produced but it 
was not active.  An SDS gel with samples from the HCT-NTR cell lines did not 
however show evidence of the NTR protein but it was not clear in the V79-NTR 
sample either (Figure 5.49).  A western blot could have been performed to confirm 
the presence of the NTR protein, and would have been more sensitive than the SDS 
gel.  However, no commercial antibody is available for the NTR enzyme, and even if 
the presence of the protein had been confirmed, this would not have guaranteed 
activity of the enzyme.  Individual clones were not selected based on expression or 
enzyme activity hence, the populations established were polyclonal.  Selection of 
monoclonal populations by serial dilution and screening the clones could have 
established a population of high-expressing cells and subsequent toxicity analysis 
could have been more informative.   
Alternatively, sub-cloning the cDNA into another vector could have given 
higher expression levels.  The F184 plasmid contained a cytomegalovirus (CMV) 
promoter/enhancer region.  The human elongation factor-1α (EF-1α) promoter is a 
stronger promoter and would give higher expression levels (Wurm and Bernard, 
1999).  In the F184 plasmid the puromycin resistance gene and the NTR gene were 
not coupled so the translation of their mRNA was not linked.  Hence, production of 
the puromycin resistance product could be present in cells without production of the 
NTR enzyme.  A growth advantage in the clones producing only the puromycin 
resistance protein over those producing both puromycin resistance protein and NTR 
protein could have occurred.  For future experiments, a plasmid producing a 
bicistronic transcript of both genes would ensure selection of cells that were 
producing both proteins.  The V79-NTR cells obtained from Morvus Technologies 
had been transfected with such a bicistronic vector.  However, Morvus Technologies 
only recommended maintaining the enzyme expressing cells for up to 10 passages, as 
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the enzyme production gradually decreases (personal communication from Morvus 
Technologies).  The cytotoxicity and enzyme assays were carried out using early 
passages, but the decrease in enzyme production indicated that the expression was not 
stable.  If the NTR protein was being produced within the cells, the activity could 
have been inhibited by incorrect protein folding, inhibition of dimer formation or a 
lack of co-factors.  Although expression and activity was seen in the V79-NTR cell 
line, conditions in the HCT116 cell line may not have been conducive to activity.   
Despite these disappointing results with the HCT-NTR cell line, the 
cytotoxicity and mass spectrometry data from the V79 cell lines indicated 
nitroreductase-mediated activation of the prodrugs 13 and 14.  The potential use of 
these compounds in a GDEPT system needs to be further examined.  Mass 
spectrometry analysis of the media from cells treated with compounds 3, 6 and 14 
could be conducted.  This may reveal details behind the toxicity seen for compound 3 
without nitroreductase activity.  No activation of compound 6 was evident and mass 
spectrometry would confirm this.  Compounds 13 and 14 should be used as lead 
compounds for the development of more active prodrugs.  In the long term, they 
could be tested in vivo in mice using a GDEPT approach.  Delivery of the NTR gene 
to the cells would initially be tested in mice to confirm production of the enzyme in 
the target cells. Administration of the prodrug alone would then examine any 
endogenous activation of the prodrugs or dose-limiting toxicities.  Following these 
two initial steps, both NTR and prodrug administration would be investigated for 
efficacy.  This work combines to provide a proof of concept for the de-activation of 
5-FU by addition of a nitro-benzyl side-chain, which acts as an efficient trigger to 
release the drug upon exposure to the NTR enzyme.   
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5.4  Summary 
 
Activation of the prodrugs 3, 6, 9, 13 and 14 was analysed firstly under 
hypoxic conditions, using the 4T1 and SW480 cell lines.  Treatment of the cells with 
prodrug for up to 72 hours under hypoxic conditions did not increase toxicity of the 
compounds.  Enzyme activation using the E. coli NTR enzyme was examined in a 
simple multi-well plate format, monitoring oxidation of NADH as the reaction 
proceeded, and also with cell extracts from pellets of NTR-expressing cells.  
Compounds 9 and 13 appeared to be good substrates for the enzyme.  Analysis of 
compounds 13 and 14 using enzyme kinetics plots allowed calculation of kcat and Km 
values.  Compound 13 had a high turnover rate of substrate (75,702 sec-1) but 
compound 14 had a higher overall efficiency value as indicated by a kcat/Km ratio of 
2.22E9.  Cytotoxicity assays using the V79 cell lines showed compounds 13 and 14 
to have increased toxicity in the NTR-expressing cells, indicating activation to the 
active drug.  The IC50 value of compound 14 was greater than 73.5-fold higher in the 
N79-NTR cell line in comparison to the V79-C cell line over 3 days.  Mass 
spectrometry confirmed that activation of compound 13 was occurring.  A clear 5-FU 
peak was evident after analysis of media from the V79-NTR cells which had been 
exposed to compound 13 for 5 days.  The cDNA for the NTR gene was acquired, 
amplified and transfected into the HCT116 colorectal cancer cell line and mRNA 
production confirmed.  However, in cytotoxicity experiments with prodrugs no 
increase in cell death was observed in the HCT-NTR cells in comparison to the HCT-
C cells.  No activity was noted in enzyme assays using cell extracts either.  Despite 
these disappointing results with the HCT116 cell line, the results from the V79-NTR 
cell line and the mass spectrometry would still suggest compounds 13 and 14 are 
potential prodrugs for used in a GDEPT system with NTR.  Optimisation of the 
expression of the NTR in the HCT116 cell line and further analysis of activation, 
followed by animal studies should prove the efficacy of these prodrugs. 
  
 
Chapter 6 
 
Summary and Conclusions 
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6.1 Summary and conclusions 
 
It is predicted that by the year 2020 there will be over 28,000 new cancer 
cases annually in Ireland (National Cancer Forum, 2006).  Widespread screening 
programmes, better detection methods and improved treatment regimes are urgently 
required.  Future prospects for cancer treatments are looking promising, with research 
into all aspects of cancer initiation, progression and metastasis to the fore of scientific 
endeavour.  Proteomic and genomic technologies have increased our understanding of 
the molecular changes that occur as cancer develops and are important tools in this 
area.  The major objectives of this thesis were to investigate the feasibility of using a 
dietary component, CLA, and novel derivatives of a standard chemotherapeutic agent, 
5-FU, as anti-cancer and anti-metastatic agents.  
CLA comprises a group of positional and geometric isomers of the fatty acid 
LA and has previously been shown to have beneficial effects against cancer, obesity, 
diabetes and atherosclerosis (Pariza et al., 2000).  A mixture of CLA isomers 
(‘CLA’), two individual isomers, c9,t11-CLA and t10,c12-CLA, and LA were tested 
for cytotoxicity in the 4T1 murine mammary cancer cell line and the Hs578T human 
breast cancer cell line.  Treatment with CLA caused the highest level of toxicity in the 
4T1 cell line after 1, 3 and 5 days.  The c9,t11-CLA isomer was more toxic than the 
t10,c12-CLA isomer after treatment for 3 days, while after 5 days t10,c12-CLA 
treatment resulted in greater cell death.  Low toxicity was observed following 
treatment with LA, except at the highest treatment concentration of 107 µM after 5 
days.  There appeared to be a threshold with regards to the cytotoxicity of CLA and 
c9,t11-CLA, with little increase in cell death observed from 3 to 5 days treatment.  
This was supported by results in animal studies which showed a maximal response to 
dietary levels of 1% CLA in comparison to 1.5% CLA (Ip et al., 2001 and Ip et al., 
1996).  Cytotoxicity was lower in the Hs578T cell line than in the murine cell line.  
CLA exhibited the highest toxicity after treatment for 5 days, while the t10,c12-CLA 
isomer had more of an effect than the c9,t11-CLA isomer.  The lower responsiveness 
of the Hs578T cell line could be due to its negative ER status (Tanmahasamut et al., 
2004).  However, despite the negative ER status of the 4T1 murine mammary cancer 
cell line, cytotoxicity was noted at higher levels than in the Hs578T cell line, 
indicating different mechanisms of action independent of ER interaction.   
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In order to determine the mechanism of action of cytotoxicity, cell cycle 
kinetics and apoptosis levels were analysed in the 4T1 cell line following treatment 
with the fatty acids.  Treatment with two different concentrations, 54 µM and 89 µM, 
resulted predominantly in a G1 phase arrest of the cells (Figures 3.17 and 3.19).  
Treatment at the higher concentration did not cause as great an arrest as at the lower 
concentration, possibly indicating apoptosis of cells from the G1 population.  A 
significant increase in apoptosis was noted at the higher concentration of CLA and 
the c9,t11-CLA isomer in comparison to the control (p<0.05).  These results, along 
with the cytotoxicity data, indicated a role for CLA as an anti-cancer agent.  Its 
presence in dairy foods such as cow’s milk and cheese, with elevated levels possible 
through variations in the cow’s diet, would allow the use of CLA as a biologically 
active supplement of a functional food (O’Shea et al., 1998).   
The effects of CLA and the individual isomers on in vitro cell migration, 
invasion and soft agar colony formation were varied.  Treatment of the 4T1 cells with 
CLA had no effect on migration, increased invasion (not significant), and caused a 
significant increase in colony formation in soft agar (p<0.01).  The c9,t11-CLA 
isomer caused an increase in migration, invasion and colony formation in soft agar 
(p<0.01).  Treatment with the t10,c12-CLA isomer resulted in decreased migration 
and invasion of the 4T1 cell line and caused a significant increase in colony formation 
in soft agar (p<0.00005).   
In order to investigate these effects on migration, invasion and colony 
formation in soft agar, the level of MMPs and TIMPs in treated cells was examined.  
An increase in MMP-9 mRNA and protein levels, and a decrease in TIMP-1 mRNA 
levels following treatment with CLA explains the increased invasion of the 4T1 cells.  
The level of MMP-9 protein was increased and TIMP-1 mRNA levels were decreased 
in the 4T1 cells following treatment with c9,t11-CLA, again possibly playing a role in 
the increased migration and invasion.  Treatment with t10,c12-CLA resulted in 
increased MMP-9 protein and mRNA levels and decreased TIMP-1 mRNA levels.   
The increase in invasion, colony formation in soft agar and MMP-9 protein 
levels in the 4T1 cell line following treatment with CLA and the c9,t11-CLA isomer 
would not support their use as anti-metastatic agents.  The t10,c12-CLA isomer 
however, caused a decrease in migration and invasion but significantly increased 
colony formation in soft agar.  MMP-9 mRNA and protein levels were increased 
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following treatment with t10,c12-CLA along with a decrease in TIMP-1 mRNA 
levels.  These results would indicate a role of other factors in the down-regulation of 
migration and invasion of the 4T1 cells, possibly including cell adhesion molecules.  
An up-regulation in cell adhesion molecules such as E-cadherin could contribute to 
inhibition of migration and invasion.  No difference in adhesion of the cells after 
treatment with the fatty acids was observed, however this was only examined on 
plastic and this result would not necessarily reflect adhesion to other cells or ECM 
components such as laminin or fibronectin.  The effect of t10,c12-CLA on colony 
formation in soft agar needs further analysis.  Possible areas of interest would be the 
Ras/Raf/ERK pathway which is involved in cell proliferation.  Unfortunately time 
restrictions did not allow these areas to be pursued further as part of this thesis but it 
is hoped this work will be continued in the near future.  Overall, the rationale for 
using CLA and the isomers as anti-metastatic agents was not convincing from these 
results.  Future studies on the anti-cancer activity of CLA should monitor the effects 
on invasion and migration of the cells as metastasis-promoting properties would not 
be beneficial to patients. 
The promotion of migration, invasion and formation of colonies in soft agar in 
the 4T1 cancer cells reported in this work could be a species-specific effect.  CLA has 
been noted to have a varied effect on PPAR-responsive genes in mice in comparison 
to rats.  Belury et al. (1997) reported increased mRNA levels of acyl-CoA oxidase, 
fatty acid binding protein and cytochrome P4504A1 in the livers of female SENCAR 
mice fed 0.5%, 1% and 1.5% CLA in the diet.  In contrast, Moya-Camarena et al. 
(1999) did not note any effect on mRNA levels of these enzymes in female Sprague-
Dawley rats.  Opposing effects on blood insulin in mice and rats have also been noted 
(Pariza et al., 2001).   
The ability of CLA to enhance the efficacy of other chemotherapeutic agents 
is also under investigation in our laboratory.  Fatty acids have previously been 
reported to modulate toxicity of anti-cancer treatments.  Menendez et al. (2004) noted 
increased toxicity in the MDA-MB-231 cell line following treatment with DHA and 
the taxanes, Taxol and Taxotere.  A synergistic interaction between GLA and 
vinorelbine was also reported by the same group in the MCF-7 cell line (Menendez et 
al., 2002).  A prodrug incorporating DHA and paclitaxel was reported to have 
promising results in phase I clinical trials in patients with advanced solid tumours 
(Wolff et al., 2003).  However, results of a phase II trial of this DHA-paclitaxel 
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conjugate in oesophago-gastric cancers were not convincing enough to warrant 
further studies (Jones et al., 2007).  In a phase II trial using DHA-paclitaxel in 
combination with carboplatin to treat patients with advanced solid tumours, the 
authors reported one partial response and 10 patients with stable disease, warranting 
further investigation of DHA-paclitaxel in combination regimens (Harries et al., 
2004).  The ability of CLA to modulate the effect of chemotherapeutic agents needs 
examination, with close monitoring of the promotion of metastasis.   
5-FU is one of the most widely used anti-cancer agents for solid tumours 
(Malet-Martino and Martino, 2002).  It is commonly administered as part of a 
combination treatment regime but response rates in advanced CRC are generally still 
below 50% (Longley et al., 2003).  These low response rates and side-effects such as 
myelosuppression and GI toxicities warrant investigation into more effective 
therapies.  Twelve novel derivatives of 5-FU and 5-FUrd were synthesized and tested 
as part of a SAR study.  Cytotoxicity of all compounds was tested in the 4T1 cell line 
and the SW480 cell line, with similar results obtained in both cell lines.  The nitro-
benzyl derivatives of 5-FU caused varied toxicity after treatment for 3 days.  
Compound 3 was less toxic than the parent 5-FU, compound 13 only caused toxicity 
at the higher concentrations and treatment with compound 14 resulted in low toxicity 
over the range of concentrations tested.  These compounds were designed as prodrugs 
so the lower toxicity of compounds 13 and 14 was expected.  The toxicity of 
compound 3 however, was unexpected and was probably due to binding and 
inhibition of thymidylate synthase.  Of the ester derivatives, compounds 10 and 11 
were more toxic than the parent 5-FU, with compound 10 exhibiting 10-fold greater 
toxicity than the parent drug.  Compounds 4 and 5 had similar toxicity to 5-FU.  The 
ester side-chains caused an increase in lipophilicity of these compounds and this 
would have resulted in greater absorption of the compounds into the cells.  The side-
chains would also have been rapidly hydrolysed within the cell to yield 5-FU, 
resulting in toxicity.  This modification of 5-FU has thus proven to be successful in 
improving the toxicity of the drug.  Further modifications of compound 10 are 
currently being conducted by Dr. Nolan’s group and testing will begin shortly.   
The 5-FUrd derivatives caused low toxicity in both cell lines over the range of 
concentrations tested, with the modifications to structure completely suppressing the 
toxicity of the parent drug.  The protected C-2 and C-3 hydroxyl groups of the sugar 
in compounds 7, 8 and 9 prevented toxicity of these compounds.  Compound 6 did 
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not have protected groups but did not exhibit toxicity, however, the size and 
lipophilicity of this compound would have affected its uptake into the cells.   
Testing of the compounds in a 5-FU resistant cell line, HCT(R), was 
conducted to determine if these compounds could bypass the resistance mechanisms 
present in these resistant cells.  After treatment for 3 days, 5-FUrd and compounds 3, 
4 and 10 all had lower fold-differences between the parental and resistant cell lines, 
indicating an increased sensitivity to these treatments in the resistant cell line in 
comparison to 5-FU.  Over 5 days, treatment with 5-FUrd and compounds 3, 4, 5 and 
10 all had lower ratios than 5-FU.  Compound 10 in particular proved quite toxic in 
the HCT(P) and HCT(R) cell lines, with IC50 values 10-fold lower than the parent 5-
FU.  The ratio of IC50 values was 0.89 over 5 days, indicating higher sensitivity in the 
resistant cell line than in the parental cell line.  Thus, this compound had escaped the 
resistance mechanisms of the HCT(R) cell line and caused greater toxicity than in the 
parental cells.   
Following the cytotoxicity results, investigation of cell cycle kinetics and 
apoptosis was conducted.  Cell cycle analysis showed the most dramatic effects 
following treatment with compounds 4 and 10 at 0.1 µM for 3 days.  Compound 4 
caused a marked increase in the G2 phase population while treatment with compound 
10 resulted in an S phase arrest (Figure 4.16).  Treatment at the higher concentration 
of 1 µM caused elimination of S phase cells and G1 phase arrest for 5-FU, 
compounds 3, 4 and 5.  Compound 10 at the higher concentration also caused an S 
phase arrest, with complete elimination of the G2 phase population.  These results 
demonstrated different mechanisms of action for these compounds.  The arrest in the 
G2 phase at lower concentrations indicates damage to DNA during replication and a 
subsequent pause for repair before mitosis.  Arrest in the G1 phase at the higher 
concentrations, with elimination of the S phase indicates cells were not beginning 
DNA replication possibly due to RNA misincorporation.  The S phase arrest noted 
after treatment with compound 10 would indicate extensive DNA damage during 
replication and subsequent cell death before cells reached the G2 phase of the cell 
cycle.  Apoptosis levels in the cells following treatment with 0.1 µM compound 10 
confirmed the high cytotoxicity noted with this derivative.  Treatment with 1 µM of 
5-FU, compounds 3, 4, 5, 10 and 11 all caused significant increases in the level of 
apoptotic cells.   
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The effect of a selected number of derivatives on migration, invasion and 
colony formation in soft agar of the 4T1 cell line was examined but unfortunately no 
significant decrease was observed in any of these properties.  Treatment with 
compounds 3, 4 and 14 resulted in significant increases in migration of the cells, 
while invasion was also significantly increased following treatment with compound 4 
(Figures 4.22 and 4.24).  This pro-invasive effect has previously been reported 
following pulse selection with 5-FU in the DKLP cell line (Liang et al., 2004).  Thus 
these compounds would not be candidates for anti-metastatic approaches to therapy 
and this aspect requires monitoring in future studies.   
The nitro-benzyl derivatives of 5-FU and 5-FUrd were designed as prodrugs, 
with cleavage of the side-chain releasing the toxic parent molecule.  The activation of 
these prodrugs was first examined using hypoxic conditions, to determine if the 
increase in one-electron reductases in the hypoxic environment could cleave the nitro-
benzyl groups.  Cytotoxicity of the prodrugs, compounds 3, 6, 9, 13 and 14, was 
examined under hypoxic conditions using the 4T1 and the SW480 cell lines.  No 
increase in toxicity was observed following incubation with the compounds under 
hypoxic conditions for 3 days.  Therefore, an alternative approach to activation of the 
compounds was investigated.  An E. coli enzyme, NTR, was tested with the 
compounds for activity.  Compounds 9 and 13 showed the most promise after enzyme 
assays (Figure 5.17).  Enzyme kinetic analysis with compounds 13 and 14, along with 
a known substrate for the enzyme CB1954, revealed compound 13 had the highest kcat 
value, an indication of the rate of conversion of substrate to product.  The Km values 
showed CB1954 to have the greatest affinity for the enzyme but this was followed 
closely by compound 14.   
A cell line which was stably transfected with the cDNA for NTR (V79-NTR) 
and the control cell line (V79-C) were obtained to test activation by the NTR enzyme 
in the cellular environment.  Testing of cell lysates with CB1954 confirmed cellular 
NTR activity (Figure 5.24).  Cytotoxicity testing in the V79 cells over 3 and 5 days 
did not show any increase in cell death for compound 3 or compound 9.  Compound 3 
had exhibited cytotoxicity in the absence of activation so this was not unexpected.  
Compound 9 had appeared to be a good substrate for the enzyme but the protected C-
2 and C-3 hydroxyls of the sugar would have prevented toxicity even when the nitro-
benzyl group was removed.  Compound 6 showed promising results over 3 days but 
this unfortunately did not extend to the 5 day treatment.  Compounds 13 and 14 
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showed the most promising results, with toxicity increased in the V79-NTR cell line.  
After treatment for 3 days with compound 14, a greater than 73-fold increase in IC50 
value was noted between the two cell lines (Table 5.2).   
The cytotoxicity results in the V79 cell lines were encouraging and 
confirmation of the activation of compound 13 was investigated using mass 
spectrometry.  Medium removed from the V79-C and V79-NTR cells which had been 
incubated with compound 13 for 5 days was analysed.  The V79-C media sample 
showed a peak for compound 13 but no peak for 5-FU (Figure 5.36 A and B).  The 
media sample which had been incubated with the V79-NTR cell line had no peak for 
compound 13 and a peak for 5-FU, indicating activation of the prodrug to the parent 
drug (Figure 5.36 C and D).  These results supported the theory that the increased 
toxicity within the V79-NTR cells was due to activation of the prodrugs to 5-FU.  
The cDNA for the NTR enzyme was obtained from Dr. Steve Hobbs (CRUK) 
in order to transfect into a cancer cell line and test the prodrugs in this environment.  
The plasmid was successfully amplified in bacteria and transfected into the HCT116 
colorectal cancer cell line.  However, cytotoxicity testing of the prodrugs in the newly 
developed HCT-NTR and HCT-C cell lines did not show a difference between the 
two cell lines.  No NTR activity was observed in enzyme assays with CB1954 using 
cell lysates from these cell lines.  Protein analysis by SDS gel electrophoresis did not 
confirm the presence of the enzyme in the HCT-NTR cells.  Unfortunately an 
antibody to E. coli NTR was not commercially available and we were unable to 
perform a western blot.  While the presence of the NTR mRNA had been confirmed 
in the transfected cells using RT-PCR, translation into the protein or activity of the 
enzyme was compromised within these cells.  These final results were disappointing 
but do not detract from the results in the V79 cell lines and the activation shown by 
mass spectrometry.  These prodrugs have provided evidence for the proof of concept 
of the ability of the nitro-benzyl side-chain to suppress toxicity of the 5-FU drug.  
The NTR enzyme in the V79-NTR cells was shown to activate the prodrugs by 
cleavage of this group.  The prodrug compounds 13 and 14, will be used as lead 
compounds for further development of a GDEPT approach to anti-cancer therapy.  
CLA and 5-FU derivatives have proven to be strong anti-cancer agents.  The 
development of functional foods will see major growth in the 21st century (Riezzo et 
al., 2005).  In theory, increased levels of CLA in dairy products would provide a 
simple delivery method of this anti-cancer component.  Thus CLA would be part of a 
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dietary approach to anti-cancer therapies.  Further monitoring of the pro-metastatic 
properties of CLA is warranted before full confidence in this anti-cancer agent can be 
confirmed.  More effective chemotherapeutic agents such as the 5-FU derivatives will 
also be required to tackle the growing cancer incidence in this country.  Compound 
10 proved a highly toxic drug against the cell lines used in this study.  The 5-FU 
prodrugs are examples of more targeted treatments to cancer cells.  A focus on 
combining these two elements for future therapies would be extremely beneficial for 
the cancer patient.   
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6.2 Future work 
 
• Further investigation into the effect of the t10,c12-CLA isomer on invasion, 
migration and colony formation in soft agar is warranted.  It would be 
interesting to investigate a possible dose-dependent effect of this isomer on the 
colony growth by varying the concentrations used for treatment.  Analysis of 
adhesion to various substrates following treatment could provide insight into the 
mode of action.  At the molecular level, the effect on cell adhesion molecules, 
such as E-cadherin and β-catenin, and on the Ras/Raf/ERK pathway might also 
provide information on the mechanism of action.  Examination of the effects of 
CLA and the individual isomers on invasion and migration in human cancer cell 
lines would shed more light on whether this was a species-specific 
phenomenon.  
• The structure activity relationship study of the 5-FU and 5-FUrd derivatives has 
provided crucial information with regards to the toxicity of these compounds.  
The design of the 5-FUrd derivatives demonstrated the ability to completely 
suppress the cytotoxic effect of the parent compound.  The ester derivatives 
proved very toxic to the cancer cell lines, with compound 10 exhibiting 10-fold 
greater toxicity than 5-FU.  Further modifications to this compound are 
currently being made and will be tested in vitro.  Future animal studies with this 
compound and derivatives will be conducted to investigate the efficacy in vivo. 
• The nitro-benzyl prodrugs, in particular compounds 13 and 14, showed 
promising results with NTR activation.  The use of these lead compounds with 
NTR in a GDEPT approach to anti-cancer therapy will be further examined.  
Optimisation of a NTR-expressing cancer cell line is required for further testing.  
An improved bicistronic vector and cloning out of individual high-expressing 
transfected cells should tackle this problem.  Testing of these prodrugs along 
with a gene delivery system in animal studies would examine their efficacy in 
vivo.  In the clinical setting, testing of the gene delivery system would be the 
first step to confirm production of the enzyme.  This would be followed by 
administration of the prodrug alone to determine any DLTs or activation in the 
tissues, before co-administration of the gene and the prodrug.   
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• Design of 5-FU prodrugs for activation by one-electron reductases, which are 
up-regulated in hypoxic cells, would eliminate the gene therapy aspect required 
with the NTR-activated prodrugs.  This approach would take advantage of the 
presence of hypoxic conditions within tumours to modify the prodrugs.   
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Appendix A 
 
 
 
Plasmid map for F179 
 
 
 
Plasmid map for F184 
 
 
 
 
 
Plasmid maps were drawn using pDRAW from Acaclone Software.  
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Plasmid map for pCH110 
 
 
 
 
Plasmid map was drawn using PlasMapper  
( http://wishart.biology.ualberta.ca/PlasMapper/).   
Xiaoli Dong, Paul Stothard, Ian J. Forsythe, and David S. Wishart "PlasMapper: a 
web server for drawing and auto-annotating plasmid maps" Nucleic Acids Res. 2004 
Jul 1;32(Web Server issue):W660-4. 
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